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1. G PROTEIN COUPLED RECEPTOR SIGNALLING
Many hormones, neurotransmitters and different stimuli with a paramount role in health and disease elicit specific cellular responses through cell surface receptors. Of the several families of membrane receptors, by far the largest, 
most versatile and most ubiquitous is that of the seven-transmembrane (7TM) receptors 
(also referred to as seven-membrane-spanning receptors and G-protein-coupled recep-
tors (GPCRs))(Pierce et al., 2002) (Fig. I1). These receptors are a physical conduit for the 
transmission of chemical signals across the cell membrane and mediate the activation of 
intracellular G proteins (Hepler & Gilman, 1992). 
a. Historical context of G-protein-coupled receptors
The British pharmacologist John Newport Langley and his student Henry Dale, wor-
king together during the first decade of the 20th century, were the first scientists who 
explicitly stated the idea of a ‘receptive substance’ on reactive cells (Langley, 1901). Their 
deductions were based on classical physiological and pharmacological experiments using 
skeletal or smooth muscle preparations, or submandibular salivary glands, and combi-
nations of adrenoceptor or acetylcholine receptor agonists and antagonists. During the 
following decades, classical receptor theory was developed from Langley´s contribution 
into basic pharmacology notions such as affinity and efficacy in drug action (Furchgott, 
1964). The 1960s and 1970s witnessed the beginning of a fruitful merge between bio-
chemistry and pharmacology with prominent figures like Sutherland, Krebs and Rodbell, 
who focused their attention on the molecular basis of hormone and drug action. This led 
to a series of seminal discoveries that were to shape all further work in the field of cell 
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signalling. Rall and Sutherland revealed that hormones such as epinephrine and glucagon 
interact with receptors in liver cell membranes to elicit the production of the second mes-
senger cyclic-3´,5´-monophosphate (cAMP) by adenylyl cyclase (Rall & Sutherland, 1958). 
Later, Krebs discovered the cAMP-dependent protein kinase, which is the primary effector 
of cAMP action (Walsh et al., 1968). In 1971, Rodbell proposed the existence of a guanine 
nucleotide regulatory protein that serves as a transducer between hormone receptors 
and adenylyl cyclase (Rodbell et al., 1971). Gilman and colleagues subsequently demons-
trated the existence of this protein (Ross & Gilman, 1977), which was later purified and 
named Gs (Gilman, 1987). Retrospectively, these discoveries shed light on the first mole-
cular events that convey signalling from the outside to the inside of the cell.
Still in the 1970s the idea of a physical receptor was very controversial. Even Suther-
land, who was confident with the notion that receptors were physicochemical entities, 
manifested his doubts that they would be independent elements, distinct from adenylyl 
cyclases, which his own group had discovered (Lefkowitz, 2004). However, shortly after, 
the development of radiolabelling techniques allowed the first receptors to be identified. 
Chen-Yuan Lee purified and implemented the use of a-bungarotoxin, an extremely potent, 
pseudo-irreversible snake toxin that acts selectively on the nicotinic acetylcholine recep-
tor (Changeux et al., 1970). Using 125I-labeled a-bungarotoxin, during 1970 and 1971, 
three groups identified binding sites that reflected the nicotinic receptor in the electric 
organ of the electric eel (Snyder & Pasternak, 2003). Subsequently, ligand labelling tech-
niques allowed new insights into the properties of receptors. The coupling of receptors 
to G proteins in a ternary complex model (Ligand/Receptor/Gprotein) as well as the two 
different receptor states (high affinity, G protein-coupled and low, uncoupled) were esta-
blished (De Lean et al., 1980).  During the last half of the 1970´s and in the 1980´s several 
adrenergic receptors were purified in Robert Lefkowitz’s laboratory, where the GPCR field 
was initiated. These adrenergic receptors, that turned out to be single polypeptide chains, 
were successfully reconstituted in vesicles along with Gs and adenylyl cyclase and this sys-
tem proved sufficient for catecholamines to catalytically activate the enzyme (Lefkowitz, 
2004). In 1986, Brian Kobilka managed to clone the gene and the cDNA of the hamster´s 
b2 adrenoceptor through genetic library screening (Kobilka et al., 1987). Surprisingly, the 
gene did not have any introns, a feature later found for other many other GPCRs such 
as the a1-adrenergic, muscarinic or dopamine receptors. Also, unanticipatedly, the b2-
adrenoceptor shared sequence homology and a predicted 7TM architecture with the vi-
sual pigment rhodopsin, also coupled to G proteins.  This was a key finding leading to the 
notion of the existence of a GPCR family. Since then, a growing number of receptors were 
cloned and identified based on suspected or serendipitous homology with already-cloned 
members of the family. Today GPCRs form a vast –the largest- family of receptors with 
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over 800 genes that include receptors for many hormones, neurotransmitters, chemoki-
nes and calcium ions, as well as sensory receptors for various odorants, bitter and sweet 
taste and even photons of light. Not only do GPCR regulate many physiological processes, 
but drugs that target these receptors — either directly or indirectly — account for most of 
the medicines sold worldwide. However, to date, the functional identity and endogenous 
ligands of many of the receptors in this family remains unknown, and these are referred 
to as orphan receptors.   
Figure I1. G protein coupled receptors (GPCR). New 
Scientist cover (15/01/2005) portraying GPCR as The 
Magnificent Seven. Image: Karina Åberg Sakmar, sak-
mark@me.com.                                                                              
b. Functional and structural features of GPCR
Despite the remarkable chemical diversity of the activating ligands and the clear 
differences in receptor amino acid sequences, all GPCRs are predicted to share a common 
three-dimensional fold consisting of seven transmembrane helices linked by alternating 
intracellular and extracellular loops. The many proteins that belong to the GPCR super-
family can in turn be grouped into three different families (A, B and C) on the basis of 
sequence similarity. Sequences within each family generally share over 25% sequence 
identity in the transmembrane core region, and a distinctive set of highly conserved resi-
dues and motifs. Among the three families, little similarity is evident beyond the predicted 
7TM architecture (Pierce et al., 2002). Family A is the largest group and includes, amongst 
others, the receptors for light (rhodopsin), adrenaline (adrenergic receptors) or odours. 
Family B contains only 25 members, all coupled to Gs and including the receptors for the 
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gastrointestinal peptide hormone family like glucagon, corticotropin-releasing hormone, 
calcitonin and parathyroid hormone. Family C is also relatively small, and comprises re-
ceptors with a very large extracellular amino terminus including the metabotropic glu-
tamate receptor family, the GABAB receptor, and the calcium-sensing receptor, as well as 
some taste receptors. 
GPCRs bind heterotrimeric Gabg proteins, their intracellular partners and the first 
elements of the cascade initiated upon activation of the receptor. Agonist binding to the re-
ceptor seems to involve rearrangements of helices 6 and 3. A recent structure of the GPCR 
rhodopsin in a constitutively active state and comparison with the structure of ground-
state rhodopsin suggests that rotation of transmembrane helix 6 is the critical conforma-
tional change in activation (Standfuss et al., 2011). These was further confirmed by the 
crystal structure of an activated b1 adrenergic receptor in complex with Gαi (Rasmussen 
et al., 2011). Activated receptors can interact with the heterotrimeric G protein and act as 
a GEF (guanine nucleotide exchange factor) promoting GDP dissociation, and GTP binding 
and activation. The activated heterotrimer dissociates into a GTP-bound α subunit and a 
βγ dimer, both of which have an independent capacity to regulate an ever-expanding list of 
independent effectors. Hydrolysis of GTP to GDP, a process known to be modulated by RGS 
(regulator of G-protein signalling) proteins, causes re-association of the heterotrimer and 
termination of the activation cycle. However, a report has challenged the current model of 
a physical dissociation of α from βγ upon activation, since it was shown that non dissocia-
ble heterotrimeric G proteins could also initiate signalling (Klein et al., 2000) . 
GPCRs have traditionally been considered monomeric membrane proteins but se-
veral lines of evidence obtained during the last two decades suggest that GPCRs can also 
form homo- and heterodimers. Assembly of different types of GPCRs into dimers would 
then create receptor complexes with unique biochemical and functional characteristics 
(Pin et al., 2007). However, the existence of such receptor dimers in native tissues remains 
uncertain because of the difficulties in identifying GPCR complexes in a native environ-
ment. Most data showing the occurrence of dimers comes from energy transfer experi-
ments between two receptors [namely, fluorescence resonance energy transfer (FRET) 
and bioluminescence resonance energy transfer (BRET)] but there is discussion over the 
question of how close two receptors should be to be considered a dimer (Lohse, 2010). 
c. Heterotrimeric G proteins
Upon activation heterotrimeric G proteins are dissociated into the monomeric alpha 
subunit and beta/gamma dimeric complex due to the exchange of GDP for GTP in the nu-
cleotide binding pocket of Galpha. GTP-bound Ga proteins are then able to interact with 
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different effectors thereby initiating an extensive number of cellular functions (Fig. I2). 
Besides, free bg dimeric complex also binds a plethora of effectors leading to the activa-
tion of alternative pathways.     
Figure I2. GPCR activation cycle. A huge diversity of ligands bind and activate GPCRs. In turn, receptors ac-
tivate heterotrimeric G proteins by promoting GDP to GTP exchange in the Ga subunit and dissociation from 
the bg subunit. Both Ga and bg initiate signalling through different effectors.                                                               
Despite the size and diversity of the GPCR superfamily, there are a relatively small 
number of G proteins to initiate a large number of different intracellular signalling casca-
des. In the human genome 35 genes encode G proteins, 16 of which correspond to a-subu-
nits, five to b and 14 to g (Milligan & Kostenis, 2006). On the basis of sequence similarity, 
the Ga subunits have been divided into five different families (Gs, Gi, Gαq, G12(Simon et 
al., 1991) and the newly discovered Gv (Oka et al., 2009)) and this classification has served 
to define both receptor and effector coupling. Since the signal transducing properties of 
the various possible bg combinations do not appear to radically differ from one another, 
these classes are defined according to the isoform of their a subunit (Wettschureck & 
Offermanns, 2005).
While most GPCRs are able to activate more than one Ga subtype, often they also 
show a clear preference for one subtype over another (Gudermann et al., 1997). The 
functional selectivity of the receptor towards a certain subtype of Galpha is determined 
by the specific conformation of the GPCR´s GEF domain that is stabilised by the ligand. For 
instance, b adrenergic receptors couple to Gs, muscarinic M1/M3/M5 receptors couple 
to Gαq/11 whereas muscarinic M2/M4 receptors couple to Gi. However, more than one 
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conformation can be stabilised which results in the activation of more than one subtype. 
Notable examples of this are G12/13-cupled GPCRs that are also capable of coupling to 
other G proteins, often Gαq/11. Also, if the availability of the preferred subtype is low, the 
activation of other isoform can occur and, also, receptor phosphorylation in internal loops 
due to feedback loops can result in G protein preference switch. 
The Gs-initiated cascade was the first cell signalling pathway to be described, and 
many key concepts, including that of second messenger, protein phosphorylation and sig-
nal transducers arouse from its characterization (Neves et al., 2002). The Gs family toge-
ther with the Gαi/o family share a same effector, the adenylyl cyclase (AC). While there are 
ten different AC gene products in mammals, each with subtle differences in tissue distribu-
tion and/or function, all catalyze the conversion of ATP into the second messenger cAMP, 
and all are directly stimulated by G-proteins of the Gαs class. Conversely, the interaction 
of Gαi/o and AC is inhibitory thus preventing the enzyme from generating cAMP. The level 
of cytosolic cAMP may then determine the activity of various ion channels, the Rap GEFS 
termed EPACs, as well as members of the Protein Kinase A (PKA) family (Milligan & Koste-
nis, 2006).  The Ga12/13 subclass activates three RhoGEFs (p115-RhoGEF, PDZ-RhoGEF, 
and LARG), that are responsible for the activation of the small GTPase Rho. Once bound 
to GTP, Rho can interact with a myriad of proteins responsible for cytoskeleton regulation 
such as the Rho-kinase (ROCK) (Milligan & Kostenis, 2006). The effectors of the Gαq/11 
pathway are the main subject of this introduction and will be covered in detail over the 
next section. No functional data has yet been gathered for the recently discovered Gv class.
Gbg subunits are also capable of binding to and activating a number of cellular pro-
teins with a particular relevance in Gαi/o-coupled GPCR signalling. The primary effectors 
of Gbg are various ion channels, such as G-protein-regulated Inwardly Rectifying K+ chan-
nels (GIRKs), P/Q- and N-type voltage-gated Ca2+ channels, as well as some isoforms of 
AC, PLCβ and Phosphoinositide-3-Kinase (PI3K) (Milligan & Kostenis, 2006).
d. GPCR regulation
In addition to the GTPase activity of Ga subunits, signalling via G protein-coupled re-
ceptors (GPCR) is classically terminated at the receptor level by a two-step mechanism: a 
GPCR kinase (GRK) phosphorylates the active receptor, converting it into a target for high 
affinity binding of arrestins. Bound arrestins shield the cytoplasmatic surface of the recep-
tor, precluding G protein binding and activation (Wilden, 1995). As a result of arrestin re-
cruitment, phosphorylated receptors are also targeted for clathrin-mediated endocytosis, 
a process that serves to resensitise and recycle receptors back to the plasma membrane. 
An additional regulatory mechanism involves a negative feedback loop from second mes-
senger-activated kinases (PKA or PKC) that phosphorylate GPCRs, thus uncoupling them 
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from G proteins. In contrast to GRK-mediated phosphorylation, there is no evidence that 
these kinases promote arrestin binding to the receptor. Alternatively, there are reports 
showing the occurrence of phosphorylation-independent events of GPCR desensitisation 
that can be mediated by recruitment of GRKs and also RGS proteins (Ferguson, 2007). 
Mammals express seven GRKs (GRK1–GRK7) and four arrestin isoforms, of which 
GRK1, GRK7, arrestin1 and arrestin4 are only found in the visual system. Of the remaining 
GRK and arrestin proteins, GRK2, GRK3, GRK5, GRK6, arrestin2 (β-arrestin1) and arres-
tin3 (β-arrestin2) are ubiquitously expressed (Magalhaes et al., 2012). GRKs are compri-
sed of three functional domains: an amino-terminal regulator of G-protein signalling (RGS) 
homology (RH) domain, a central catalytic domain and a carboxyl-terminal membrane-
targeting domain. GRKs are targeted towards the plasma membrane to phosphorylate 
serine and threonine residues within the third intracellular loop and carboxyl-terminal 
tail domains of activated receptors. Both GRK2 and GRK3 encode pleckstrin homology 
domains that allow association with the Gbg subunit as well as with phosphatidylinositol 
4,5-bisphosphate. Also, their RH domains, but not that of other GRKs, have been involved 
in Gαq binding and sequestering (Carman et al., 1999b). Indeed, GRK2/3 display an addi-
tional level of negative regulation on GPCR signalling; besides phosphorylation and des-
ensitisation of the receptor it also directly binds Gαq and displaces it from receptor and 
effector binding complexes (discussed in section 5i).  
As mentioned above, GRK-mediated phosphorylation promotes the binding of 
β-arrestins, which function as endocytic adaptor proteins that facilitate the targeting of 
receptors for clathrin-mediated endocytosis (Ribas et al., 2007) (Fig. I3). Both β-arrestin1 
and β-arrestin2 specifically bind to the clathrin heavy chain and to b2-adaptin subunit of 
the clathrin adaptor protein complex AP2 to facilitate endocytosis (Goodman et al., 1996). 
In addition, Src-mediated phosphorylation of b2-adaptin regulates the dissociation of the 
b2-adaptin/β-arrestin complex (Zimmerman et al., 2009). Thus, clathrin-coated pits inva-
ginate inwards and pinch off to form a clathrin-coated vesicle in a process that requires 
the GTPase dynamin. Several clathrin-independent pathways of endocytosis also exist, 
involving lipid rafts and caveolin-enriched domains, although the precise mechanisms 
and structural components involved in these pathways are not well understood. Interna-
lised receptors, as any other endocytic cargo, follow two different endocytic routes lea-
ding to either degradation or dephosphorylation and recycling back to the plasma mem-
brane. Endosomal trafficking is controlled by several small GTP-binding proteins of the 
Ras superfamily named Rab proteins (Fig. I3). Following GPCR internalization into early 
RAB5-containing endosomes, they can rapidly recycle back to the plasma membrane by 
a RAB4-mediated process, traffic to the recycling compartment that contains RAB11A or 
remain in endosomes, which mature into multivesicular bodies (MVBs) and late endoso-
mes. Early-to-late endosome maturation involves the acquisition of RAB7 and the removal 
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of recycling endosomal components. Fusion of late endosomes and MVBs with lysosomes 
carrying proteolytic enzymes results in cargo degradation (Sorkin & Von Zastrow, 2009). 
Also, receptor ubiquitylation serves as a chlatrin-coated pit targeting signal and plays a 
key role in lysosomal targeting (Hislop & Von Zastrow, 2010). β-arrestins bind MDM2, an 
E3 ubiquitin ligase best known for its role in regulating the tumor suppressor p53. When 
a receptor such as b2AR or the vasopressin receptor is stimulated, it binds β-arrestin, trig-
gering MDM2-mediated ubiquitination of the β-arrestin (Shenoy et al., 2001). This ubiqui-
tination step is necessary for β-arrestin to perform its adaptor role in clathrin-mediated 
endocytosis, although the mechanisms remain to be elucidated.
Figure I3. GPCR deactivation cycle. Activated GPCR is phosphorylated by GRKs on the internal loops. Phos-
phorylated residues are recognised by arrestins that, together with AP2, promote clathrin-mediated recep-
tor internalisation into Rab5-containing vesicles. These can progress into Rab7-containing multivesicular 
bodies and degradation, or into Rab11A-containing vesicles to recycle back to the plasma membrane.             
Endocytosis is an important cellular mechanism to attenuate signal strength and 
duration. The reduction of physically available receptors for ligand binding leads to a ra-
pid decay in signal and allows for subsequent inputs to be rapidly processed. Failure to 
undergo desensitisation and the resulting continuous signalling is found in many types 
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of cancer (Lappano & Maggiolini, 2011). However, mounting evidence supports the occu-
rrence of sustained signalling in endosomes, which act as important signalling platforms. 
It is proposed that the type of signalling displayed at the endosomes can either be equi-
valent to plasma membrane signalling, or interestingly, it can also be exclusive for the-
se compartments.  In this novel type of signalling, b-arrestin as a multidomain scaffold 
protein that can bind an ever-expanding array of signalling molecules, plays a key role in 
the initiation of many different pathways both at the plasma membrane and within the 
endosomes. 
e. Relative contribution of G proteins and β-arrestins in GPCR            
signalling
The classical model for GPCR action involves G protein-mediated signal transduction 
and desensitisation by GRKs/b-arrestins. For decades, this understanding has disregar-
ded b-arrestins as mere regulators instead of active players in GPCRs signalling. Over the 
last few years there has been a new appreciation of the capacity of β-arrestins to act as 
multifunctional adaptor proteins that have the ability to signal through multiple media-
tors such as mitogen-activated protein kinases (MAPKs), Src, nuclear factor-κB (NF-κB) 
and phosphoinositide 3-kinase (PI3K). The action of G proteins and b-arrestin is diverse 
and are often spatially and temporarily segregated. For instance, the action of G protein/b-
arrestin towards the activation of ERK1/2 by the angiotensin II receptor AT1 is additive but 
differs in kinetics, timeframe and location (Ahn et al., 2004). Upon stimulation of the AT1A 
receptor, ERK1/2 is immediately, but transiently, activated via the G protein-dependent 
pathway, whereas β-arrestin2-mediated ERK1/2 activation is relatively slow but persis-
tent. Interestingly, G protein-activated ERK is found in the nucleus whereas it localises in 
the cytoplasm upon b-arrestin activation. This localisation difference opens new avenues 
towards the characterization of differential substrates, especially in the cytoplasm where 
ERK targets have been much less scrutinised. Additionally, mutational studies have deter-
mined the independence of both pathways. Mutant versions of the angiotensin AT1A and 
b2A receptor are unable to couple to G proteins while still correctly recruiting β-arrestins 
(DeWire et al., 2007).
Upon the characterization of b-arrestins as important signalling nodes, the action 
of the most known GPCRs is now being revisited in an attempt to characterise the rela-
tive contribution of G protein versus b-arrestin for a given response. It seems that the 
activation strength of one or the other pathway is not always balanced and depends on 
the stimulus, receptor and cell type. This phenomenon has been referred to as “biased 
agonism” to describe the preference of a certain ligand (biased ligand) or receptor (biased 
receptor) towards one of the aforementioned routes. A growing number of examples of 
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biased agonism have been described in the last few years and it is being actively studied 
to improve the efficacy of pharmacological therapies. To date, β-arrestin-biased agonists 
have been chemically developed for the angiotensin AT1A, b1 adrenergic and vasopressin 
2 receptors (Rajagopal et al., 2010). In all cases, the impaired ability to activate G protein 
does not affect b-arrestin mediated responses. In a naturally occurring example of biased 
agonism, the chemokine receptor CCR7 binds to two different ligands. One ligand, ter-
med ELC/CCL19, can activate both G protein and β-arrestin signalling, and another ligand 
(SLC/CCL21) activates only G protein signalling and does not recruit β-arrestins (Kohout 
et al., 2004). However, in this system the independence of each response is not as clear as 
with synthetic ligands since b-arrestin activity depends upon G protein activation.
It is also noteworthy that the resulting functional and physiological effects of these 
pathways are usually different and, occasionally, they can antagonise each other. This is 
especially well illustrated in the heart, where Gαq is a known initiator of cardio-damaging 
cascades that result in hypertrophy and heart failure (see section 6) and b-arrestin seems 
to start cardioprotective responses (Noma et al., 2007). Mechanical stress can activate 
the angiotensin AT1 receptor without the need of its natural ligand through a β-arrestin-
biased mechanism. Rakesh et al (2010) reported that mechanical stretch selectively ac-
tivates the ERK1/2 pathway through β-arrestin, with no signs of G protein activation. 
This stimulus also led to receptor phosphorylation and internalisation as well as to EGFR 
transactivation and Akt phosphorylation (Rakesh et al., 2010). These effects mimic those 
produced by the chemically synthesised AT1R biased agonist, SII, and pose a novel mecha-
nism by which the heart responds to acute challenges by activating survival pathways in a 
β-arrestin-biased manner. The effect of biased agonists might be a promising therapeutic 
tool for treating cardiovascular disease. Recently, an angiotensinII agonist that competiti-
vely antagonises with G protein signalling, but promotes b-arrestin recruitment and ERK 
phosphorylation, has been shown to reduce arterial pressure, increase contractility and 
improve cardiac performance (Violin et al., 2010).  
  
2. THE Gαq/11 FAMILY
The Gαq family of G proteins were initially identified through affinity purification 
and molecular cloning strategies (Hubbard & Hepler, 2006). There are four family mem-
bers; Gαq and Gα11 are ubiquitously expressed, Ga14 is found in kidney, liver and lung, 
and Ga15/16 (mouse/human orthologues, respectively) is only expressed in hematopoie-
tic cells. Gαq is the most widely studied member of the family and will be the main focus 
of this introduction. 
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Gαq has been shown to canonically activate the b-isoforms of phospholipase C 
(PLCβ), their major downstream effectors (Rhee, 2001). Subsequently, membrane-bound 
PIP2 is hydrolized into diacylglycerol and inositol-1,4,5-triphosphate leading to the acti-
vation of conventional and novel protein kinase C (PKC) isoforms and to the mobilization 
of internal Ca2+, respectively. However, to date Gαq is known to interact with more than 
20 proteins and the real complexity of Gαq pathways, driven by interactions between ac-
tivated G protein and different effectors, is yet very much at its infancy. A crucial study 
performed by Golebiewska et al (2006) revealed the existence of distinct preassembled 
Gαq signalling complexes and showed independent binding of Gαq to two different effec-
tors (PLCβ and PI3K) in the same cellular scenario. This was in agreement with the finding 
that PLCβ cannot account for all of Gαq-mediated cellular functions since the estimated 
Gαq molecules expressed in a cell significantly outnumbers those of PLCβ (Golebiewska & 
Scarlata, 2008). Thus, a growing body of evidence suggests alternative Gαq effectors that 
are responsible for some PLCβ-independent Gαq functions. Such is the case of p63RhoGEF 
(Lutz et al., 2007), that directly binds to Gαq/11 linking GPCRs and RhoA activation. There 
also seems to be a competitive relationship between PLCβ and p63RhoGEF for binding 
to Gαq which suggests the existence of alternative and mutually exclusive Gαq-initiated 
pathways (Lutz et al., 2005). Most recently we have described a novel signalling axis for 
the activation of ERK5 by Gq-coupled GPCRs that is independent of the activation of PLCβ. 
This pathway, which relies upon the interaction between Gαq and two novel effectors 
(PKCζ and MEK5), will be covered in detail in section 5, together with all known Gαq-
dependent signalling.
The Ga subunit structures reveal a conserved protein fold comprising a GTPase do-
main and a helical domain (Oldham & Hamm, 2008). The GTPase domain is similar to 
that of other GTP-binding proteins, including monomeric small GTPases and translational 
elongation factors (Mizuno & Itoh, 2009). The GTPase domain of Gαq participates in the 
hydrolysis of GTP to GDP and is involved in binding the Gbg subunit, GPCRs and effectors. 
Amongst the most highly conserved sequences of this domain are five loops containing 
the consensus sequences for guanine nucleotide binding and also three flexible loops (ter-
med switches I, II and III) that undergo important conformational changes between the 
GDP/GTP-bound forms of the protein. The helical domain is composed of six a-helices 
that form a lid over the nucleotide-binding site. This domain is involved in increasing the 
affinity of Ga for guanine nucleotides and increasing intrinsic GTP hydrolysis activity of 
the protein (Echeverria et al., 2000). Since this is the most dissimilar domain amongst the 
Ga families it might also play certain role in effector specificity. 
Not much structural information on the two remaining regions of Ga subunits, the 
N- and C-terminus, could be gathered from crystal structures as they were disordered 
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or removed. Both termini are essential for receptor specificity, interaction with the Gbg 
subunit and for membrane targeting of the G protein. All Ga subunits studied to date are 
lipid-modified at their N-terminus, and all except Gat contain palmitate, a post translatio-
nally characteristic of transmembrane and peripheral membrane proteins. Gαq is dually 
palmitoylated at adjacent cysteines (C9 and C10) (Linder et al., 1993). Fatty acid modifica-
tion mediates membrane attachment and targeting, promotes interactions with proteins 
and lipids, and even modulates enzymatic activity of target proteins. Consistently, some 
studies have shown that receptor stimulation promotes palmitate turnover on Gαq (Sta-
nislaus et al., 1997). Both the palmitoylation and the interaction with the Gaq subunit, 
which provides some lipid itself (Gg is prenylated), are key determinants for membrane 
localisation of the G protein (Wedegaertner et al., 1993; Wise et al., 1997). 
a. Structural determinants for Gαq-effector interactions
The effector recognition site in Ga proteins is formed almost entirely of the region 
extending from the C-terminal half of a2 (Switch II) together with the a3 helix and its 
junction with the b5 strand (Sprang et al., 2007). Since the structure of these regions is 
well conserved amongst the different Ga families it is assumed that effector specificity is 
mostly determined by the aminoacid sequence (Oldham & E. Hamm, 2006). Indeed, as re-
vealed by extensive mutagenesis analysis and crystalised structures, within the same Ga 
family, different subsets of residues are known to activate different effectors. This implies 
that although effectors are thought to be mutually exclusive and to compete for binding to 
the effector binding site (Carman et al., 1999b; Lutz et al., 2005), the specific determinants 
of these interactions are different. 
In all crystalised structures of G protein-effector complexes, a general binding do-
main within the effectors has been identified. A hydrophobic side chain of the effector 
would be inserted into the N-terminus of the a2 (switch II) and a3 helices within the G 
protein. Besides, effector specificity within the same Ga protein is achieved through addi-
tional contacts with the a2/b4 and a3/b5 loops. Specifically, available crystal structures 
of Gαq in complex with three different partners (PLCβ3 (Waldo et al., 2010a), p63RhoGEF 
(Lutz et al., 2007) and GRK2 (Tesmer et al., 2005)) shed light on the effector-Gαq binding 
surfaces. Comparison of the structures for PLCβ and p63RhoGEF reveals that both effec-
tors independently evolved a Gαq-binding interface with essentially identical residues. 
This Gαq-binding surface comprises a helix-turn-helix grafted onto the end of a DH/PH 
cassette to bind the a3/Sw2 declivity of Gαq (Waldo et al., 2010a). The aminoacid sequen-
ce and the helix-turn-helix motif are not conserved in the rest of the reported effectors for 
other G proteins, except for the hydrophobic character of the region (Ross, 2011). Also, 
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the regulator GRK2 forms an effector-like interaction with Gαq in a very similar fashion to 
PLCβ3 and p63RhoGEF, and different to the regulators of G protein signalling (RGS) pro-
teins (Tesmer et al., 2005). Indeed, RGS proteins have been shown to bind into high order 
G protein-effector complexes without competing for the effector binding site, but instead 
allosterically inhibiting effector association (Shankaranarayanan et al., 2008) (see section 
2c).
b. Effector activation mechanisms
The mechanisms for effector activation by Ga proteins are diverse. For instance, Gas 
acts as both allosteric activator and inhibitor of adenylyl cyclase, and Gαi is an allosteric 
inhibitor. In the activation of GMP phosphodiesterase by Gαt, the G protein sequesters an 
inhibitory subunit of the effector (Sprang et al., 2007). As for Gαq, the effector-activation 
mechanism reported for PLCβ and p63rhoGEF seems to be similar. The activity of both 
proteins is promoted upon Gαq binding by the relief of an autoinhibitory loop buried wi-
thin an active region of the effector and, in turn, this domain also participates in the acti-
vation of the G protein (Lyon et al., 2011; Shankaranarayanan et al., 2010). In the case of 
RhoGEFs, they contain a catalytic Dbl homology (DH) domain that is immediately followed 
by a pleckstrin homology (PH) domain (Rossman et al., 2005). In an inactive state, the PH 
domain inhibits the intrinsic GEF activity of the DHdomain (Welch et al., 2002) and this 
constrain is released by interactions with the plasma membrane and activator proteins 
like Gαq. Similarly, the active site of PLC-b3 is occluded by a poorly conserved loop na-
med X/Y linker which is presumably forced out by the surface of the plasma membrane 
coupled to the engagement of Gαq (Waldo et al., 2010a). Despite membrane targeting is 
believed to be an important component for the activation of some effectors, especially in 
the case of RhoGEFs, both PLCβ and p63rhoGEF reside basally at the plasma membrane, 
so the activation mechanism is proposed to be simple allosterism.  
c. Structural basis for Gαq deactivation
Gαq can be deactivated by the enhancement of its intrinsic GTPase activity by RGS 
proteins (GTPase-activating proteins (GAPs)) as well as effectors such as PLCβ. 
The structure of Gαi in complex with RGS reveals that these proteins exert negati-
ve regulatory action by stabilising the transition state for GTP hydrolysis (Tesmer et al., 
1997). This structure has shown that the interaction footprints in G protein structure are 
primarily located around the switch I/II, from aminoacids 180 to 220, a region that is 
supposed not to involve effector binding. Additionally, the structure of Gαq/PLCβ3 has 
contributed to map out the binding region for GAPs specifically in Gαq. The mechanism 
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of the interaction, referred to as kinetic sacaffolding (Waldo et al., 2010a), involves rapid 
activation of PLCβ which, in parallel, deactivates the G protein by promoting GTP hydroly-
sis. This ancient mechanism provides a structural basis for rapid and transient activation 
of the G protein. Indeed it was found that both PLCβ and RGS proteins action on Gαq is 
very similar. Thus, the Gαq surface involved in engaging the GAP function of PLCβ, mostly 
the switch I and the N terminal part of the switch II, is similar to the reported contacts for 
RGS proteins (Ross, 2011). Although there is no sequence similarity between PLCβ and 
RGS proteins, they both carry flexible loops that place asparagines to stabilize residues 
in Gα that are important for GTP hydrolysis (Ross, 2011). These residues, glutamine 209 
and arginine 183, if mutated lead to constitutive activation of the G protein that is unable 
to hydrolise GTP. Mutation on Gln209 has been recurrently reported as a frequent somatic 
mutation in uveal melanoma and blue navi (Raamsdonk et al., 2008).
Figure I4. Gαq structure. A) Linear representation of Gαq sequence with corresponding three-dimensional 
motifs and binding regions. B, C) Crystal structure of Gαq (PDB: 2BCJ) highlighting the conformational chan-
ge-susceptible switch regions (B) or the effectors/RGS proteins contacts.                                                                         
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3. PROTEIN KINASE C
a. General features
The protein kinase C (PKC) was initially identified as a family of serine/threonine ki-
nases that transduce the myriad of signals promoting lipid hydrolysis. The importance of 
this protein family in signalling was exemplified by the diverse transduction mechanisms 
that result in the generation of the main protein kinase C’s activator, diacylglycerol. Signals 
initiated from GPRCs, tyrosine kinase receptors, or non-receptor tyrosine kinases can cau-
se diacylglycerol production, either by activation of  phospholipase C or  phospholipase 
D to yield phosphatidic acid and then diacylglycerol (Newton, 1995). In addition, fatty 
acid generation by phospholipase a2 activation was shown to modulate protein kinase 
C activity. Thus, multiple receptor pathways feeding into several lipid pathways converge 
into second messenger-induced activation of protein kinase C. Also, phorbol esters, potent 
tumor promoters, can stimulate PKC activity and phosphatidylserine (PS), an acidic lipid 
located exclusively on the cytoplasmic face of membranes, is required by all PKC isozymes. 
In addition, some isozymes require calcium for optimal activity. However, the classical no-
tion for PKC activation was challenged in the light of novel reported family members that 
did not fulfill most of the premises above. 
To date, there are 12 members of the PKC family which are classified on the basis of 
structural and activation characteristics (Mackay & Twelves, 2007) (Fig. I5). Classical or 
conventional PKCs (cPKCs; PLCα, PLCβ1, PKXbIΙ and PKCg), which are calcium-dependent 
and activated by both PS and DAG; novel PKCs (nPKCs; PKCσ, PKCδ, PKCε, PKCη and PKCθ), 
which are calcium independent and regulated by DAG and PS; atypical PKCs (aPKCs; PKCζ 
and PKCλ), which are calcium independent and do not require DAG for activation, although 
PS can regulate their activity; and the PKN subfamily (PKN1, PKN2, and PKN3) that can 
also be regulated by PS.
The structure of all PKCs consists of a regulatory domain and a catalytic domain 
tethered together by a hinge region (Mellor & Parker, 1998) (Fig. I5). The regulatory do-
main located at the amino-terminus of PKCs contains C1 and C2 domains and a pseudo-
substrate region. The C1 domain is present in all of the isoforms of PKC and has a binding 
site for DAG and phorbol esters. This domain is functional and capable of binding DAG in 
both conventional and novel isoforms; however, atypical PKCs have a pseudo-C1 domain 
since it cannot bind DAG or phorbol esters. The C2 domain only displays calcium sensing 
properties in conventional PKCs although it is also present in novel isoforms. The pseudo-
substrate region, which is found in all classes of PKC, is a small sequence of amino acids 
that mimics a substrate and binds within the substrate-binding cavity in the catalytic do-
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main. It acts as an autoinhibitory loop in the inactive/basal state of the kinase since it 
lack critical serine/threonine phospho-acceptor residues and cannot be phosphorylated. 
Additionally, the PKN subfamily possess three leucine-zipper-like heptapeptide repeat 1 
domains (HR1) at their regulatory region, which bind Rho-GTP and regulate phosphoryla-
tion by phosphoinositide-dependent protein kinase 1 (PDK1)(Diaz-Meco & Moscat, 2012).
The catalytic (kinase) domain is highly conserved among the different isoforms, as 
well as, to a lesser degree, between the catalytic regions of other serine/threonine kina-
ses. The kinase domain is usually phosphorylated and this is supposed to be essential 
for its function. Conventional and novel PKCs have three phosphorylation sites located 
on specific motifs (the activation loop, the turn motif, and the hydrophobic motif). The 
atypical PKCs and PKN are not phosphorylated on the hydrophobic motif where the pre-
sence of a negatively charged glutamic acid in place of a serine mimics a phosphorylated 
residue. It seems that phosphorylation events are essential for the activity of all PKCs and 
require the upstream kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1) to 
trans-phosphorylate the activation loop (Balendran et al., 2000).
Figure I5. The PKC family. Graphical representation of the four subfamilies of the PKC family with different 
domains, binding regions within the regulatory domain and phosphorylation sites within the kinase do-
main.                                                                                                                                                                                                          
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The current model for the activation of PKCs proposes that this happens through di-
fferent mechanisms involving phosphorylation and allosteric interactions (Disatnik et al., 
1994). In an inactive state the pseudosubstrate region, which is isoform-specific, is buried 
within the active site of the kinase. The removal of this loop is thought to be preceded by a 
series of maturation steps through phosphorylation of the kinase domain on three (cPKC 
and nPKC) or two (aPKC and PKN) residues (Newton, 2003). These steps seem to be ne-
cessary for full activation of the PKC family. Two upstream kinases have been reported to 
play this role. One is PDK1 that phosphorylates the activation loop in the kinase domain, 
and the other is the mammalian target of rapamycin 2 complex (mTORC2), which regu-
lates phosphorylation of the turn and hydrophobic motifs (when present) (Diaz-Meco & 
Moscat, 2012).
The activation step takes place in response to binding of lipid second messengers, 
allosteric effectors, or both, to specific domains at the regulatory region of the PKC. For 
conventional and novel PKC, increases in plasma membrane DAG levels trigger the mem-
brane recruitment and activation. Thus, allosteric interactions with the membrane seem 
to activate PKC, but they are thought to be contingent upon a previously phosphorylated 
kinase domain to occur. Other protein modifications, such as tyrosine phosphorylation or 
proteolysis, might also be critical factors in mediating PKC activation (Diaz-Meco & Mos-
cat, 2012).
The DAG-insensitive atypical PKCs have been suggested to respond to other lipids 
such as phosphatidylinositols, phosphatidic acid, arachidonic acid and ceramide (Moscat 
& Diaz-Meco, 2000). In addition, interaction with specific cellular partners might alter 
aPKC activity. For instance, the zinc-finger harboured in the C1 domain of aPKCs binds to 
Par-4 and this interation blocks PKC enzymatic activity (Díaz-Meco et al., 1996). The main 
site for aPKC modulation by adapters is the PB1 domain, which will be discussed in detail 
in the next section.
b. Atypical PKC zeta
The atypical protein kinase C (aPKC) subfamily of kinases is composed of two 
members, PKCζ and PLCλ/i. These proteins are highly related and they share an overall 
72% amino acid identity (Nishizuka, 1995). These kinases have been involved in several 
functions, namely proliferation/survival (Berra et al., 1995) and apoptosis (Díaz-Meco et 
al., 1996), glucose transport (Liu et al., 2006), inflammation (Diaz-Meco & Moscat, 2012), 
neuronal differentiation (Wooten, 1999) and in the control of cell polarity (Wu et al., 
2007). Additionally, the use of a PKCζ knockout mouse model (PKCζ-/-) has pinpointed a 
major role in the activation of the transcription factor NFκB (Leitges et al., 2001).
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The activation of PKCζ has been reported to involve several alternative or complemen-
tary mechanisms (Fig. I6). Standert et al. (2001) reported that insulin provokes increases 
in PKCζ enzymatic activity through PDK-1-dependent T410 loop phosphorylation, T560 
autophosphorylation, and phosphorylation-independent/conformational-dependent re-
lief of pseudosubstrate autoinhibition. Thus, it seems that there is a fraction of PKCζ acti-
vation that is not mediated by phosphorylation and represents an unforeseen mechanism 
for other PKCs. This was suggested after results indicating the phosphomimetic mutant 
of PKCζ (T410E/T560E) was still able to be further activated by insulin (Standaert et al., 
2001). In these lines, Graybill et al (2010) have recently published a mechanism for PKCζ 
activation mediated by an interaction with Par6. This was achieved by a specific interac-
tion involving the PB1 domains of both proteins, and the C2 domain of Par6, which results 
in the removal of the pseudosubstrate region from the catalytic site of PKCζ (Graybill et al., 
2012). This novel mechanism poses interesting questions on the diverse functions of PB1 
domains, which will be covered in detail below. Another phosphorylation-independent 
mechanism for PKCζ activation is caspase processing. It has been shown that a number of 
caspases (-3, -6, -7 and -8) process PKCζ to carboxyl-terminal fragments that are catalyti-
cally active (Smith et al., 2000). Caspase processing was found to be PKCζ-specific since 
the highly similar PLCλ lacks the caspase-processing sites. Stimulation with TNFa in HeLa 
cells promotes PKCζ processing without increasing phosphorylation on T410. Thus, the 
free kinase domain was found to have higher catalytic activity than the holoenzyme but 
a shorter half life, which was even increased in phospho-deficient T410A mutants, due 
to ubiquitin-mediated proteasomal degradation (Smith et al., 2003). Finally, PKCζ is also 
known to function as a scaffold protein independently of its kinase activity. Diaz-Meco et 
al (2001) reported that PKCζ was a component of the EGF-initiated pathway for the activa-
tion of ERK5 through a direct interaction with MEK5 (see details below in this section). In 
this system, PKCζ kinase activity was speculated not to be required for this function since 
the T410A mutant was still able to activate ERK5 (Diaz-Meco & Moscat, 2001). However it 
remains unclear whether different activation mechanisms other than T410 phosphoryla-
tion are operating in this system. Taken together, these data illustrate the diversity of ac-
tivation mechanisms for PKCζ (Fig. I6) and indicate the need to determine the relative 
contribution of each of these mechanisms to a given function of the protein. 
The PKC family is known to display a relatively low substrate selectively which calls 
for additional regulation mechanism to confer a high-degree functional specificity. Indeed, 
the functionality of the aPKC family is highly dependent on accessory and adaptor pro-
teins. p62 provides a useful example to understand the role of these adaptors. This protein 
was isolated independently by two groups as a novel atypical PKC-interacting partner that 
binds to the first 126 amino acids upstream of the zinc finger domain (Puls et al., 1997). 
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Early evidence suggested that p62 provides a scaffold linking the aPKCs to the tumour 
necrosis factor α (TNFα) and interleukin-1 (IL-1) receptor signalling complexes for the 
activation of the transcription factor NFκB (Sanz et al., 1999). p62 acted as an adaptor 
since neither did it affect the catalytic activity of the aPKC nor was it a substrate for the 
kinase. This scaffold role was found to profoundly affect the function of both PKCζ and 
PLCλ. The site of p62 to which the aPCKs bind has been narrowed down to a short stretch 
of acidic amino acids termed AID (for atypical PKC-interacting domain). This domain was 
later found to be present in a plethora of other signalling proteins (including aPKC) and to 
form an intrincated protein-protein interaction network. This distinct structural domain 
was named Phox⁄Bem 1 (PB1) as it was originally found in the phagocyte oxidase (phox) 
activator p67phox and the yeast polarity protein Bem1 (Ito et al., 2001). 
Figure I6. Different activation mechanisms of PKCζ. (A) PDK1-mediated phosphorylation at Thr410. (B) 
Autophosphorylation at Thr560. (C) Conformation-dependent pseudosubstrate release by PB1-PB1 inte-
ractions. (D) Caspase-dependent cleavage of the N-terminus.                                                                                         
The PB1 domain is a protein-protein interaction module conserved in animals, fungi, 
amoeba and plants. The proteins harbouring this domain, that characteristically adopt a 
ubiquitin-like b-grasp fold, can be classified into 3 types: PB1-type I proteins are defined 
by an acidic motif (OPCA);  PB1-type II are defined by a predominantly basic motif invaria-
bly governed by a lysine on the first b strand; and PB1-type I/II proteins have  both types 
(Sumimoto et al., 2007) (Fig. I7). Homo- and heterodimerisation between PB1 proteins 
are established through electrostatic interactions between the basic residues of type II 
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and the acidic residues of type I. The human genome contains at least 13 PB1 domain-
harbouring proteins including NADPH oxidase subunits (p67phox and p40phox), atypical 
PKC signalling modules (PKCζ, PLCλ, Par6, p62), mitogen-activated kinases (MEK5 and its 
upstream kinase MEKK2), or the scaffold protein Nbr1.
 
Figure I7. PB1 domains. Graphical representation of the three different types of PB1 domains. PB1-type I 
proteins harbour an acidic motif (OPCA), PB1-type II harbour a predominantly basic motif invariably gover-
ned by a lysine on the first b strand and PB1-type I/II that have both types of motifs.                                               
The PB1 domain in PKCζ is known to participate in several functions through spe-
cific interactions with different PB1-harbouring protein partners (Fig. I8). Roughly, these 
can be divided into three main roles; the control of cell polarity through interactions with 
Par6 proteins, the control of NFκB function and others through an interaction with p62, 
and finally, the control of MAPK activation through interactions with MEK5. 
Animal cell polarisation involves 6 partition defective (par) gene products, including 
adaptor proteins Par6 and Par3. From studies carried out in Caenorhabditis elegans it was 
established that the essential complex for polarity was formed between Par-6, Par-3 and 
PKC-3, the atypical PKC homolog (Macara, 2004). Both aPKC and Par-6 dimerise through 
their PB1 domains; aPKC acting as a type I (acidic) to interact with Par-6 type II domain 
(basic). Although, Par-3 does not have a PB1 domain, it is able to interact through other 
domains with aPKC and Par-6.  This complex seems to have a conserved function in pola-
rity from nematodes to mammals. Additionally, it also regulates tight junction formation 
and determines basal/apical polarity in mammalian epithelial cells (Noda et al., 2003). 
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An interaction between Par6 and PKCζ also seems to be crucial for Ras activated cystoske-
letal remodelling (Coghlan et al., 2000). It is possible that the novel activation mechanism 
for PKCζ involving PS displacement by Par6 (Graybill et al., 2012) accounts for some of the 
functions described above. 
The aPKC/p62 signalling platform, as mentioned above, is thought to participate 
mainly in NFκB-activation dependent processes. The pathways leading to the activation of 
NFκB are diverse. Both IL-1 and TNFa activation of NFκB rely on an interaction between 
p62 and a specific adaptor, RIP and TRAF6, respectively (Moscat & Diaz-Meco, 2000). This 
association links the activated receptor with PKCζ which is activated through an unknown 
mechanism and can then phosphorylate either IKK (NFκB upstream kinase) or the p65 
subunit of NFκB, depending on the tissue. Thus, active NFκB will be transported to the 
nucleus to promote the transcription of important survival genes (Moscat et al., 2009). A 
clear implication of the p62/aPKC complex has been reported for the regulation of allergic 
responses and asthma (Soloff et al., 2004). This interaction is required for the differentia-
tion of T cells through a sustained activation of NFκB and for the IL-4-mediated activation 
of the Jak1/STAT6 pathway (Moscat et al., 2006). Additionally, p62 and PKC participate 
in the retrograde activation of ERK5 in neurons which will be discussed in the next sec-
tion. It is noteworthy that p62 is a very polyvalent multidomain protein that is involved in 
cancer, autophagy and apoptosis (Moscat & Diaz-Meco, 2009). However, the requirement 
for aPKC/p62 interaction in these processes is not clearly established. This is the case 
for the characteristic cellular speckles in autophagy formed of aggregated proteins in the 
cytoplasm. There is preliminary evidence for an increase of p62 aggregates in the absence 
of aPKC/p62 interaction (Puls et al., 1997), but further evidence is required to determine 
aPKC function in autophagy. Also, the contribution of p62 and PKCζ to cancer progression 
and apoptosis is diverse and often they play opposing roles which suggest independent 
functions in these complex processes (Moscat et al., 2009). 
Another PB1-dominated process is the activation of the MAPK ERK5, which will 
be covered in detail in the next section. MEKK2 and MEKK3 are the upstream kinases of 
MEK5, which is in turn responsible for the phosphorylation of ERK5. Both MEKK2/3 and 
MEK5 harbour a PB1 domain through which they establish interactions that lead to the 
activation of MEK5. The PB1 domain in MEK5 is also capable of interacting with ERK5, 
which does not have a PB1 domain, resulting in the phosphorylation of the MAPK (Naka-
mura & Johnson, 2003; Nakamura et al., 2006). The involvement of PKCζ in this process 
became clear when it was reported that it directly interacts with MEK5 and is required for 
the activation of ERK5 by EGF (Diaz-Meco & Moscat, 2001). This interaction is also esta-
blished through PB1 domains and results in an enhancement of MEK5 kinase activity that 
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then becomes autophosphorylated. The activation of MEK5 in this system is likely due 
to allosteric effects of PKCζ binding, since the kinase activity of the latter is not required. 
More recently, we reported that this same signalling module was utilised by Gq-coupled 
GPCR to activate the ERK5 pathway (see section 5e).
 
Figure I8. PKCζ-PB1 domain functions. The PB1 domain of PKCζ participates in several functions through 
different protein-protein interactions: Control of cell polarity through interactions with Par6 proteins, the 
control of ERK5 activation through interactions with MEK5 and the control of NFκB and other functions 
through an interaction with p62.                                                                                                                                                    
4. MITOGEN-ACTIVATED KINASES
a. General features
Members of the family of mitogen-activated protein kinases (MAPKs) are proline-
targeted serine/threonine kinases that play an essential role in signalling through the 
modulation of gene transcription in the nucleus in response to changes in the cellular en-
vironment. MAPKs control key cellular functions, including proliferation, differentiation, 
migration and apoptosis, and participate in a number of disease states including chronic 
inflammation and cancer (Turjanski et al., 2007). In humans, there are at least 11 mem-
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bers of the MAPK superfamily, which can be divided into six groups based on sequen-
ce similarity: the extracellular signal-regulated protein kinases (ERK1 and ERK2); c-Jun 
N-terminal kinases (JNK1, JNK2, JNK3); p38s (p38a, p38b,p38g, p38d); ERK5 (ERK5); 
ERK3s (ERK3, p97 MAPK, ERK4) and ERK7s (ERK7, ERK8) (Pearson et al., 2001). Each 
subfamily of MAPKs can be stimulated by a separate protein kinase cascade that involves 
the sequential activation of a specific MAPK kinase kinase (MAPKKK) and a MAPK kinase 
(MAPKK), which in turn phosphorylates and activates downstream MAPKs (Fig. I9). For 
complete activation MAPK ought to be phosphorylated in two highly conserved residues, 
serine and threonine, located in the activation loop. It seems that specificity between di-
fferent subfamilies is achieved through an intercalated residue between the two phos-
phorylation sites; glutamic acid in ERK1/2 and ERK5 (TEY motif), glycine in p38 (TGY 
motif) and proline in the case of JNK (TPY motif) (Turjanski et al., 2007). These signalling 
modules have been conserved throughout evolution, from plants, fungi, nematodes and 
insects to mammals (Widmann et al., 1999). MAPK research has grown exponentially over 
the last two decades (more than 3000 articles published in 2012) to become a paradigma-
tic example of the cell signalling field.  
b. Activation of classical MAPKs by Gαq
The activation of Gαq/11 family of G proteins triggers different signals that have 
been implicated in the control of the ERK1/2, p38 and JNK cascades. 
Gαq-mediated PKC activation leads to ERK1/2 activation through both Ras-depen-
dent and Ras-independent mechanisms. PLCα can activate Raf-1 by direct phosphoryla-
tion (Kolch et al., 1993), and stimulation of ERK by the Gαq/11-coupled a1 adrenergic 
and M1 muscarinic receptors in fibroblasts can occur through a Raf-dependent, but Ras-
independent, mechanism that is blocked by PKC downregulation and mimicked by ove-
rexpression of PLCβ2 (Faure et al., 1994). In many cases, however, Gαq/11 activation cau-
ses ERK1/2 activation independently of PKC. Two of the most common PKC-alternative 
mechanisms are receptor transactivation and calcium-induced responses. In fibroblasts, 
shedding of the extracellular ligand HB-EGF is promoted upon stimulation of Gαq/11-
coupled receptors (endothelin-1 and a-thrombin receptors). Despite the fact that the 
MMP ADAM-9 mediates PKC-dependent HB-EGF cleavage in response to phorbol esters, 
the Gαq/11 effect, like that mediated by Gβγ subunits, apparently involves neither PKC 
nor ADAM-9 (Prenzel et al., in press). In cultured vascular smooth muscle cells, transacti-
vation of PDGF-B receptors apparently accounts for ERK activation in response to stimula-
tion of the Gαq/11-coupled angiotensin AT1a receptor (Linseman et al., 1995). Additiona-
lly, calcium-dependent mechanisms may play a role in Gαq/11-mediated ERK activation, 
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particularly in cells of neuronal origin. Gαq/11-dependent activation of the calcium- and 
cell adhesion-dependent focal adhesion kinase (FAK)-family member, Pyk2, leads to Ras- 
dependent ERK1/2 activation. In this context, intracellular calcium, released as a result 
of PLCβ-mediated inositol phosphate production, triggers Pyk2 autophosphorylation, re-
cruitment of the non-receptor tyrosine kinase c-Src, tyrosine phosphorylation of Shc, and 
Ras-dependent ERK1/2 activation (Dikic et al., 1996).
In vivo studies have also shown the involvement of Gαq in the activation of JNK (Mi-
namino et al., 2002). As it was the case for ERK1/2, diverse mechanisms operate in the 
activation of JNK downstream of Gq-coupled receptors. Both DAG- and calcium-mediated 
pathways can activate JNK, in a process that requires Src and Pyk2 activation, respectively, 
of Rac-1 or R-Ras. These monomeric GTPases activate specific MAP4K, such as MLK3, that 
lead to the initiation of the JNK cascade (Goldsmith & Dhanasekaran, 2007). Ask1 is the 
main MAPKKK in the activation of both JNK and p38 pathways by GPCRs. The activation 
mechanisms of p38 MAPK by Gq-coupled GPCRs are similar to those described for JNK. 
The release of DAG and calcium activates PKC that, in turn, activates Src. Subsequently, Src 
activates GEFs that will then promote GTP binding in monomeric G proteins. Two specific 
GEFs for Rac have been reported to be activated by Src: Tiam and Ras-GRF (Buchsbaum 
et al., 2002).
Figure I9. MAPK cascades. Mitogen-activated protein kinase (MAPK) cascades are phospho-relay systems 
in which a MAPK kinase kinase (MAPKKK) is phosphorylated and, in turn, phosphorylates a MAPK kinase 
(MAPKK), which leads to the phosphorylation of a MAPK. Main MAPK cascades (ERK1/2, p38, JNK, ERK5) 
are depicted here.                                                                                                                                                                              
c. The extracellular signal regulated kinase 5 (ERK5) MAPK
The ERK5 MAPK is classically activated by different stimuli like mitogens (EGF, 
granulocyte-colony-stimulating factor), cytokines (leukemia inhibitory factor, cardio-
trophin-1), and stress (Hayashi & Lee, 2004; Obara & Nakahata, 2010; Wang & Tournier, 
2006). Also, Gq-coupled GPCRs are known to activate ERK5 thereby  regulating c-jun ex-
pression through the activation of members of the MEF2 class of transcription factors 
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(Marinissen et al., 1999). However, because of the relative paucity of investigations on this 
pathway, there are fewer known upstream activators described for ERK5 compared to the 
other families (ERK1/2, p38 and JNK) of MAPK (Rose et al., 2010).
Although ERK5 is phophorylated in TEY, the same consensus motif as ERK1/2, it is 
structurally very different to the latter. ERK5 contains a unique loop-12 structure and an 
unusually large C terminal domain which confers this protein a large molecular weight 
(115KDa)(Hayashi & Lee, 2004). Hence, ERK5 is also known as big MAPK 1 (BMK1). The 
MAPK signalling module of ERK5 is composed of three sequentially activated kinases: ups-
tream kinases (MAPKKK) are MEKK2 and MEKK3 that activate MEK5 (MAPKK), which is 
the direct activator of ERK5. Indeed, a distinctive feature of this pathway is the high speci-
ficity conferred by MEK5 since ERK5 is its only known substrate. Thus, any signal conver-
ging into the activation of MEK5 will only result in the activation of ERK5. On the contrary, 
MEKK2 and MEKK3 are not specific for the ERK5 pathway for they are known activators 
of JNK and p38 (Deacon & Blank, 1999). Phosphorylated ERK5 has been reported to act on 
several nuclear substrates including the myocyte enhancer 2 (MEF2) family of transcrip-
tion factors, Sap1a (Ets-domain transcription factor), connexin 43 (a gap junction protein) 
or the pro-apoptotic protein Bad (Roberts et al., 2009) (Fig. I10). 
The activation mechanism of ERK5 illustrates a number of distinctive features of 
this kinase in comparison to the rest of MAPKs (Fig. I10). According to the classical view, 
inactive ERK5 resides in the cytoplasm and it translocates to the nucleus upon phos-
phorylation (Esparís-Ogando et al., 2002).  However, this does not seem to be always the 
case since nuclear localisation of ERK5 has been reported in unstimulated cells and also 
active MEKK2 has been shown to translocate to the nucleus, suggesting that ERK5 activa-
tion might also occur within this cellular compartment (Raviv et al., 2004). Additionally, 
the large C terminal region of ERK5 confers unique functional proprieties that are not 
found in any other MAPK. It is required for maximum activation of most ERK5 substrates 
and, most strikingly, this domain alone has the ability to increase transcriptional activi-
ty (Kasler et al., 2000). It is proposed that interactions of ERK5 C-Terminal domain with 
transcription factors increases their transcriptional activity up to 50-fold. The C terminal 
domain is known to fold over the kinase domain in an inactive conformation. Upon phos-
phorylation of the TEY motif, the kinase domain is activated and it transphosphorylates 
the C terminus that is then released. Although the precise dynamics of the activation are 
not well understood it seems that ERK5 would be able to display both functions (kinase 
and transcriptional) simultaneously in the nucleus. 
ERK5 characteristic pro-survival/anti-apoptotic function is involved in a number of 
important patho-physiological processes such as carcinogenesis, neuronal survival, en-
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dothelial integrity and cardiovascular function (specific involvement of ERK5 in the heart 
will be covered in 6c). Cancer is characterised by deregulated signalling and aberrant res-
ponse to mitogenic stimuli. As it is the case for all other MAPKs, ERK5 has been associa-
ted with various malignant properties of human cancers including augmented metastatic 
potential of prostate cancer, sustained growth of ErbB2-positive breast carcinomas and 
chemoresistance of breast cancer cells (Hayashi & Lee, 2004). Also, the overexpression of 
MEK5 correlates with bone metastasis possibly due to an increased de novo synthesis of 
matrix metalloproteinase 9 that degrades extracellular matrix thus facilitating the inva-
sion and spreading of cancer cells (Mehta et al., 2003). 
Figure I10. C l a s s i c a l 
ERK5 activation pathways. 
Ligands binding to tyrosi-
ne kinase receptors lead to 
activation of ERK5 by pro-
moting a dual phosphoryla-
tion on the kinase domain 
(TEY motif). Activated 
ERK5 phosphorylates a 
number of substrates. Au-
tophosphorylation of the 
long C-terminus promotes 
the transcriptional activa-
tion function.                            
Growth factors synthesised and released by target tissues promote survival of inner-
vating neurons. This retrograde survival response is initiated when growth factors bind 
receptors at nerve terminals which are internalised and transported via the endocytic ma-
chinery through the axon to the soma, where they activate different cascades. Neurotro-
phins are the growth factors involved in retrograde signalling and they act through recep-
tors termed Trks on the nerve terminals. It has been shown that ERK5, but not ERK1/2, 
is essential for this retrograde signalling and for neuronal survival (Watson et al., 2001). 
This process was found to be dependent on the PB1 domain-dominated interaction bet-
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ween p62 and aPKC (Samuels et al., 2001). Indeed, p62 was shown to establish an interac-
tion with TrkA and TRAF6 that promoted receptor internalisation and subsequent ERK5 
activation (Geetha & Wooten, 2003). 
The analysis of tissue-specific ERK5 knockout mice has suggested that this kinase 
is essential for the development and normal function of the endothelium. ERK5-null mice 
die at embryonic day 10 due to cardiovascular defects due to a failed maturation of cardiac 
vasculature. Indeed, cardiomyocyte-specific ERK5-KO mice develop normally whereas en-
dothelium-specific mice recapitulate the global knockout defects (Hayashi et al., 2004). 
Also, neuron-specific KO develop normally which, together with the rest of the knockout 
data, suggests that compensatory mechanisms operate in all tissues were ERK5 is acting 
except from the endothelium where it seems to be indispensable. Endothelial ERK5 is 
activated by stress and induces the phosphorylation and inactivation of the pro-apoptotic 
protein Bad which prevents its nuclear translocation and caspase 3 activation (Pi et al., 
2004). Interestingly, PKCζ is a known pro-apoptotic factor activated by shear flow stress 
in the endothelium which results in the down-regulation of ERK5-initiated eNOS pathway. 
PKCζ was reported to directly interact with and phosphorylate ERK5 on serine 486 there-
by inhibiting its transcriptional activity (Nigro et al., 2010). However, no evidence for the 
inhibition of ERK5 kinase activity was shown. Besides, the presence of p62 has been de-
termined crucial for this process (Kim et al., 2012). This negative regulation is a puzzling 
finding, possibly endothelium-specific, since PKCζ has been extensively shown by us (see 
section 5e, 6c and results) and others to be necessary for ERK5 activation by a number of 
stimuli (Diaz-Meco & Moscat, 2001; García-Hoz et al., 2010, 2012). However, it is clear that 
ERK5 function is highly interconnected to that of PKCζ and other PB1 domain proteins. 
Since PB1 domains are known to serve as signalling organising platforms it is likely that 
other proteins are present in the active complexes with ERK5. Thus, the description of the 
differential cellular determinants that account for the surprising opposing roles described 
above clearly deserves further investigation. 
ERK5 is one of the numerous proteins activated downstream of Gαq. All these pa-
thways emanating from the activated G protein rely on specific interactions between 
Galphaq and a myriad of cellular effectors. This subject will be covered in detail in the 
following section.
5. THE Gαq INTERACTOME
A number of cellular proteins have been reported to interact with Gαq. The effect on 
Gαq signalling achieved by these interactions can be activatory, if as a result of the inte-
raction Gαq signal is propagated or inhibitory, if the opposite effect is achieved and Gαq is 
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deactivated (Fig. I11). The effectors belong to the first type and are proteins whose activi-
ty depends on direct association with GTP-bound Galphaq in vivo in response to receptor 
activation. Other activatory interactors are scaffold molecules that organise and facilitate 
Gαq signalling. The second type of interactors are named regulators and they limit Gαq 
signalling by enhancing the GAP activity of the G protein or by sequestering it and preven-
ting effectors to interact. Although most Gαq functions are tied to the activation of one or 
more effectors, to date there still are Gαq-dependent processes for which no effector has 
yet been identified. Such is the case of the activation of the glycogen synthase kinase-3 
(GSK-3) promoted by Gαq independently of PLCβ (Fan et al., 2003). A brief description 
of most relevant Gαq functional interactions is included below and summarised in Figure 
I11.1.
Figure I11. Gαq effectors and regulators. Gαq versatile binding potential allows for a diverse functional 
activity. Gαq can bind to PLCβ (and adaptor proteins WDR36 and EBP50), p63RhoGEF, Btk, PI3K, PKCζ and 
MEK5. Gprotein-effector complexes are responsible for the activation of different pathways. The formation 
of these complexes is negatively regulated by GRK2 and RGS proteins.                                                                          
a. Gαq initiates lipid and calcium-dependent signalling through 
PLCβ
Phospholipase Cs are Ca2+-dependent enzymes that catalyze the hydrolysis of 
phosphatidylinositol 4,5 bisphosphate (PI(4,5)P
2
) to yield inositol 1,4,5 trisphosphate 
(Ins (1,4,5)P
3
) and diacylglycerol (DAG), which are important secondary cellular messen-
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gers (Rhee, 2001). These enzymes can be found at all stages in evolution from the simplest 
bacterial PLC consisting only of the catalytic domain which requires Ca2+ for activity to 
the complex multidomain organization of mammalian PLC (Drin & Scarlata, 2007). The 
PLCβ family has four isoforms (1–4) all of which can be stimulated directly (although with 
different potency) by both Gαq-GTP and Gβγ to hydrolyze PI(4,5)P
2
 and trigger inositol 
lipid and calcium-mobilising signalling (Rhee, 2001). The involvement of PLC activation 
in mobilization of intracellular Ca2+ and activation of protein kinase C in response to many 
GPCR ligands was elucidated in the 1970s and early 1980s (Harden et al., 2011). Later 
it was shown that PLCβ could be activated by GTP in cell-free preparations, however, it 
was not until 1991 that a recently discovered class of G proteins, the Gαq/11 family was 
reported to directly and specifically activate PLCβ isozymes ((Harden et al., 2011)and re-
ferences therein).
Signal transfer between Gαq and PLCβ is tightly regulated by these two proteins in 
a coordinated process of activation/deactivation. The particular structural properties of 
PLCβ confers it the ability to both be activated like an effector and to act on the G protein 
promoting its GAP activity and deactivation (Waldo et al., 2010b) (see section 2c). Thus, 
the capacity of Gα-subunits to hydrolyze GTP and therefore self-regulate their activation 
state is aided by PLCβ. On the other hand, controversial reports have put forward the 
possibility that Gαq protein needs to be phosphorylated on its C-terminus (tyrosine 356) 
to reach full activation of PLCβ in response to carbachol (Liu et al., 2002; Umemori et al., 
1997).
b. Gaq-mediated Rho activation by RhoGEFs
The Rho GTPases are a family of peripheral membrane proteins that regulate im-
portant cellular processes such as cell shape, cell migration, cell cycle progression, and 
gene transcription (Etienne-Manneville & Hall, 2002). RhoA, Rac1 and Cdc42 are the best 
characterized members of this family, known to control the dynamics of the actin cytos-
keleton and to stimulate gene transcription through several transcription factors, such as 
the serum response factor (SRF) or nuclear factor kB(NFκB)(Ridley, 2006). The activation 
of these small GTPases can be enhanced by their interaction with Rho-guanine nucleotide 
exchange factors (RhoGEFs) that catalyze the exchange from protein-bound GDP to GTP. 
RhoGEFs increase the speed of the rate-limiting step, GDP dissociation, which is followed 
by GTP occupation of the nucleotide-binding pocket, a more favourable process due to the 
higher cytosolic concentration of GTP (10:1 ratio)(Bos et al., 2007). RhoGEFs can serve 
as direct downstream effectors of heterotrimeric G proteins thus linking GPCR activation 
to Rho GTPases. The Gαq/11 family has been shown to activate RhoA, albeit with a lower 
potency than proteins of the Gα12/13 family (Vogt et al., 2003). 
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The first candidate suggested to participate in this activation through a direct in-
teraction with Gαq was the leukemia associated Rho guanine nucleotide exchange fac-
tor (LARG) (Booden et al., 2002). Since LARG possesses an RGS box region, a known Gαq 
interacting domain present in the regulators of G protein signalling family (section 5h), 
this region was initially proposed to participate in the association with Gαq, although the 
subject is currently under discussion (Booden et al., 2002; Chikumi et al., 2002; Fukuhara 
et al., 2000). Also, other RhoGEFs without an RGS domain such as Trio, Duet and p63Rho-
GEF are known to interact with Gαq and promote RhoA activation (Lutz et al., 2005, 2007; 
Rojas et al., 2007; Williams et al., 2007). Lbc, another RhoGEF family member was also 
shown to bind Gαq but no cellular effects of the interaction have been described (Sagi et 
al., 2001). 
p63RhoGEF is the best characterised non canonical and selective effector of Gαq. 
A crystal structure of the complex revealed the mechanism underlying the activation of 
RhoA by this heterotrimeric G protein subunit (Lutz et al., 2007). Interestingly, p63Rho-
GEFand PLCβ have been described to inhibit each other´s downstream responses (serum 
response element activation and IP3 production, respectively) thus providing an interes-
ting model for the competition between alternative effectors following G protein activa-
tion (Lutz et al., 2005). Although the authors did not directly show whether this mutual 
inhibitory effect was due to competition for the Gαq binding site, it  seems likely since they 
both bind to a similar  surface of the G protein (Waldo et al., 2010a).
A regulatory mechanism for Gαq-induced Rho activation was recently revealed. It 
involves a direct interaction between the mitogen-activated kinase MLK3 and p63rhoGEF 
that prevents Gαq from associating with the latter thereby abrogating Rho activation. This 
process happens in a MLK3 kinase activity-independent manner and seems to regulate 
important Rho-mediated functions such as cell migration (Swenson-Fields et al., 2008). 
c. Gaq activates the p38 pathway through Btk
Bruton tyrosine kinase is a protein that appears mutated in the immunodeficien-
cy disease X-linked a-gammaglobulinaemia and was one of the first non-phospholipase 
effectors of Gαq to be suggested. In vitro experiments showed that Gαq, but not Gi1, Go or 
Gz, interacts with the kinase and promotes its autophosphorylation (Bence et al., 1997). 
The authors also showed that Btk was necessary for the activation in vivo of p38 MAPK by 
Gq-coupled receptors. Subsequent work mapped out the interface on Btk for association 
with Gαq and proposed an activation model that entailed the disruption of an intramole-
cular inhibitory interaction (Ma & Huang, 1998), much in the lines of the later-to-be des-
cribed activation mechanism for other effectors (section 2b). However novel at the time, 
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these findings have not been substantiated with additional work on the cellular repercus-
sions of the interaction and extensive reviews devoted to Btk even fail to mention the link 
with Gαq (Lindvall et al., 2005; Mohamed et al., 2009). 
d. Gaq modulates PI3K and the Akt pathway 
Phosphatidil-inositol 3 kinase (PI3K) has also been reported to be regulated by Gαq. 
First evidences showed that the activation of PI3K and Akt by insulin growth factor 1 
(IGF-1) and platelet derived growth factor (PDGF) were inhibited by the Gq-coupled re-
ceptor a1-adrenergic thus promoting apoptotic responses (Ballou et al., 2000). Later it 
was shown that activated Gαq inhibited p110 PI3K and Akt, independently of PLCβ (Ba-
llou et al., 2003). This effect was suggested to be due to a direct and inhibitory effect of 
GTP-bound Gαq on p110α/p85α PI3K that competes with Ras, a PI3K activator (Ballou 
et al., 2006). This was the first account of a Gαq interaction that played a negative role on 
the effector. However, it is noteworthy that it has been speculated that the effect of Gαq on 
the Akt pathway can vary depending on the cell type. Indeed, several reports have shown 
that Gq-coupled receptors such as bradykinin, thrombin or carbachol induce Akt phos-
phorylation in a variety of cell types ((Xie et al., 2000) and references therein). Also, Gαq 
is proposed to be upstream of PI3K in the pathway that leads to the translocation of the 
glucose transported GLUT4 (Imamura & Vollenweider, 1999). A link between PI3K and 
Gαq has not been established in this system.
Since Gαq can either be a proliferative factor or induce apoptosis (see section 6), it 
is tempting to suggest that Gαq-mediated regulation of the PI3K/Akt pro-survival cascade 
and of other additional pathways will drastically vary in different cellular contexts.   
e. Gaq activates ERK5 through PKCζ and MEK5
Until very recently, the GPCR-initiated pathway leading to ERK5 was unknown as 
the classical routes for the activation of MAPK by GPCR (involving Ras, Rho, Rac, and/or 
Cdc42) did not seem to be involved (Fukuhara et al., 2000). In 2010 our group described 
the molecular mechanism for the activation of ERK5 by the Gq-coupled M1 muscarinic 
receptor in epithelial cells (García-Hoz et al., 2010). The activation did not require PLCβ 
activity as demonstrated by the unaffected phosphorylation of ERK5 upon treatment with 
the specific PLCβ inhibitor U73122. In fact, ERK5 was activated by a constitutively active 
mutant of Gαq and this was also true for an active Gαq mutant unable to interact with 
PLCβ (GαqQ209L-R251A/T252A, characterised in (Venkatakrishnan & Exton, 1996)). We 
found that the atypical protein kinase C zeta (PKCζ), previously reported to participate 
in the activation of ERK5 by the EGF receptor, was required for the new pathway. Indeed, 
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Gq-coupled receptors were not able to activate ERK5 in PKCζ-deficient cells or upon phar-
macological inhibition of the kinase. PKCζ was reported to interact directly and in a stimu-
lus dependent manner with Gαq, thus favoured by the active state of the G protein. This 
interaction is highly specific since neither other G alpha family members nor PLCλ, the 
other member of the atypical PKC family could interact with PKCζ and Gαq, respectively. 
MEK5, the activatory upstream kinase of ERK5, was also present in the multimolecular 
complexes of activated Gαq and, surprisingly, it associated directly and in an activation-
dependent manner with this G protein subunit. Thus, Gαq was found to bind to two novel 
effectors in the activation of ERK5. Analysis of the time courses for these associations 
and of the different combinatorial possibilities of protein complexes revealed a previously 
unreported adaptor role for Gαq. The G protein sequentially binds to both effectors for-
ming a transient ternary complex and allowing for PKCζ and MEK5 to interact and ac-
tivate ERK5 (Fig. I12). The necessary transient character of the complex was revealed 
by a mutant form of MEK5 (MEK5dAID) that cannot interact with PKCζ but preserves its 
Gαq-binding ability. The  Gαq/PKCζ complex, usually disrupted by MEK5wt, was however 
stabilised by MEK5dAID and this resulted in an abrogated ERK5 activation (García-Hoz et 
al., 2010). Thus, our recent work put forward PKCζ and MEK5 as two novel Gαq effectors 
that participate in ERK5 activation by GPCR. 
Figure I12. Working model for 
ERK5 activation by Gq-coupled 
GPCR. Activated Gαq forms a com-
plex with PKCζ, the first effector of 
the pathway. MEK5 is attracted into 
the complex through a direct inte-
raction with Gαq and forms a tran-
sient ternary complex. This is stabi-
lised by a MEK5 mutant with no PB1 
domain (MEK5dPB1). MEK5 rapidly 
binds PKCζ and displaces Gαq from 
the complex. This is inhibited by 
PKCζ-PB1 domain. PKCζ allows for 
MEK to bind and phosphorylate 
ERK5 (García-Hoz et al., 2010).                      
f. Accessory proteins in effector coupling
G protein-effector complexes are not isolated entities as they are usually depicted 
in classic text-book biochemistry but are instead supported by numerous other proteins 
playing accessory roles. These complexes might be confined to very specific locations and 
the aid of scaffolding proteins can be essential for effector coupling and effective signa-
lling (also see next section). 
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An interesting example of this was recently reported by Cartier et al (2011). WDR36 
was identified as an interacting partner of the tromboxane A2 receptor b type (TPb) and 
this association was positively modulated by receptor stimulation. Additionally, it was 
found that WDR36 could also interact with Gαq and PLCβ, thus acting as a scaffold and 
tethering receptor, G protein and effector within the same active complex (Cartier et al., 
2011). Besides, the scaffold competes for the binding site of GRK2 in Gαq and prevents 
deactivation by the kinase. The presence of WDR36 was indeed shown essential for Gαq 
signalling and disease-associated variants of the protein proved unable to fully activate 
the G protein. Another example is provided by CD9 and CD81 proteins, members of the 
tetraspanin family that act as protein organizers for extensive signalling complexes on 
the membrane. They were found to interact with the GPCR GPR56 and with Gαq (Little et 
al., 2004) thereby facilitating receptor-G protein coupling. This mechanism was not de-
pendent on lipid rafts or other microdomains and illustrates the variability of signalling 
microenvironments for Gαq. 
Scaffold proteins can also play negative regulatory roles. Ezrin-radixin-moesin-bin-
ding protein 50 (EBP50) is a multifunctional adaptor that was found to interact with ac-
tivated Gαq and inhibit PLCβ signalling (Rochdi et al., 2002). EBP50 also blocks the Gαq-
induced internalisation of the TPb receptor (Rochdi & Parent, 2003). The study of this 
inhibitory relationship could provide some clues on PLCβ-independent signalling by Gαq 
since alternative pathways could be emanating from these complexes.
g. Cellular microenvironments in Gaq signalling
The study of localisation of Gαq in diverse signalling microenvironments could help 
understanding the complex effector coupling potential of the G protein. Gαq is known to 
interact with components of the cytoskeleton such as tubulin or filamentous actin (F-ac-
tin) as well as with important organisers of membrane microdomains such as caveolin-1 
and flotillin. 
G proteins can regulate the microtubule cytoskeleton, thus affecting many aspects of 
cell morphology, by direct binding rather than or in addition to impacting the cytoskeleton 
through the modulation of downstream signalling pathways (Hewavitharana & Wedegaert-
ner, 2011). Several heterotrimeric G proteins are known to interact with high affinity with 
tubulin (Wang et al., 1990). The effects of these interaction are antagonistic; whereas G 
proteins (Gαi1, Gas and Gαq) destabilize the microtubules by stimulating tubulin´s GTPa-
se activity, Gβγ subunits promote microtubule stability (Dave et al., 2009). Also, the locali-
zation of the protein complexes differs between the G protein subtypes. Whereas Gas, the 
only G protein known to internalize, seems to interact with tubulin in the cytosol (Sarma 
et al., 2003) directed by lipid rafts-derived vesicles (Yu & Rasenick, 2002), the stimulation 
of Gq-coupled receptors appears to recruit tubulin to the  membrane  (Ciruela & McIlhin-
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ney, 2001). This interaction occurs in a similar time course to PLCβ activation (Popova & 
Rasenick, 2003) although no causal relationship has yet been established between these 
two phenomena. Additionally, G proteins also interact with the actin cytoskeleton. Gαq/11 
was reported to colocalise with F-actin and disruption with the drug cytochalasin inhibi-
ted Gαq/11-mediated generation of IP
3
 in cells (Ibarrondo et al., 1995).
Thus, there is a cooperative relationship between cytoskeletal components, GPCRs 
and G proteins to confine signalling molecules in specific microdomains. Particularly, tu-
bulin is an important component of lipid rafts, membrane microdomains comprised of a 
dynamic assembly of cholesterol and sphingolipids (Simons & Toomre, 2000). Both GPCRs 
and G proteins are often found in these detergent-resistant domains at higher concentra-
tion than elsewhere in the membrane. Indeed, Gαq is often used as an experimental mar-
ker of lipid rafts enriched in caveolae (Qiu et al., 2011) whereas other G proteins like Gαi 
or Gαs target lipid rafts with abundant glycosylphosphatidylinositol (GPI)-anchored pro-
teins. Caveolin 1, a major protein component of lipid rafts, is known to interact with Gαq 
and modulate dependent Ca2++ signalling (Sengupta et al., 2008). Also, caveolin 1 is known 
to modulate Gαq-signalling through interactions with receptors such as the 5-HT2A sero-
tonin receptor (Bhatnagar et al., 2004). Additionally, G proteins can traffic in and out of 
lipid rafts upon receptor stimulation thus revealing the important functional implications 
of these membrane domains. Chronic stimulation of the thyrotropin-releasing hormone 
receptor induces Gαq to exit detergent-resistant membranes (Pesanová et al., 1999). 
Flotillins are other lipid rafts resident proteins that are known to interact with Gαq. 
The authors found that this protein participated in the activation of p38, but not ERK1/2, 
by the Gq-coupled receptor PY2 (Sugawara et al., 2007).
h. RGS proteins promote Gaq signal termination
Duration of G protein signalling is limited by the rate of GTP hydrolysis. After retur-
ning to the GDP-bound state, Gαq reforms the complex with Gβγ and becomes available 
for another activation round. The rate of hydrolysis is naturally low and can be accelerated 
by interaction between GTPase-activating proteins (GAPs) and the G protein. Although 
some effectors, such as PLCβ, are known to accelerate GTP hydrolysis, the main group of 
GAPs for G proteins belong to the Regulators of G protein signalling (RGS) family (Watson 
et al., 1996).   
The rate of GTP hydrolysis by Gαq can be accelerated by many different RGS proteins 
(Hubbard & Hepler, 2006), but two of the best characterized are RGS2 and RGS4, both of 
which are members of the RGS B/R4 subfamily (Bansal et al., 2007). In cells, RGS4 inhibits 
both Gαi- and Gαq-mediated signalling, whereas RGS2 is selective for Gαq (Xu et al., 1999). 
Introduction
75
As previously discussed, PLCβ has evolved to display both effector and GAP functions 
within the same protein so it is likely that the regulation of PLCβ signalling by RGS pro-
teins will differ from that exerted on other effectors. Indeed, while PLCβ binding clearly 
overlaps with RGS binding region and regulation is likely due to competition, the binding 
of p63rhoGEF and GRK2 to Gαq seems compatible with that of RGS. Thus, it has been pro-
posed that RGS proteins form ternary complexes with G proteins and effectors with little 
or no interaction between RGS and effectors. A recent report shows a mutual allosteric re-
gulation between the effector and RGS binding sites (Shankaranarayanan et al., 2008). In 
these ternary complexes both RGS2 and RGS4 negatively regulate the binding of GRK2 and 
p63rhoGEF to Gαq. Besides, RGS protein activity was also affected by effectors although 
marked differences were observed between the different subtypes. Most importantly, the 
Gαq-mediated enhanced activity of the effector p63rhoGEF was allosterically reduced by 
RGS proteins (Shankaranarayanan et al., 2008). The authors speculated on the possible 
physical conduit of this allosterism and pointed at N-terminus of the switch II of Gαq, a do-
main sensitive to nucleotide binding and located in between the effector and GAP binding 
interfaces.  Thus, a dual negative regulation is exerted by RGS proteins on Gαq: GTPase 
activity enhancement and negative allosterism on effector binding. This last mechanism 
explains why RGS2/4 can inhibit PLCβ-induced activity promoted by a nonhydrolyzable 
GTP analog, GTPgS (Xu et al., 1999).
i. GRK2 sequesters Gαq and inhibits downstream signalling
G protein-coupled receptor kinases (GRKs) phosphorylate target GPCRs, recruiting 
arrestins and other proteins involved in receptor desensitization. Additionally, they play 
a role in a growing number of important cellular functions independently of their action 
on receptors (Penela et al., 2010). All GRK isoforms possess an amino terminal RH do-
main, homologous to that present in RGS proteins, and it can differentially interact with 
members of the Gαq family (Day et al., 2003). Particularly, GRK2 has been reported to 
interact in a stimulus-dependent manner with Gαq and to display a poor GAP activity 
towards the G protein compared with RGS proteins (Carman et al., 1999b). It is thought 
that GRK2 does not predominantly function as an allosteric regulator of Gαq but instead it 
interacts with the G protein and sequesters it away from receptors and effectors (Ribas et 
al., 2007). Indeed, the GRK2 RH domain is able to inhibit Gαq-mediated phospholipase C 
activity both in vitro and in intact cell assays, and is more potent a blocker than RGS4 (Car-
man et al., 1999b; Sallese et al., 2000). These evidences suggest that GRK2 modulatory 
effect on GPCR signalling can be detected both on the activated receptor as well as on Gαq. 
GRK2 is able to dampen signalling downstream of several Gq-coupled receptors such as 
endothelin A and B, thromboxane A2, α1b- adrenergic, M1 and M3 muscarinic cholinergic, 
Introduction
76
parathyroid hormone, thyrotropin-realising hormone (TRH), 5-hydroxy-tryptamine 2C, 
metabotropic glutamate receptor-1A (mGluR1A), type 1A angiotensin II and human H1 
histamine receptors (Ferguson, 2007). For some of these receptors the sole expression of 
the RH domain of GRK2 was sufficient to downregulate signalling although it seems gene-
rally accepted that GRK2 action has to be dual, both on Gαq and on the GPCR, for efficient 
attenuation (Ribas et al., 2007). 
Cellular responses mediated by Gαq can also be abrogated by GRK2. Insulin stimu-
lates glucose transport through GLUT4 translocation to the plasma membrane by insu-
lin receptor-dependent phosphorylation of Gαq (Imamura & Vollenweider, 1999). This 
process was shown to be inhibited by the RH domain of GRK2 in 3T3-L1 adipocites and, 
inversely, the down-regulation of GRK2 increased insulin-mediated GLUT4 translocation 
(Usui et al., 2004). The sensitization towards insulin pathways in a GRK2-deficient setting 
has recently been demonstrated to have a major role in insulin resistance and obesity 
(Garcia-Guerra et al., 2010).  
The interaction between Gαq and GRK2 also appears to be regulated by the phos-
phorylation state of the kinase. We found that phosphorylation of GRK2 by c-Src on tyro-
sine residues enhances the Gαq/GRK2 interaction, which was consistent with the time-
course in vivo observed in response to M1 receptor stimulation. Besides, c-Src activation 
promoted the downregulation of the Gαq/PLCβ signalling pathway in a GRK2 tyrosine 
phosphorylation-dependent manner (Mariggiò et al., 2006).
GRK2 is also found in lipid rafts through a specific interaction with caveolin media-
ted by the PH domain of GRK2 (Carman et al., 1999a). Interestingly, caveolin-1/3-bound 
GRK2 is unable to phosphorylate substrates suggesting that this could be a mechanism for 
controlling basal GRK activity. The coexistence of GRK2 and Gαq in caveolins has not been 
reported but it is tempting to speculate that the observed enhancement in Gαq function in 
caveolae (Sengupta et al., 2008) might be due to a positive scaffolding function of caveolin 
keeping GRK2 at bay. 
The crystal structure of the Gαq-GRK2-Gβγ complex revealed that GRK2 binds to the 
effector-binding site of Gαq (Tesmer et al., 2005), raising the possibility that GRK2 could 
indeed be an effector that initiates specific signalling cascades in response to the activa-
tion of Gαq. However, despite it has been shown that Gαq can activate GRK2 through PKC 
(Malhotra et al., 2010), to date there are no reports of a direct involvement of the Gαq/
GRK2 complex in triggering downstream signalling. 
Introduction
77
6. CELLULAR AND PHYSIOLOGICAL FUNCTIONS OF Gαq
It has been estimated that almost 40% of all identified GPCRs rely upon the Gαq/11 
family to stimulate inositol lipid signalling (Hubbard & Hepler, 2006). These receptors 
communicate signals from a number of hormones, neurotransmitters, chemokines, and 
autocrine and paracrine factors. 
The most established role for Gαq is the control of cardiovascular physiopathology, 
which will be the subject of this section. However, the spectrum of Gαq-mediated cellular 
functions is very wide and includes a number of other noteworthy examples. Smooth mus-
cle tone is controlled through the action of Gq-coupled receptors such as the angiotensin 
AT1R, the endothelin ET
A
 receptor or the a1 adrenoceptor (Wettschureck & Offermanns, 
2005). Long-term exposure to angiotensin II results in hypertension and this effect can 
be ameliorated with the smooth muscle specific overexpression of the carboxyl-termi-
nal  end of Gαq, which inhibits receptor coupling (Keys et al., 2002). Additionally, airway 
smooth muscle responds to Gq-coupled ligands such as acetylcholine to mediate broncho-
constriction (Caulfield, 1993). Gαq also participates in platelet function as shown by the 
impaired ability of Gαq-/- platelets to aggregate in response to thromboxane A2 (Johnson 
et al., 1996) which is reflected in the increased bleeding times of Gαq-/- mice (Offermanns 
et al., 1998). The endocrine system also relies on Gq-coupled receptors: hormone relea-
se from the anterior pituitary is controled by hypothalamic releasing hormones, most of 
which act through Gαq. This is the case for gonadotropin releasing hormone, thyrotro-
pin-releasing hormone and prolactin-releasing hormones (Wettschureck & Offermanns, 
2005). Additionally, Gαq is necessary for certain steps of glucose metabolism. 3T3-L1 adi-
pocytes rely on Gαq for basal and insulin-induced translocation of the glucose transporter 
GLUT4 which is inhibited upon overexpression of RGS2 (Imamura & Vollenweider, 1999). 
In line with this notion, inhibition of GRK2 increased GLUT4 translocation in response to 
insulin (Usui et al., 2004). The modulation of synaptic transmission is another example 
of Gαq involvement in physiology. An important role of Gαq has been described at the pa-
rallel fibre-Purkinje cell synapse in the cerebellum, where IP
3
-dependent calcium pulses 
are required for the induction of long-term depression (Miyata et al., 2000). Finally, Gαq 
signals have a notable proliferative potential and they have transformation properties, 
but exacerbated Gαq activation results in apoptosis (Fig. I13). After this dual action, Gαq 
has been referred to as a conditional oncogene (Dhanasekaran et al., 1998).  However, 
mutations in Gq-coupled receptors have been recently demonstrated in multiple human 
cancers (Kan et al., 2010), and activating mutations in the genes for Gαq family members, 
Gαq and Gα11, have been identified in approximately 80% of uveal melanomas, where 
they are now considered to collectively represent the driver oncogene (Raamsdonk et al., 
2008; Van Raamsdonk et al., 2010). 
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a. Gαq function in the heart 
The role of Gαq/11 protein family in the heart becomes clear from early stages of 
embryonic development. Mice lacking both Gαq and Gα11 die at embryonic day 11 as a 
result of severe thinning of the heart myocardial layer (Offermanns et al., 1998). There 
likely is some degree of redundancy/compensatory effect since only dual elimination of 
Gαq and Gα11, but not individual knock-outs, resulted in important phenotypic defects. 
Gq-coupled GPCR have also been implicated in cardiac growth. Inactivation of 5-HT(2B) 
gene leads to embryonic and neonatal death caused by heart defects (Nebigil et al., 2000). 
Hearts from these animals show a lack of trabeculae and ventricular hypoplasia caused by 
impaired proliferative capacity of myocytes. Also, knock-out mice models for endothelin 1 
(ET-1) and its receptors ET
A
 and ET
B
, that couple to Gαq, express a number of cardiac diffe-
rentiation abnormalities (Giannessi et al., 2001) and the lack of both ET
A
 and ET
B
 resulted 
in mid-gestational heart failure (Yanagisawa et al., 1998). 
The onset of cardiac hypertrophy is an adaptative phenomenon in conditions of sus-
tained pressure overload. It is characterised by increased myocyte size and protein content 
as well as by a characteristic gene expression profile of foetal genes (Rapacciuolo et al., 
2001). Despite initially beneficial, hypertrophy has often been identified as a maladaptati-
ve process affecting contractile function and increasing the risk of cardiac mortality (Frey 
& Olson, 2003). Several evidences place Gαq at the centre of hyperthropic pathways in the 
heart. Agonists such as epinephrine/norepinephrine, angiotensin II, endothelin 1 and se-
rotonin (acting through a1-adrenergic, AT1, ET
A
 and 5-HT(2B) receptors)  have shown to 
induce hyperthrophy (Wettschureck & Offermanns, 2005). Both cardiac-specific overex-
pression of the AT1 receptor (Hein et al., 1997) and chronic administration of angiotensin 
II (Ikeda et al., 2005) can trigger cardiac hypertrophy in mice.  Besides, the administration 
of angiotensin receptor blockers can prevent the development of hypertrophy in mice and 
in humans (Hunyady & Catt, 2006; Liu et al., 1997). The direct involvement of Gaq-media-
ted signalling is further stressed by reports showing that cardiac-specific over-expression 
of Gaq in transgenic mice is enough to trigger cardiac hypertrophy in a similar manner to 
pressure overload challenges and that it enhances the expression of foetal genes (Liggett, 
2006). Finally, conditional inactivation of Gαq/Gα11 in cardiomyocytes leads to a comple-
te absence of hypertrophic response in response to pressure overload (Wettschureck et 
al., 2001). Taken together these results indicate that Gαq signalling is both necessary and 
sufficient for the development of cardiac hypertrophy. 
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Figure I13. Diversity of Gαq effects in 
the heart. Activated Gαq signalling con-
tributes to a proliferative/hypertrophic 
phenotype. Overactivated Gαq signa-
lling initiates apoptotic pathways lea-
ding to heart failure.                                      
The development of a cardiac hypertrophy phenotype has been correlated with a 
higher risk of heart failure (Hunter & Chien, 1999). Interestingly, it has become increasin-
gly clear that both events are tied to the activation/presence of Gαq (Fig. I13). Mice ove-
rexpressing Gαq are a well established model of cardiac failure (Fan et al., 2005), which 
has been linked to the mitochondrial death pathway and to the loss of mitochondrial 
membrane potential (Adams et al., 2000) as well as to the production of mitochondrial 
reactive oxygen species (ROS)(Dai et al., 2011). Indeed, whereas the ectopic expression 
of Gαq in cardiac myocytes recapitulated the hypertrophic phenotype produced by angio-
tensin II administration, the expression of a constitutively activated mutant of Gαq, which 
further increased Gαq signalling, produced initial hypertrophy that rapidly progressed to 
apoptotic cardiomyocyte death. This was also recapitulated by high expression levels of 
wild-type Gαq. The consequence of cardiomyocyte apoptosis was a transition from com-
pensated hypertrophy to a lethal cardiomyopathy (Adams et al., 1998). These data sug-
gest that moderate levels of Gαq stimulate cardiac hypertrophy signalling whereas high 
levels of Gαq activation result in cardiomyocyte apoptosis. 
Additionally, Gαq also participates in other pathological processes in the heart diffe-
rent from pressure overload-induced hypertrophy such as diabetic cardiomyopathy. Gαq 
levels and PKC activity were shown to be increased in the streptozotocin-induced diabetic 
rat heart (Harris et al., 2004).  
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b. Classical Gαq signalling pathways in the heart
Inhibition of several downstream regulatory proteins has been shown to interfere 
with Gαq-mediated responses in the heart. 
The primary actions of Gq-coupled GPCR in the heart have been tied to the activation 
of its canonical effector phospholipase Cb (Fig. I14). A 32-amino acid C-terminal peptide 
of PLC 1b was sufficient to prevent sarcolemmal membrane targeting of PLC 1b in rat neo-
natal cardiomyocytes, PLC-mediated IP
3
 production and hypertrophic responses elicited 
by a1AR stimulation (Filtz et al., 2009). PLCβ-initiated pathways can lead to the regulation 
of the calcineurin/NFAT cascade stimulation and the activation of conventional and novel 
PKC isoforms. 
Inositol phosphate production leads to calcium release into the cytosol where it 
binds calmodulin (CAM). The Ca2++/CAM complex modulates the function of several pro-
teins. Particularly, calcium-bound CAM will interact with CAMKII and calcineurin, both of 
which have been shown to play a role in the development of hypertrophy. CAMKII acts di-
fferentially through its two isoforms (db, dc) likely controlling different subsets of cardiac 
proteins and inhibition of CAMKII signalling appears to be a viable mechanism to attenua-
te hypertrophy and progression to heart failure (Mishra et al., 2010). 
DAG promotes PKC activation which leads to the initiation of MAPK signalling as a 
major route by which Gαq mediates cell growth responses in the heart (Kehat & Molken-
tin, 2010). Seven different isoforms of PKC  (PKCα, -β1, -β2, -δ, -ε, -λ and -ζ) are expres-
sed in most adult mammalian myocardia (Dorn & Force, 2005). PKC activation regulates 
contractility and hypertrophy in cultured cardiomyocytes but mouse models deficient 
in individual isoforms do no present a cardiac phenotype, a phenomenon likely due to 
functional compensation. Most notably, PLCα overexpression promotes hypertrophy and 
its inhibition blocks heart failure both in cultured myocytes and in mice (Braz et al., 2004). 
Also, the normalisation of PLCα protein levels in Gαq-overexpressing hypertrophy models 
(where PLCα is uregulated) improves contractility, which points to an additional role of 
PLCα on systolic and diastolic function by b-adrenergic receptor desensitisation (Hahn et 
al., 2003). Transgene expression of PLCβ in adults caused ventricular hypertrophy that 
was associated with impaired diastolic relaxation, whereas expression in newborns cau-
sed sudden death associated with marked abnormalities in the regulation of intracellular 
calcium (Bowman et al., 1997). Additionally, PLCε pharmacological inhibition during de-
velopment causes embryo lethality due to cardiac hypoplasia but enhancement on its ac-
tivity in the adult heart (by promoting plasma membrane translocation) reduces cardiac 
hypertrophy (Mochly-Rosen et al., 2000; Wu et al., 2000). These data support the notion 
Introduction
81
that PLCε signalling is a compensatory event in hypertrophy, rather than a pathological 
event, and suggest the therapeutic potential of PLCε enhancement to improve cardiac in-
sufficiency. 
MAPKs are the primary downstream effectors in cardiovascular function acting as 
signalling switches between apoptosis and adaptive hypertrophy. For example, in mice, 
p38 mitogen-activated protein kinases are strongly activated by pressure overload, and 
upstream kinases that specifically activate p38 cause the growth of cultured myocytes 
but this activation is also accompanied by an increase in the rate of apoptosis (Wang et 
al., 1998a). Specific activation of the JNK pathway in cardiac myocytes induced characte-
ristic features of hypertrophy but, in contrast, co-activation of both JNK and p38 led to an 
induction of cytopathic responses and suppression of hypertrophic programmes (Wang 
et al., 1998b). Similarly, the specific implication of ERK1/2 is diverse. Whereas it is known 
to contribute to concentric cardiomyocyte hypertrophy, associated with increased car-
diomyocyte width due to new sarcomeres synthesis and ERK1/2 autophosphorylation 
(Lorenz et al., 2009), the inhibition of ERK1/2 signalling increases eccentric hypertro-
phy, associated with augmented cardiomyocyte length (Kehat et al., 2011). Besides, the 
inhibition of several ERK1/2 downstream targets, including mitogen and stress-activated 
kinase 1 and MAP kinase-interacting kinase 1, has also been shown to reduce hypertrophy 
in cardiomyocytes (Markou et al., 2009; Spruill & McDermott, 2006) thus suggesting that 
the ambiguous effect of ERK1/2 in hypertrophy could be due to the differential action of 
alternative downstream cascades. 
Despite the relevance of PLCβ as a primary effector of Gαq actions in the heart, there 
is evidence that unveils a lack of correlation between PLCβ activation and the hypertro-
phic phenotype in the Gαq-overexpressing mouse model (Mende et al., 2001). Additiona-
lly, several reports have shown MAPK activation independently of PLCβ activity in a num-
ber of cellular contexts (Berts et al., 1999; Coso et al., 1995; Heasley & Storey, 1996; Peavy 
et al., 2001; Seo et al., 2000). Thus, alternative players are thought to be mediating part of 
the essential function of Gαq in the heart. Indeed, we recently described the occurrence 
of the Gαq-PKCζ-ERK5 signalling axis as an important mediator of hypertrophic genetic 
programmes in the heart (see next section and results).
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Figure I14. Classical Gαq hypertrophic pa-
thways in the heart. Gαq hypertrophic respon-
ses in the heart are thought to be mediated by 
PLCβ and they can be calcium-dependent or 
independent. The first lead to calcineurin acti-
vation and the latter lead to MAPK activation. 
All these responses are negatively regulated by 
GRK2 and RGS proteins. Additional effectors re-
main to be elucidated.
c. Emerging roles of PKCζ and ERK5 in the heart
PKCζ and ERK5, recently described components of a novel Gαq-initiated signalling 
axis (see section 5e), have also been involved in different cardiovascular functions.  
As mentioned above, the role of MAPK signalling in Gαq-promoted hypertrophy has 
been extensively characterised and usually associated to the activation of the ERK1/2 pa-
thway. However, also ERK5 plays an important role in heart function that is clear since early 
stages of development. Deletion of either ERK5 or MEK5 is embryonic lethal at approxi-
mately E10 due to an underdeveloped myocardium, disorganization of the trabeculae, and 
vascular defects (Hayashi & Lee, 2004). However, at least part of the lethal phenotype in 
development cannot be ascribed to the function of ERK5 in cardiomyocytes since targeted 
deletion of the kinase in this cell type showed normal development, whereas specific de-
fect in endothelial ERK5 recapitulated the phenotype from the global knockout (Hayashi 
& Lee, 2004; Hayashi, 2004). However, the role of ERK5 in cardiovascular function has 
been extensively demonstrated. It has been reported that Angiotensin II promotes ERK5 
activation in mice myocardium (Ikeda et al., 2005), that cardiac-specific overexpression 
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of either upstream activators (MEK5)(Nicol et al., 2001) or downstream targets (MEF2A 
and C)(Xu et al., 2006) of ERK5 induces cardiac hypertrophy in mice, and that the activity 
of ERK5 is increased during left ventricular hypertrophy (Kacimi & Gerdes, 2003; Takeishi 
et al., 2001), whereas targeted deletion of ERK5 in cardiomyocytes attenuates the hyper-
trophic response in the heart (Kimura et al., 2010). 
Also PKCζ has been shown as an increasingly important molecule in cardiac function. 
PKCζ has been reported to augment atrial natriuretic factor in ventricular cardiomyocytes 
(Decock et al., 1994) and more recently to be involved in cardiac sarcomeric protein phos-
phorylation (Wu & Solaro, 2007), which can be a relevant process during mechanical heart 
stress (Borges et al., 2008). Additionally, the protein kinase C (PKC)-interacting cousin of 
thioredoxin (PICOT) exerts two distinct effects, through previously unknown mechanisms, 
in the heart: it inhibits cardiac hypertrophy and enhances cardiac contractility (Jeong et 
al., 2006). Recently it was reported that PICOT affected cardiac contractility by inhibiting 
PKCζ and leading to higher calcium release and sensitivity in cardiomyocytes (Oh et al., 
2012). This phenotype can be recapitulated by the PKCζ pseudosubstrate specific inhibi-
tor. Besides, data in isolated adult cardiac myocytes demonstrate that stimulation of a Gq-
coupled GPCR, the thromboxane TxA2 receptor, directly induces cardiac myocyte apopto-
sis which can be ascribed, to some degree, to a reduction in Akt activity mediated by PKCζ 
(Shizukuda & Buttrick, 2002). As reported for ERK5, PKCζ is also involved in endothelial 
function, which indirectly affects cardiovascular homeostasis. Indeed, pharmacological 
inhibition of PKCζ was shown to exert cardioprotective effects in ischemia-reperfusion in-
jury due to a decrease in nitric oxide released by the endothelium (Phillipson et al., 2005).
Taken together, these data put forward PKCζ and ERK5 as main players in cardiovas-
cular function. As detailed in section 5e we have recently described the activation of ERK5 
by Gq-coupled GPCR involving PKCζ in epithelial cells (García-Hoz et al., 2010). Thus, we 
investigated the occurrence of this novel signalling axis in cardiac cells. The first part of 
this research project is included in the Results section so it will not be explained in detail 
here. Briefly, we established that ERK5 is activated by the Gq-coupled ligand angioten-
sin II in both adult and neonatal cardiac myocytes and in neonatal fibroblasts. This pa-
thway was dependent upon PKCζ activity or presence as demonstrated by the abrogated 
activation of ERK5 upon PKCζ knockdown or pharmacological inhibition. Additionally, we 
established the occurrence of the pathway in cardiac tissue from angiotensin II-treated 
wild-type mice whereas this could not be detected in PKCζ-/- mice (see Results section). 
In order to assess the relevance of the pathway in vivo we induced cardiac hypertrophy in 
PKCζ KO mice and control littermates through chronic angiotensin infusion for 14 days. A 
global microarray was performed to determine differential expression patterns between 
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AngII or PBS-treated mice of the two different breeds, and compared it with published 
results for mouse models of hypertrophy (TAC or AT1-overexpressing mice). The 1,536 
probesets that achieved statistically significant criteria for differential expression were 
listed in two groups as either overexpressed (group I) or underexpressed (group II) in 
hypertrophy, compared to controls. According to this classification, the models for hyper-
trophy segregated differently with respect to control animals, which served us to define 
a hypertrophic expression pattern. In our experimental conditions, angiotensin-treated 
wt mice showed a clear hypertrophic expression pattern whereas the expression profile 
of angiotensin-treated PKCζ KO mice segregated with control animals. Thus, we reported 
that the presence of PKCζ was necessary to display a hypertrophic genetic profile in res-
ponse to angiotensin II. We found that hypertrophic markers such as ANP (Nppa) or type 
I collagen (Col1a2) were not overexpressed in angiotensin II-treated PKC-deficient mice 
compared to wild-type. This was further confirmed by quantitative real time PCR. Addi-
tionally, several downstream targets of ERK5 (ets-1, ccna2, bcl2), and ERK5 itself, were 
upregulated in control as opposed to PKCζ KO animals. Finally, several physiological mar-
kers of hypertrophy were found to be consistent with the genetic profile data. Plasma ANP 
was increased in control but not in PKCζKO animals. Similarly, heart weight/body weight 
or heart weight/tibial length ratios were increased in controls compared to PKCζ KO. Also, 
an electrocardiographic analysis showed an increase in QRS and QT components (which 
has been correlated to left ventricular hypertrophy (Salles et al., 2005)) in control animals 
whereas this was not observed in PKCζ-/- mice. Taken together, these results show that 
PKCζ is essential for the promotion of a hypertrophic phenotype upon angiotensin II cha-
llenge (García-Hoz et al., 2012) (Fig. I15).
d. Gαq signalling regulation in the heart
The regulation of Gαq function in the heart is an important process for limiting sig-
nal duration and amplitude. As expected, the two main families of G protein regulators, 
GRKs and RGS proteins, have been involved in cardiovascular physiopathology. However, 
the outcome of their regulatory functions is not at all straightforward, especially in the 
case of GRK2 that plays numerous roles besides the downregulation of Gαq signalling 
(Ribas et al., 2007).
 The overexpression of a dominant-negative Gaq peptide or the Gαq negative regula-
tor RGS4 in murine heart, renders resistance to pressure overload-triggered hypertrophy 
(Rogers et al., 1999; Rohini et al., 2010). However, as mentioned above, the function of Gαq 
in the heart is dual since it can mediate potent proliferative signals, which results in hy-
pertrophy, and also pro-apoptotic signals leading to heart failure. Thus, RGS4 overexpres-
sion not only abrogates hypertrophy but also results in rapid cardiac decompensation, de-
pressed systolic function, and increased mortality (Rogers et al., 1999). However, another 
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report for the heart-specific overexpression of RGS4 in mice found that it provides protec-
tion against different models of diabetic cardiomyopathy and, conversely, expression of a 
RGS-resistant Gαq caused sensitization towards this type of pathology (Yang et al., 1999).
Figure I15. The Gαq/PKCζ/ERK5 is involved in heart hypertrophy. Wild-type or PKCζ-/- mice were sub-
jected to Angiotensin II chronic stimulation to detect changes in hypertrophy development. Hypertrophy 
parameters such as electrocardiogram, plasma ANP, morphometric or gene expression analyses indicate 
that PKCζ-/- do not develop AngII-induced hypertrophy(García-Hoz et al., 2012).                                                     
 GRK2 is a multifunctional protein that not only acts as a negative regulator of GPCR 
signalling but also has been pointed as an important signalling hub that initiates a large 
number of pathways (Penela et al., 2010). In order to study the role of GRK2 as Gαq re-
gulator in isolation with respect to other functions, the overexpression of the RH domain 
of the kinase has demonstrated to be a fruitful approach. It is in this domain where the 
Gαq binding/sequestering function resides (section 5i) and its overexpression has been 
shown to interfere with a1 adrenoceptor-induced cardiomyocyte hypertrophy (Maruya-
ma, 2002). This is yet another proof of concept for the strict requirement of Gαq function 
for the promotion of hypertrophy. However, it has been described that the effect of GRK2 
on Gαq activation in the heart coexists with an important role in the desensitisation of b 
adrenergic receptors, Gs-coupled GPCRs that are main mediators of cardiac contractility. 
Introduction
86
Hemizygous GRK2 mice expressing 50% less protein than control littermates are hyper-
responsive to catecholamines and present increased cardiac contractility and function. 
The opposite is observed in transgenic GRK2-overexpressing mice (Koch et al., 1998). 
Additionally, increased left ventricular GRK2 mRNA and activity were reported in patients 
with ischemic or idiopathic dilated cardiomyopathy, cardiac ischemia, volume overload 
and left ventricular hypertrophy (Penela et al., 2006). These increased levels might re-
flect a compensating mechanism in pathologies with predominance of b adrenergic and 
Gαq-mediated signalling. Finally, the overexpression of GRK2-C terminal domain rescues 
cardiac dysfunction and improves survival in many different mouse models of heart failu-
re, although it does not prevent cardiac deterioration in Gαq transgenic mice despite the 
fact that normal bAR signalling was restored (Penela et al., 2010). These results suggest 
that the negative role in Gαq-driven responses is not mediated by receptor desensitisa-
tion by the C terminal domain, as it is the case for bAR regulation, but occurs more likely 
through Gαq sequestering. Moreover, it is important to highlight that GRK2 displays an 
array of functions independently of GPCR signalling through various different protein-
protein interactions. Thus, the possibility that the positive therapeutic outcomes of the 
use of GRK2ct might be partly due to interference with binding partners such as PI3K/Akt, 
tubulin, ezrin or GIT1 cannot be ruled out.
7. CONCLUDING REMARKS
 In the light of novel findings on the large plethora of Gαq-interacting proteins the 
scientific community is now able to define a much more detailed map of the different 
effectors involved in each Gαq-initiated pathway and in the subsequent cellular events. 
Thus, a careful inspection of novel pathways will provide the basis of a deep understan-
ding on Gαq function. The performance of this approach to the interaction of Gαq with the 
novel effector PKCζ has been the conceptual foundation for this thesis.
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Objectives
1. Investigate the occurrence of the Gαq/PKCζ/ERK5 axis in the cardiovascular system.
2. Establish the relative contribution of Gαq and b-arrestin routes towards the activation 
of ERK5 by Gq-coupled GPCRs. 
3. Determine the occurrence and specificity of the Gαq/PKCζ complex in living cells
4. Identify the interaction surfaces involved in the formation of the Gαq/PKCζ complex 
5. Establish the requirement of Gαq/PKCζ association for the activation of the ERK5 
 pathway.
6. Identify the regulation mechanisms exerted by GRK2 on the Gαq/PKCζ complex as well 
as on ERK5 activation. 
7. Study the activation mechanisms of PKCζ by Gq-coupled GPCRs.
8. Explore the potential role of the Gαq/PKCζ axis in other cellular processes such as  
proliferation and apoptosis.
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1. MATERIALS 
a. Buffers and solutions
Buffer Composition Comments
DNA sample 
buffer 6x
18% (v/v) glycerol
0.15% (w/v) bromophenol blue
0.15% (w/v) xylencyanol
15mM EDTA
ERK5 buffer 50 mM Tris-HCl pH 7.5
150 mM NaCl
1mM NP-40
0.25% deoxycholate
1 mM EGTA pH 8.0
1 mM NaF
stored at 4°C
0.1 µM PMSF
0.5 µM Benzamidin 
1 µg/µl Aprotinin
0.1 µM NaVO
3
added fresh
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Hanks 
medium
137 mM NaCl, 5 mM KCl, 
0.8 mM MgSO
4
0.33 mM Na
2
HPO
4
  
0.44 mM KH
2
PO
4
  
1.0 mM MgCl
2 
0.15 mM Tris-HCl 
1.0 mM sodium butirate, pH 7.4
Laemmli po-
lyacrylamide 
gel (6-12%)
20-40% (v/v) acrylamide/
N,N’methylen-
 bisacrylamide 30:0.8 (w/v)
0.375 M Tris-HCl pH 8.9
0.1% SDS
Laemmli 
running buffer 
(10x)
0.25 M Tris base
2.0 M glycine
1% SDS
LB broth 1% (w/v) bacto-tryptone
0.5% (w/v) bacto-yeast extract
1% (w/v) NaCl (171 mM)
autoclaved
LB-agar LB broth + 1.5% (w/v) agar autoclaved
PBS (1x) 137 mM NaCl (0.8% w/v)
2.7 mM KCl (0.02% w/v)
10 mM Na
2
HPO
4
 (0.144% w/v)
1.75 mM KH
2
PO
4
 (0.024% w/v)
pH 7.4
autoclaved
Ponceau stai-
ning solution
0.2% Ponceau-S in
3.0% TCA
RIPA buffer 
(2x)
0.08 ml 0.5 M EDTA pH 8.0
0.72 ml 37% formaldehyde
2.00 ml 100% glycerol
3.084 ml formamide
4.00 ml 10x MOPS buffer
0.016 ml bromophenol blue 
RNase free water to 10 ml
store at 4°C for
less than 3 months
0.1 µM PMSF
0.5 µM Benzamidin 
1 µg/µl Aprotinin
0.1 µM NaVO
3
Added fresh
Sorting buffer PBS
5mM EDTA 
25mM HEPES pH 7 
supplemented with 2% FBS 
stored at -20°C
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b. Oligonucleotides
All oligonucleotides for mutagenesis were purchased from Sigma-Aldrich Spain 
whereas those used for cloning were purchased from Integrated DNA Technologies (IDT), 
Quebec, Canada.
Sample buffer 
(4x)
80 mM Tris-HCl pH 6.8
2% SDS
10% glycerol
0.2% (w/v) bromophenol blue
50 ml/ml (v/v) 2-mercaptoethanol
stored at 4°C
TAE buffer 
(1x)
40 mM Tris-acetate pH 7.6
1 mM EDTA
autoclaved
TBS (10x) 0.1 M Tris base
1.5 M NaCl
pH 7.4 with HCl conc.
TBS-Tween 
(10x)
0.1 M Tris base
1.5 M NaCl
0.5% Tween-20
pH 8.0 with HCl conc.
Tyrode 
 solution
37 mM NaCl 
2.7 mM KCl 
1 mM MgCl
2
1.8 mM CaCl
2
0.2 mM Na
2
HPO
4
12 mM NaHCO
3
5.5 mM D-glucose
Transfer 
 buffer (10x)
0.2 M Tris base
1.5 M glycine
20% methanol (v/v)
Primer name 5´-3´ sequence
Gαq E234A FW CT CCA TCA TGT TTC TAG TAG CGC TTA GCG CGT 
ATG ATC AAG TTC TTG TGG A
Gαq E234A REV T GTC TGA CTC CAC AAG AAC TTG ATC ATA CGC GCT 
AAG CGC TAC TAG AAA CA
Gαq D236A FW GTA GCG CTT AGT GAA TAT GCG CAA GTT CTC GTG 
GAG TCA 
Gαq D236A REV TGA CTC CAC GAG AAC TTG CGC ATA TTC ACT AAG 
CGC TAC
Gαq D243A FW CAA GTT CTC GTG GAG TCA GCG AAT GAG AAC CGA 
ATG GAG
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Gαq D243A REV CTC CAT TCG GTT CTC ATT CGC TGA CTC CAC GAG 
AAC TTG
Gαq N244A FW GTT CTC GTG GAG TCA GAC GCG GAG AAC CGA ATG 
GAG GAA
Gαq N244A REV TTC CTC CAT TCG GTT CTC CGC GTC TGA CTC CAC 
GAG AAC
Gαq E245A FW T CAA GTT CTT GTG GAG TCA GAC AAT GCG AAC 
CGC ATG GAG GAG AG
Gαq E245A REV C TTT GCT CTC CTC CAT GCG GTT CGC ATT GTC TGA 
CTC CAC AAG AA
Gαq E249A FW GAC AAT GAG AAC CGA ATG GCG GAA AGC AAG GCT 
CTC TTT
Gαq E249A REV AAA GAG AGC CTT GCT TTC CGC CAT TCG GTT CTC 
ATT GTC
Gαq S251A FW GAG AAC CGA ATG GAG GAA GCG AAG GCT CTC TTT 
AGA ACA
Gαq S251A REV TGT TCT AAA GAG AGC CTT CGC TTC CTC CAT TCG 
GTT CTC
Gαq E245A/S251A 
FW
GAG TCA GAC AAT GCG AAC CGA ATG GAG GAA GCG 
AAG GCT CTC TTT
Gαq E245A/S251A 
REV
AAA GAG AGC CTT CGC TTC CTC CAT TCG GTT CGC 
ATT GTC TGA CTC
Gαq E241/D243/
E245 FW
CAA GTT CTT GTG GCG TCA GCG AAT GCG AAC CGA 
ATG GAG 
Gαq E241/D243/
E245 REV
CTC CAT TCG GTT CGC ATT CGC TGA CGC CAC AAG 
AAC TTG
Gαq E243/E244/
E249 FW
AAT GCG AAC CGC ATG GCG GCG AGC AAA GCA CTC 
TTT
Gαq E243/E244/
E249 REV
AAA GAG TGC TTT GCT CGC CGC CAT GCG GTT CGC 
ATT
PKCζ R15A FW ATG GAC CGG AGC GGC GGC GCG GTC CGT CTG AAG 
GCG CAC 
PKCζ R15A REV GTG CGC CTT CAG ACG GAC CGC GCC GCC GCT CCG 
GTC CAT 
PKCζ R17A FW CGG AGC GGC GGC CGC GTC GCG CTG AAG GCG CAC 
TAC GGC 
PKCζ R17A REV GCC GTA GTG CGC CTT CAG CGC GAC CGC GCC GCC 
GCT CCG
PKCζ K19A FW GGC GGC CGC GTC CGT CTG GCG GCG CAC TAC GGC 
GGG GAC 
PKCζ K19A REV GTC CCC GCC GTA GTG CGC CGC CAG ACG GAC GCG 
GCC GCC
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PKCζ H21A FW CGC GTC CGT CTG AAG GCG GCG TAC GGC GGG GAC 
ATC CTG
PKCζ H21A REV CAG GAT GTC CCC GCC GTA CGC CGC CTT CAG ACG 
GAC GCG 
PKCζ I26A FW GCG CAC TAC GGC GGG GAC GCG CTG ATT ACC AGC 
GTG GAC 
PKCζ I26A REV GTC CAC GCT GGT AAT CAG CGC GTC CCC GCC GTA 
GTG CGC
PKCζ I92A FW GGC AGG GAC GAA GTG CTC GCG ATC CAC GTT TTC 
CCA AGC
PKCζ I92A REV GCT TGG GAA AAC GTG GAT CGC GAG CAC TTC GTC 
CCT GCC
PKCζ R15A/K19A 
FW
GAC CGG AGC GGC GGC GCG GTC CGT CTG GCG GCG 
CAC TAC GGC GGG
PKCζ R15A/K19A 
REV
CCC GCC GTA GTG CGC CGC CAG ACG GAC CGC GCC 
GCC GCT CCG GTC
PKCζ R17A/K19A 
FW
CGG AGC GGC GGC CGC GTC GCG CTG GCG GCG CAC 
TAC GGC GGG GAC
PKCζ R17A/K19A 
REV
GTC CCC GCC GTA GTG CGC CGC CAG GCG GAC GCG 
GCC GCC GCT CCG
PKCζ I26A/K19A 
FW
GTC CGT CTG GCG GCG CAC TAC GGC GGG GAC GCG 
CTG ATT ACC
PKCζ I26A/K19A 
REV
GGT AAT CAG CGC GTC CCC GCC GTA GTG CGC CGC 
CAG ACG GAC
Gαq Q209L FW GAT GTA GGG GGC CTA AGG TCA GAG AGA
Gαq Q209L REV TCT CTC TGA CCT TAG GCC CCC TAC ATC
Gαq R183C FW CAA GAC GTC CTT AGA GTT TGT GTC CCC ACT ACA 
GGG ATC
Gαq R183C REV GAT CCC TGT AGT GGG GAC ACA  AAC TCT AAG GAC 
GTC TTG
Gαq Y261F FW ACA ATT ATC ACC TTC CCC TGG TTC CAG
Gαq Y261F REV CTG GAA CCA GGG GAA GGT GAT AAT TGT
PKCζ-V1 (IN-
SERT) FW
CAC AGT GGC GGC CGC ACC ATG CCC AGC AGG ACC 
GAC CC
PKCζ-V1 (IN-
SERT) REV 
GAG CCA CCG CCA CCA TCG ATC ACG GAC TCC TCA 
GCA GAC A
PKCζ-V1 (PLAS-
MID) FW
TGT CTG CTG AGG AGT CCG TGA TCG ATG GTG GCG 
GTG GCT C
PKCζ-V1 (PLAS-
MID) REV
GGG TCG GTC CTG CTG GGC ATG GTG CGG CCG CCA 
CTG TG 
V1-PKCζ (IN-
SERT) FW
GAG GTG GTG GGT CCT CCG GAA TGC CCA GCA GGA 
CCG ACC C
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c. DNA enzymes
V1-PKCζ (IN-
SERT) REV 
GTT TAA ACG GGC CCT CTA GAT CAC ACG GAC TCC 
TCA GCA G
V1-PKCζ (PLAS-
MID) FW
CTG CTG AGG AGT CCG TGT GAT CTA GAG GGC CCG 
TTT AAA C
V1-PKCζ (PLAS-
MID) REV
GGG TCG GTC CTG CTG GGC ATT CCG GAG GAC CCA 
CCA CCT C
Gαq-V1 (INSERT) 
FW
CAC AGT GGC GGC CGC ACC ATG ACT CTG GAG TCC 
ATC ATG GCG
Gαq-V1 (INSERT) 
REV
GAG CCA CCG CCA CCA TCG ATG ACC AGA TTG TAC 
TCC TTC AGG TTC A
Gαq-V1 (PLAS-
MID) FW
TGA ACC TGA AGG AGT ACA ATC TGG TCA TCG ATG 
GTG GCG GTG GCT C
Gαq-V1 (PLAS-
MID) REV
CGC CAT GAT GGA CTC CAG AGT CAT GGT GCG GCC 
GCC ACT GTG 
V1-Gαq (INSERT) 
FW
GAG GTG GTG GGT CCT CCG GAA TGA CTC TGG AGT 
CCA TCA TGG C
V1-Gαq (INSERT) 
REV
GTT TAA ACG GGC CCT CTA GAT TAG ACC AGA TTG 
TAC TCC TTC AGG TTC
V1-Gαq (PLAS-
MID) FW
GAA CCT GAA GGA GTA CAA TCT GGT CTA ATC TAG 
AGG GCC CGT TTA AAC
V1-Gαq (PLAS-
MID) REV
GCC ATG ATG GAC TCC AGA GTC ATT CCG GAG GAC 
CCA CCA CCT C
GαqSEC CAG AAT GGT CGA TGT AGG GGG CCA AAG
GαqSEC II TGA TCC TGG AAT CCA GGA ATG CTA TGA TAG ACG 
ACG AGA
Enzyme Supplier
Pfu ultra Stratagene
Platinum Taq Invitrogen
Taq polymerase Biolabs
T4 DNA ligase Invitrogen
BspeI NEB
ClaI NEB
NarI NEB
NheI Fermentas
NotI NEB
PspOMI NEB
XbaI Fermentas
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d. Primary antibodies
Primary antibodies were used at concentrations ranging 1:500-1:1000 in TBS-
Tween 1x, except from anti-phosphoERK5 antibodies when used for detection of endoge-
nous phosphorylation that were freshly made in 3% phosphoblocker (Cell Biolabs). 
Antigen Reference Supplier Species
Actin sc-1616 Santa cruz Goat
Akt 9272 Cell Signaling Rabbit
Akt 9272 New England Biolabs Rabbit
a-Tubulin DM1A Sigma Mouse
Erk1 (C-16): sc-93 Santa cruz Rabbit
Erk2 (c-14): sc-154 Santa cruz Rabbit
ERK5 3372 Cell Signaling Rabbit
ERK5 Q13164 Millipore Rabbit
ETS-1 (C-20) sc-350 Santa cruz Rabbit
FLAG M1 F3040 Sigma Mouse
GAPDH  ab8245 Abcam Mouse
Gαq (e-17) sc-393 Santa cruz Rabbit
Gαq/11 (C-19) sc-392 Santa cruz Rabbit
GRK2 (C-15) sc-562 Santa cruz Rabbit
GRK2/3 (b-ARK 1/2) 05-465 Millipore Mouse
GRK2 PF1 Generated in the laboratory Rabbit
GST (Z-5): sc-459 Santa cruz Rabbit
HA Y-11 sc-805 Santa cruz Rabbit
HA(F-7) sc-7392 Santa cruz Rabbit
HA(F-7)-agarose sc-7392-AC Santa cruz Mouse
HA-11 afc-101p Covance Mouse
MEF2c (C-17) sc-13268 Santa cruz Goat
MEK5 ab-24828 Abcam Rabbit
p-Akt (S473) 9271 Cell Signaling Rabbit
p-Akt (T308) 9275 Cell Signalling Rabbit
p-Erk1-2 (T202/T204) 9101 Cell Signaling Rabbit
p-ERK5 (T218/Y220) 44612g Invitrogen Rabbit
PKCζ (C-20) sc-216 Santa cruz Rabbit
PKCζ (C24E6) 9368 Cell signalling Rabbit
PKCζ (H-1) sc-17781 Santa cruz Mouse
p-MEF2c (S387) sc-13920-R Santa cruz Rabbit
p-PKCζ (Thr-410) sc-12894-R Santa cruz Rabbit
p-PKCζ(T560) ab62372 Abcam Rabbit
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e. Secondary antibodies
f. Plasmids
Name, antigen Company Dilution
Alexa Fluor 680, goat anti-mouse IgG Molecular probes 1 mg/ml
IRDyeTM 800 CW, donkey anti-mouse IgG Rockland 0.5 mg/ml
Alexa Fluor 680, goat anti-rabbit IgG Molecular probes 1 mg/ml
IRDyeTM 800 CW, goat anti-rabbit IgG Rockland 0.5 mg/ml
Alexa Fluor 680, donkey anti-goat IgG Molecular probes 1 mg/ml
Soluble rabbit peroxidase-anti-mouse IgG Nordic immunology 1/50000
Soluble mouse peroxidase-anti-rabbit IgG Nordic immunology 1/50000
cDNA Species Vector Origin
ERK5 Human pcDNA3.1 Dr J. Moscat (Sanford-Burn-
ham, La Jolla, USA)
Gαq wt Mouse pCIS Dr A.Aragay (IBMB, Spain)
Gαq R183C Mouse pCIS Dr A.Aragay (IBMB, Spain)
Gαq Q209L Mouse pCIS Dr A.Aragay (IBMB, Spain)
Gαq T257E Mouse pCMV Dr T. Kozasa 
Gαq W263D Mouse pCMV Dr T. Kozasa 
Gαq Y261F Mouse pCMV Dr T. Kozasa 
Gαq Y261F Mouse pcDNA3.1 Generated as part of this thesis
Gαq R183C-Y261F Mouse pcDNA3.1 Generated as part of this thesis
Gαq E234A Mouse pCIS Generated as part of this thesis
Gαq D236A Mouse pCIS Generated as part of this thesis
Gαq D243A Mouse pCIS Generated as part of this thesis
Gαq N244A Mouse pCIS Generated as part of this thesis
Gαq E245A Mouse pCIS Generated as part of this thesis
Gαq E245A Mouse pCIS Generated as part of this thesis
Gαq E249A Mouse pCIS Generated as part of this thesis
Gαq S251A Mouse pCIS Generated as part of this thesis
Gαq E234/245-AA Mouse pCIS Generated as part of this thesis
Gαq E245/S251-AA Mouse pCIS Generated as part of this thesis
Gαq E234/E241/D243/E245-
AAAA 
Mouse pCIS Generated as part of this thesis
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Gαq E234/E243/E244/E249-
AAAA 
Mouse pCIS Generated as part of this thesis
Gαq R83C-E234/245-AA Mouse pCIS Generated as part of this thesis
Gαq wt (inducible) Mouse pcDNA-
4TO
Dr A.Aragay (IBMB, Spain)
Gαq R183C (inducible) Mouse pcDNA-
4TO
Dr A.Aragay (IBMB, Spain)
Gαq Q209L (inducible) Mouse pcDNA-
4TO
Generated as part of this thesis
Gαq R83C-E234/245-AA (indu-
cible)
Mouse pcDNA-
4TO
Generated as part of this thesis
Gαq Q209L-E234/245-AA (in-
ducible)
Mouse pcDNA-
4TO
Generated as part of this thesis
Gαq-Venus YFP[F1] Mouse pcDNA3.1 Generated as part of this thesis
Venus YFP[F1]-Gαq Mouse pcDNA3.1 Generated as part of this thesis
Gαq-Venus YFP[F2] Mouse pcDNA3.1 Generated as part of this thesis
Venus YFP[F2]-Gαq Mouse pcDNA3.1 Generated as part of this thesis
Gα11-Venus YFP[F1] Human pcDNA3.1 Dr SW Michnick (Universite 
de Montreal, Canada)
Gαi1-Venus YFP[F1] Human pcDNA3.1 Dr SW Michnick (Universite 
de Montreal, Canada)
IQ23 (Gαi-ct Gαq) Human pcDNA1 Dr C. Berlot (Yale University, 
USA)
QI4 (Gαq-ct Gαi) Human pcDNA1 Dr C. Berlot (Yale University, 
USA)
PKCζ-HA wt Rat pcDNA3.1 Dr J. Moscat (Sanford-Burn-
ham, La Jolla, USA)
PKCζ-HA R15A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA R17A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA K19A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA H21A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA I26A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA I92A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA R15A/K19A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA R17A/K19A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA I26A/K19A Rat pcDNA3.1 Generated as part of this thesis
PKCζ-HA PB1 Rat pcDNA3.1 Dr J. Moscat (Sanford-Burn-
ham, La Jolla, USA)
PKCζ-HA KD Rat pcDNA3.1 Dr J. Moscat (Sanford-Burn-
ham, La Jolla, USA)
PKCζ-Venus YFP[F1] Rat pcDNA3.1 Dr SW Michnick (Universite 
de Montreal, Canada)
PKCζ-Venus YFP[F2] Rat pcDNA3.1 Generated as part of this thesis
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g. Agonists and inhibitors
h. Cell lines
Venus YFP[F2]-PKCζ Rat pcDNA3.1 Generated as part of this thesis
PLCβ-YFP[F1] Human pcDNA3.1 Dr SW Michnick (Universite 
de Montreal, Canada)
GRK2 Human pcDNA3.1 Dr J Benovic (The Kimmel 
Cancer Center, USA)
GRK2 K220R Human pcDNA3.1 Dr J Benovic (The Kimmel 
Cancer Center, USA)
GRK2 D110A Human pcDNA3.1 Dr JG Tesmer (University of 
Michigan, USA)
GRK2-RGS 2-187 Human pcDNA3.1 Generated in the laboratory
MEK5 (GST) Human pcDNA3.1 Dr J. Moscat (Sanford-Burn-
ham, La Jolla, USA)
Common cell lines Origin
HELA ATCC
HEK293 ATCC
COS-7 ATCC
Name Function Concentration Time
Acetycholine Muscarinc receptor natural agonist 
(M1, M2, M3)
0.01mM-100mM Timecourse
Carbachol Muscarinc receptor non-hydrolysable 
agonist (M1, M2, M3)
10mM Timecourse
AngII AT1 and AT2 receptor natural agonist 100nM Timecourse
SII (Sar1-Ile4-Ile8 
Ang II)
β-arrestin-biased Angiotensin agonist 30mM Timecourse
Pertussis toxin Gαi protein family inhibitor 100ng/ml 16h
PKCζ myristoylated 
pseudosubstrate
PKCζ inhibitor 10mM 30min
U73122 PLC inhibitor 10mM 30min
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2. METHODS
a. DNA manipulations  
DNA cloning 
Venus-YFP expression constructs for the protein complementation assay (PCA) 
were obtained as follows: GNAQ (mouse, accession number NM_002072) and PRKCZ (rat, 
 accession number NM_022507.1) were subcloned into the 5´ and 3´-end of the Venus YFP 
PCA fragments, referred to here as N-terminal fragment (1 – 158 aa; F[1]) and the C-termi-
nal fragment (159 – 239 aa; F[2]), respectively, as previously described (Remy & Michnick, 
2004). Original cDNAs from pCDNA3.1(+)-HAPKCζ and pCIS-Gαq (see plasmid section) 
were PCR amplified with specific primers to insert compatible restriction sites at both 
ends of the PCR fragment. Due to the existence of internal restriction sites within PKCζ or 
Gαq of some of the enzymes to be utilised, those were replaced with alternative enzymes 
that generate compatible restriction sites. Both N- and C-terminal tagging options were 
generated for our proteins of interest to check for optimal expression and proper folding 
of the tagged protein. For cloning at the 5´end of the venus YFP fragment (NotI-ClaI sites), 
PspOMI-NarI sites (compatible with NotI-ClaI sites) were inserted into 5´and 3´, respecti-
vely, of PKCζ and NotI-ClaI sites were inserted into 5´and 3´, respectively, of Gαq. Alternati-
vely, for cloning at the 3´end of the venus YFP fragment (BspeI-XbaI sites), BspeI-XbaI sites 
were inserted into 5´and 3´, respectively, of PKCζ and BspeI-NheI sites were inserted into 
5´and 3´, respectively, of Gαq.
Stable cell lines Origin
CHO M1 Dr AB Tobin (University of Leicester, UK)
CHO M3 Dr AB Tobin (University of Leicester, UK)
CHO M3 SASS Dr AB Tobin (University of Leicester, UK)
CHO M1 flip in Dr AB Tobin (University of Leicester, UK)
CHO M1 flip in phosphodef Dr AB Tobin (University of Leicester, UK)
CHO M3 flip in Dr AB Tobin (University of Leicester, UK)
CHO M3 flip in phosphodef Dr AB Tobin (University of Leicester, UK)
3T3-M1 Dr P Crespo (IIB, Santander, Spain)
Primary cultures Origin
Rat adult cardiomyocytes Obtained in the laboratory
Mouse neonatal cardiomyocytes Obtained in the laboratory
Mouse neonatal cardiac fibroblasts Obtained in the laboratory
Rat neonatal cardiomyocytes Obtained in the laboratory
Rat neonatal cardiac fibroblasts Obtained in the laboratory
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Renilla luciferase expression constructs for utilising in the protein complementa-
tion assay (PCA) were obtained as follows: GNAQ (mouse, accession number NM_002072) 
and PRKCZ (rat, accession number NM_022507.1) were subcloned into the 5` end of the 
 10-aa linker (GGGGS)
2
 and of the Rluc-PCA fragments [Rluc-F(1):1–110aa; Rluc-F(2): 
 111–310aa of the humanised Rluc; pcDNA3.1] as described above. 
DNA mutagenesis
PKCζ binding-deficient mutants, Gαq binding-deficient mutants and Gαq constituti-
vely active mutants were prepared using the QuickChange site-directed mutagenesis kit 
(Stratagene). Complementary oligonucleotide pairs (usually 40-45 bp long) were desig-
ned to contain the desired point mutations in the middle of the primer sequence and had 
annealing temperatures higher than 78ºC and a minimum GC content of 40%. The primers 
were extended by PCR using the reagents provided in the kit under the following condi-
tions: a total volume of 50 µl with 30 ng of template plasmid DNA, 1x reaction buffer, 100 
nM of each primer, 1 µl dNTP mix and 2.5 U of PfuUltraTM DNA polymerase was subjected 
to 16 cycles of a) 50 seconds denaturing at 95°C, b) 50 seconds annealing at 60°C and c) 
6-8 minutes template elongation at 72°C. The PCR reactions were further incubated with 
10 U DpnI restriction enzyme for 1 hour at 37°C to digest the parental DNA and directly 
transformed into 50 µl of E. coli XL1-Blue supercompetent cells (provided in the kit) and 
plated onto LB-ampicillin (50 µg/ml) agar plates. Resulting colonies were grown in LB 
broth-ampicillin (10 µg/ml) for plasmid preparation (Qiaprep Spin Miniprep Kit, Qiagen). 
Plasmids were subjected to DNA sequencing to verify the mutation and the fidelity of the 
whole cDNA sequence. 
DNA agarose gel electrophoresis
Size determination and separation of DNA was achieved by agarose gel electropho-
resis. 1% (w/v) of electrophoresis grade agarose (Invitrogen) was added to a volume of 
TAE buffer and heated in the microwave until molten. 0.6 µg/ml of ethidium bromide was 
then added and poured into the gel casting tray with comb. DNA samples were loaded into 
the wells in DNA loading buffer and run along-side of 1 μl of HindIII digestion fragments 
of λ and ø29 phages as DNA size markers. Gels were run at 0.01 Volts/mm2 and DNA was 
visualised using a UV transilluminator.
Quantification of DNA
DNA was quantified by reading the absorbance of purified DNA at 260 nm using the 
DNA/RNA program of the BioRad Smart Spec™ spectrophotometer. DNA was  appropriately 
diluted in dH
2
0 and a minimum of 200 µl placed in a quartz cuvette (Starna) with a  path 
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length of 1 cm. Alternatively, the concentration of DNA samples was measured with a 
 Nanodrop spectrophotometer and software (Thermo Scientific).
DNA digestion and 5’ dephosphorylation
Approximately 1 μg of DNA was digested with 2 U of restriction enzyme for 1-3 hours 
in the enzyme buffer recommended by the supplier´s catalogue. Reactions were carried 
out in a 20μl volume and 0.2 mg/ml BSA was also added when appropriate. Linearised 
DNA vector was 5’ dephosphorylated using 1 U of Alkaline Phosphatase (Invitrogen) in 1x 
dephosphorylation buffer. Dephosphorylation reactions were carried out in a final volume 
of 20μl at room temperature for 15 minutes and deactivated at 65 °C for 15 minutes.
DNA purification from agarose gels
DNA bands were excised from agarose gels using a sterile scalpel blade and DNA was 
extracted with the Quiagen® gel extraction kit following manufacturer´s instructions. 
Ligation of DNA
Vector and insert DNA, both after digestion, were ligated together in a molar ra-
tio of 1:3/1:6 using T4 ligase (Invitrogen) and the accompanying 5x buffer. Ligation was 
 performed at room temperature overnight in order to maximise the number of ligations 
after which 2 µl of the ligation mixture were transformed into 50 µl of competent E. coli 
DH5-α cells and selected with the appropriate antibiotic. 
Transformation of electrocompetent bacteria 
50 μl of electrocompetent E. coli (XL1-Blue supercompetent cells, Stratagene, or 
electrocompetent DH5a cells) were thawed on ice for 10 min. Subsequently, 10 ng of 
 plasmid were mixed with the bacteria and incubated on ice for 30 minutes. The bacterial 
cells were heat-shocked at 42 ºC for 45 seconds and returned to ice for another 2 minutes. 
500 μl of pre-heated LB medium was added to the bacteria and then they were incubated 
at 37ºC for 1 hour with shaking (250rpm) to develop antibiotic resistance. The bacteria 
were spread onto agar plate containing the appropriate antibiotic and grown overnight at 
37ºC in an inverted position. 
PCR colony check
Colonies grown overnight were picked with a 20μl tip and resuspended in a PCR 
mix that contained a total volume of 50 µl with 1x reaction buffer, 100 nM of each primer, 
1mM total dNTPs and 2.5 U of Taq (Biolabs) DNA polymerase. The remaining bacteria 
were streaked onto an LB-Ampicillin plate to obtain duplicates and incubated overnight 
110
Materials & Methods
at 37ºC in an inverted position. The PCR was 1) 95ºC for 5 min, 2) 95ºC for 30 sec, 3) 55ºC 
for 30 sec, and 4) 72ºC for (1 min/Kb), followed by cycling from step 2 to Step 4 for 30 
cycles, and by a final extension at 72ºC for 10 min. Resulting amplification products were 
run alongside the control vector in an agarose gel to check for the presence of the insert. 
DNA sequencing
Isolated plasmids were sequenced by an external sequencing facility: Parque Cien-
tífico (Madrid) or IRIC Genomic Platform (Montreal). Specific primers were utilised for 
Gαq and PKCζ was sequenced from the t7 promoter. The chromatograms were analysed 
with the Chromas Lite 2.1 software (http://technelysium.com.au/?page_id=13) and fasta 
files were analysed with Ape software  (http://biologylabs.utah.edu/jorgensen/wayned/
ape/) to annotate the final sequence.
Small-scale purification of plasmid DNA (Mini-Preps) 
Small scale purification of plasmid DNA was carried out with the Wizard® Plus SV Mi-
nipreps DNA Purification System Protocol, following manufacturer´s instructions.  Usually 
plasmids were resuspended in 30μl of dH
2
0 to reach a final concentration of 200ng/μl.
 Large-scale purification of plasmid DNA (Maxi Preps)
Large-scale purification of plasmid DNA was performed using Endofree Plasmid 
 purification kit® (Quiagen) according to the manufacturer’s instructions. A saturated 
250 ml culture of bacteria containing the plasmid of interest was grown overnight with 
 aeration at 37ºC. Plasmid DNA was eluted into 5 ml of dH
2
0 and concentrated using etha-
nol precipitation before resuspension in 100 µl of dH
2
0. Typical DNA yield was 1 µg/µl. 
Storage of bacteria 
The long-term storage of bacteria containing transformed plasmids was at -80ºC in 
10% glycerol.
DNA sequence alignment
Alignments of DNA sequences were performed using the Multiple sequence 
 alignment (Multalin) software (Corpet, 1988) that can be accessed on http://multalin.
toulouse.inra.fr/multalin/.
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b. Culture of mammalian cell lines
Maintaining and subculturing the cells
Commonly used cell lines (specified above) were maintained in medium contai-
ning DMEM supplemented with 10% heat inactivated fetal calf serum (FBS, Invitrogen) 
 glutamine 2mM and penicillin/streptomycin (0.01%/0.063%) at 37°C and 5% CO
2
. CHO 
cells stably expressing muscarinic M1 and M3 receptors were grown in alphaMEM (In-
vitrogen, no nucleosides) with 10% FBS and 500μg/ml G418 for selection. In order to 
detach cells from the plate for subculturing, they were washed with PBS and incubated 
with trypsin for 5 minutes (0.5 ml of trypsin for 10 cm dish). Afterwards, cells were resus-
pended in 10ml of fresh media. The appropriate passage of cells was performed, usually 
ranging between 1:5 and 1:15, depending on the case.
Freezing/thawing
Cells from a confluent 10 cm dish were collected and resuspended in 1 ml of ice-cold 
freezing medium (90% fetal calf serum, 10% DMSO) and transferred to a 1.5 ml cryo-tube 
(Nunc). Cells were first stored at -80ºC for 2-3 days and then were transferred to liquid N
2 
for long term storage. Cells were quickly thawed by warming them in a 37ºC waterbath. 
Next, the suspension was transferred into a 15 ml plastic tube (Falcon), 9 ml of prewar-
med growth medium was added and the suspension was centrifuged at 1200 rpm for 5 
minutes. The medium was aspirated to remove the traces of DMSO and the cells were re-
suspended in 10 ml of growth medium and plated in a dish.
Transient transfection
For transient transfections, cells were plated in 6 well, 6 cm, 10 cm or 15 cm dishes. 
The next day, cells were transfected with Lipofectamine/Plus reagents (Invitrogen). First, 
equal DNA amounts of different plasmid combinations were pipetted into 1.5ml tubes 
and resuspended in one volume of Optimem medium (Sigma) with Plus reagent. After 10 
min of incubation, another volume of Optimem medium was mixed with the appropriate 
amount of Lipofectamine reaction and added to the DNA mix. Meanwhile, medium was 
removed from the plates and replaced with a minimal volume of Optimem. After 10 min 
of incubation, the solution was added to the plates. After 3 hours the transfection medium 
was removed to lower the cytotoxic effect of lipofectamine. 
siRNA transfection
The siRNAs for PKCζ (mouse PRKCZ, NM_008860, On-target PLUS SMARTpool 
L-040823-00-0005, sequences GAUCGACCAGUCCGAAUUU, CAAGGCCUCACACACGUCUUA, 
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CAUCAAGUCUCAUGCCUUC, and GGGCAUGCCUUGUCCUGGA), clathrin (mouse CLTC, heavy 
chain), GAPDH (mouse) and scrambled used as a controls were obtained from Dharmacon 
(Lafayette, CO). NIH-3T3-M1 cells and cardiomyocytes were grown to 75% confluency 
and transfected with Dharmafect Reagent 1 (Dharmacon) according to the manufacturer’s 
protocol. 
Cell sorting with cytometer
When experiments required a homogeneous population of cells expressing the 
 desired plasmid combination they were cotransfected with GFP and subjected to sorting 
with a cell cytometer. CHO-M3 cells were plated on 150cm2 plates (Falcon) to reach a 
confluency of 80% for transfection after 24h. Different plasmids were cotransfected along 
with the pEGFP plasmid. In order to guarantee that all cells expressing GFP were also ex-
pressing the protein of interest the ratio between transfected μg of plasmid of interest/
pEGFP  plasmid was kept to 8:1.  Twenty-four hours after transfection, cells were detached 
from the plate with trypsin, resuspended in PBS and centrifuged. Cells were resuspended 
in sorting buffer (PBS, 5mM EDTA and 25mM HEPES pH 7 supplemented with 2% FBS) to 
reach a final concentration of 5 million cells per millilitre, and separated in the cytometer. 
Collecting the cells
To collect the cells for different experiments they were washed with PBS and usually 
frozen at -20ºC for a short period of time until they were lysed. Alternatively, they were 
trypsinized with 0.5 ml of trypsin for 10 cm dish or 0.25 ml for 6 cm dish for 5 minutes 
and resuspended in 10 ml of fresh media. The suspension was centrifuged in a tabletop 
centrifuge at 1200 rpm for 3 minutes. The supernatant was discarded, and the cell pellet 
was resuspended in 10 ml of PBS to remove excess of PBS. Cells were centrifuged again for 
3 minutes, the supernatant was discarded and the pellet was frozen. 
c. Culture of mammalian primary cells
Primary cultures of neonatal mouse cardiomyocytes and fibroblasts were prepared 
from C57BL/6J mice or PKC-deficient mice or wild-type animals (SV129J background) 
by dissociation of neonatal (1–2 days) hearts. After excised, hearts were kept in Ca2+-free 
HANKS medium at 4ºC and were mechanically disaggregated using a sterile scalpel blade. 
For the chemical disaggregation the tissue was transferred to a culture flask (T25) and 
kept in trypsin (0,05%) and type II collagenase (Worthington) for 15min at 37ºC after 
which  the supernatant was collected and mixed with HANKS medium with calcium to stop 
the reaction. The macroscopical tissue fragments that remained in the flask were further 
disaggregated in up to 5 trypsinization steps. Each medium collected after these steps was 
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centrifuged (5min, 1500 rpm.), resuspended in 10% FBS-DMEM and kept at 37ºC. Upon 
conclusion of the disaggregation, cells were plated onto a conventional tissue culture plate 
(10cm) to allow cardiac fibroblasts to attach for 2 h. After,   cardiomyocyte-containing su-
pernatant was plated in M12 multiwell plates precoated with 0.02% gelatin (300,000 cells 
per well) and cultured in DMEM plus 10% serum for 48 h. Cardiomyocytes were cultured 
for 2 days before use, whereas cardiac fibroblasts were expanded and passaged twice be-
fore the assay to remove contamination by endothelial cells. Both cell types were cultured 
in DMEM (D5648, Sigma- Aldrich) supplemented with 10% FBS. 
Isolation of adult cardiac myocytes was performed as previously described (Fernán-
dez-Velasco et al., 2003). Adult male C57BL6 mice or Wistar rats were heparinized (4 
units/g) and anesthetized with sodium pentobarbital (50 mg/kg). The hearts were remo-
ved and mounted on a Langerdorff perfusion apparatus. The ascending aorta was cannu-
lated, and a retrograde perfusion was set up. The hearts were perfused  successively with 
the following oxygenated solutions at 36 °C: 1) standard nominally Ca2+ Tyrode solution 
(3min) and 2) standard nominally Ca2+-free Tyrode solution (15 min) containing type II 
collagenase (Worthington). The hearts were removed from the Langerdorff apparatus, 
and after removal of atria, the ventricles were cut off and gently shaken for 3 min in a 
standard Tyrode solution containing 0.1 mM CaCl
2
 to disperse the isolated cells. The re-
sulting cell suspensions were filtered through a 250mm nylon mesh and centrifuged for 4 
min at 20G. Finally, the cell pellets were stored in Tyrode solution containing 1mM CaCl
2
.
d. Cell treatments
Primary neonatal cardiac cells were stimulated with angiotensin II (100 nM) in 
serum-free medium, during the indicated time periods. The cells were serum-starved for 
5–6 h before ligand addition to minimize basal kinase activity. Treatment with the PKCζ 
pseudosubstrate inhibitor (10mM) was initiated 30 min before agonist stimulation. For 
the inactivation of Gi proteins, cells were pretreated with pertussis toxin (100 ng/ml) for 
16 h.
Primary adult cardiac myocytes were stimulated in Tyrode solution containing 1mM 
CaCl
2
 shortly after extraction. 
NIH-3T3-M1 cells were stimulated with carbachol (10μM) after being  serum-starved 
for 5-6h.
CHO cells stably expressing muscarinic receptors were stimulated with carbachol at 
different concentrations after being serum-starved for 2h.
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e. Preparation of cell lysates
To prepare cellular lysates, collected cells were resuspended in 100-1000 µl of 
 ice-cold lysis buffer with protease and phosphatase inhibitors (Roche), transferred to a 
precooled 1.5 ml reaction tube and incubated in a rocker (250rpm) for 1 hour. RIPA  lysis 
buffer was utilised in immunoprecipitations with PKCζ, MEK5, Gαq and GRK2. For the 
detection of phosphorylation, a low detergent lysis buffer (ERK5 buffer) was preferred. 
 Afterwards, the lysates were centrifuged for 10 minutes at 4ºC in a microfuge (14000 
rpm). The cleared lysates were transferred to fresh precooled 1.5 ml reaction tubes and 
stored at -80ºC.
f. Determination of protein concentration
The protein concentration in cellular lysates was determined using the DC Protein 
Assay Reagents A, B and S (Bio-Rad). Three μl of cellular lysates were mixed with 25μl of 
solution obtained by the combination of 10 μl DC Protein Assay Reagents S and 500 μl of 
Reagent A. Afterwards, 200 µl of Reagent B was added and the solution was incubated 10 
minutes at room temperature. Absorbance at 750 nm was measured in a Biorad iMark 
 microplate Reader. Protein concentration was determined with respect to the absorban-
ces of known concentrations of BSA protein. In general, 40-60 µg of total protein were 
used for western blotting.
g. Immunoprecipitation 
For immunoprecipitations, 20μl of anti-HA agarose beads (Santa Cruz) or 0.5μl of 
GRK2 monoclonal antibody were incubated with 1 mg of cell lysates for 3 h at 4ºC. In the 
case of GRK2, protein A/G (Santa Cruz), was added and incubated for another hour. The 
beads were then washed 5-7 times in RIPA or ERK5 buffer and analyzed by  immunoblotting.
h. Immunoblotting
Cellular lysates/immunoprecipitations were separated by SDS-PAGE (sodium 
 dodecyl  sulphate-polyacrylamide  gel electrophoresis)  on  a 6-12% Laemmli gel for ce-
llular lysates. After electrophoresis, the proteins were transferred from the polyacryla-
mide gels to nitrocellulose membranes (0.2 μm, Whatman) using a wet blotting appara-
tus  (Bio-Rad). The efficiency of transfer was always evaluated by staining with Ponceau 
S staining solution for 2 minutes.  Ponceau S was washed out with TBS-tween and the 
membranes were blocked for 1 hour in TBS-tween supplemented with 5% BSA at room 
temperature, or alternatively, for detecting endogenous protein phosphorylation Phos-
phoBLOCKER™ Blocking Reagent (Cell Biolabs, Inc) was used. Membranes were incubated 
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with primary antibodies in TBS-Tween supplemented with 3% BSA overnight at 4ºC (see 
Materials for antibodies dilution). Afterwards, the blots were washed three times for 10 
minutes in TBS-Tween followed by incubation with the secondary antibodies 1 hour at 
room temperature (see Materials for antibodies dilution). After extensive washing with 
TBS-Tween, secondary antibodies bound to the proteins on the membranes were detected 
using ECL (Enhanced ChemiLuminiscence) from Amersham Pharmacia Biotech and Agfa 
films. Alternatively, in the case of fluorescent secondary antibodies, the Odyssey Infrared 
Imaging System was utilsed. Bands were quantified using by laser densitometry with a 
Biorad GS-700 scanner. 
i. GST pull-down
GST-pull down cell lysates were incubated with 20μl of Glutathione Sepharose 4B 
resin (GE Healthcare life sciences) overnight. Washing procedure and analysis was similar 
to immunoprecipitations. 
j. Immunohistochemistry and Histological Analysis of PKCζ KO and 
wild-type mice
The generation of PKC knock-out mice (SV129J background) has been described 
previously (Leitges et al., 2001). Littermate wild-type and PKCζ-/- male mice (32 weeks 
of age) were subjected to continuous infusion of angiotensin II (or PBS as a control) for 
14 days, a well established model for the induction of cardiac hypertrophy. Angiotensin II 
dissolved in PBS was continuously and subcutaneously infused at a rate of 432g/kg/day 
using Alzet osmotic mini-pumps (model 2002, Alza Corp., Mountain View, CA) implanted 
dorsally under isofluorane anesthesia Several physiological parameters were measured 
before sacrifice but are not detailed here as they are part of a different PhD thesis (Carlota 
García-Hoz, 2008). Hearts from wild- type or knock-out mice were excised and cleaned of 
blood to be fixed in formalin and embedded in paraffin wax. Sections of 5μm were proces-
sed for immunohistochemistry.
To compare the expression of Ets-1 and the activation of MEF2C and MEK5 in 
 wild-type versus knock-out mice, a high temperature antigen unmasking technique (10-
min microwaving of slides in Tris-EDTA, pH 8.0, for 90 s) was carried out. Antigen retrieval 
was performed after deparaffinization to enhance staining. Sections were then incubated 
with 5% horse serum for 30 min, and then washed three times with sterile PBS (pH 7.5) 
prior to incubation with the appropriate primary antibodies at 1:50/1:100 dilutions. Bio-
tin-conjugated secondary antibodies were purchased from Jackson ImmunoResearch La-
boratories and used at 1:4000 dilution. For all antibodies, signal was amplified using avi-
din peroxidase (ABC Elite Kit Vector) and visualized using  diaminobenzidine as a  substrate 
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(DAB kit, Vector Laborato- ries). Finally, sections were stained with  hematoxylin. Image 
analysis was performed with ImageJ 1.46a software (Wayne Rasband, National Institutes 
of Health, Bethesda, MD). Four images were acquired from randomly selected locations in 
each slide. Random RGB images were converted to 8-bit images for the quantification of 
the DAB signal to obtain the integrated density parameters (Wang et al., 2010).
k. Inositol phosphate assay 
Twenty-four hours after transfection with the desired combinations of cDNA cons-
tructs, HEK-293 cells were seeded in 24-well plates at a density of 4×105 cells per well. 
Cells were labelled overnight with 5 μCi/ml myo-inositol (Perkin Elmer) in  inositol-free 
10% FBS DMEM. Labelled cells were washed with pre-warmed PBS, detached with 
 trypsin and centrifuged in a microfuge tube. Then, cells were resuspended in inositol-
free DMEM plus 10 mM LiCl and incubated at 37 °C for 15 min. The reactions were sto-
pped by  centrifugation, removal of the incubation buffer and addition of ice-cold 6% 
 perchloric acid/1.5mM EDTA. Phenol red pH indicator was added to the sample to reach 
a final  concentration of 0.5μg/ml and the pH was adjusted to 7.0 with 10 M KOH. The 
cell debris was removed by centrifugation (5 min at room temperature in a microcentri-
fuge). The supernatants,  containing the intracellular inositol phosphates, were applied 
to  AG1-X8 ion-exchange chromatography columns (200–400 mesh, formate form). Each 
column was washed with two volumes of unlabeled inositol (5 mM) and two volumes 
of 5 mM  sodium tetraborate/60 mM ammonium formate. The total inositol phosphates 
fraction was  eluted with 3 ml of 0.1 M formic acid/1.5 M ammonium formate and quanti-
fied by  liquid  scintillation counting, as previously described6. Incorporation of radioactive 
 titrated  inositol phosphate by cell populations expressing different constitutively active 
mutants was normalised to the cpm counts of control cells (pCDNA3 transfected). 
l. Protein Complementation Assay (PCA)
In the protein-fragment-complementation assay (PCA), protein-protein interactions 
(PPIs) are measured by fusing each of the proteins of interest (A and B) to complemen-
tary N- or C- terminal regions of a reporter protein. Upon transfection of the constructs 
and expression in mammalian cells, if the proteins A and B interact, the reporter frag-
ments are brought together, fold into the native structure of the reporter and  reconstitute 
its  activity. PCA reporter proteins have been chosen as those producing a variety of 
 detectable  activities, including fluorescent, luminescent, and colorimetric signals, as well 
as  simple survival selection assays (Remy & Michnick, 2007).  Common features for this 
assay include the ability to detect protein-protein interactions in vivo and in vitro in any 
cell type, in appropriate subcellular compartments or organelles, and it allows detection 
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of  interactions that are specifically induced in response to developmental, nutritional, 
 environmental, or hormone-induced signals.
Fluorometric analysis and fluorescence microscopy of Venus-PCA
Equal amounts of CHO-M3 cells grown in 6-well plates were co-transfected with the 
Venus YFP PCA expression vectors (pcDNA3.1) coding for prey-F[1] and / or bait-F[2] 
using lipofectamine 2000 reagent (Invitrogen). Twenty-four hours after transfection, cells 
were subjected to fluorimetric analysis and fluorescence microscopy. For the fluorimetric 
analysis cells were washed with PBS, gently trypsinized and resuspended in 200 µl of PBS. 
Total cell suspensions from each well were transferred to 96-well black microtitre plates 
(Dynex; VWR Scientific,Mississauga, Ontario) and subjected to fluorometric analysis (in-
tegration time 10sec, excitation wavelength 470nm, emission wavelength 528nm) (Spec-
tra MAX GEMINI XS; Molecular Devices, Sunnyvale, CA). The background fluorescence 
intensity corresponding to non-transfected cells was subtracted from the fluorescence in-
tensities of all of the samples. For fluorescence microscopy experiments cells were grown 
in low-fluorescent media (HBSS, Invitrogen) and images were taken using a Nikon Eclipse 
TE2000U inverted microscope with  40x objective and YFP filter cube (41028, Chroma 
Technologies). Images were captured with a CoolSnap CCD camera (Photometrics) using 
Metamorph soſtware (Molecular Devices). In the case of continuous monitoring of fluo-
rescence upon the addition of a ligand, cells were kept in a closed chamber at 37ºC.
Bioluminescence measurement in Renilla luciferase PCA 
Twenty-four hours after transfection, cells grown in 6-well plates were starved for 
2 hours with serum-free DMEM. After, they were detached and resuspended in 500μl of 
PBS. A total of 100 μl of each cell suspension (aprox 105 cells) was transferred (in tripli-
cates) to 96-well white-walled plates (Corning) and transferred to a preheated (37ºC) 
LMaxII384 luminometer (Molecular Devices). Carbachol was added to the wells and en-
dpoint bioluminescence measurements were made at different times by addition of the 
Renilla  luciferase substrate, benzyl-coelenterazine (5μM, Nanolight). Rluc activity was 
monitored for the first 10 seconds after addition of the substrate (integration time 10sec, 
post-injection delay 5 sec, peak emission wavelength 482 nm).
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m. Real-time monitoring of cell adhesion, spreading, proliferation 
and cell viability using the xCELLigence System. 
Cells were seeded in 96-well gold electrode sensor plate (E-plates) pre-coated 
with fibronectin (10 mM) and monitored using the xCELLigence system RTCA SP instru-
ment (Roche Applied Science). The conceptual basis of this technology is that cells, when 
attached to the plate, act as mini-condensers and change the electrical impedance that is 
being continuously recorded by means of several electrodes located underneath the plate. 
Cellular impedance was converted to a cell index (CI) that allows for the assessment of 
different cellular processes. As cells attach and proliferate over time, impedance rises as 
does the cell index recorded. Changes in their adherence, viability and morphology also 
change the impedance and can thus be monitored. Therefore, cell proliferation, cell sur-
face coverage, cellular adhesion strength or cell viability can be measured in a real-time 
label-free cellular setting.  
This technique has been previously shown to strongly correlate with classical me-
thods for the detection of these cellular processes. The effect of the cytotoxic drug pacli-
taxel was measured by the XCELLigence system and the Sulforhodamine B (SRB) assay 
showing a good correlation (Limame et al., 2012). Similarly, cell migration was assayed 
by Matrigel-coated Transwells and crystal violet staining, which strongly correlated with 
data obtained through the XCELLigence system. The measurement of cell viability is usua-
lly performed by tetrazolium salt-based colorimetric assays (MTT, XTT, WST-1) that ac-
count for the number of active mitochondria in a cell population. Additionally, apoptosis 
can be measured by DNA fragmentation assays. It was recently demonstrated that the 
effect of two cytotoxic drugs (5-FU and MG-132) with different cell-killing kinetics was 
reliably monitored with the XCELLigence system compared to classical detection methods 
(Ke et al., 2011). Thus, this novel detection system allows for continuous label-free mo-
nitoring of cellular processes, allowing for the selection of the optimal timepoints for the 
performance of end-point classical assays.
For each experiment growth media baseline impedance was measured in each well 
before the addition of the cells to ensure all changes recorded were normalised to those 
initial values determined by the ionic composition of the media. Approximately 4000 cells 
were added per well and monitoring started shortly afterwards. Changes in cell index 
were measured each 15min for varying times (70-150hrs). 
In order to define the specific parameters to be measured in each experiment a care-
ful analysis of the global kinetics was performed. The first 16h after the cells were plated 
were excluded from every analysis as they correspond to the adhesion phase. Usually wi-
thin 6h the cells were already attached, however, 16h was chosen in order to be  confident 
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about the complete competence of the cells in response to treatments. No differences 
in adhesion were observed between the different populations. The specific analysis for 
 carbachol and cell viability experiments is explained below. 
Measurement of carbachol-induced effects 
Carbachol at varying concentrations was usually added 16h after plating the cells. 
Two different parameters were measured; cell blebbing and cell growth arrest. Cell ble-
bbing was analysed for 1h after carbachol addition when invariably all the populations 
reached a maximum increase in the cell index. This effect is transient and within 2-3h all 
the populations had decreased the cell index to basal levels before carbachol addition. The 
parameter chosen to express the blebbing capacity of each cell population was expressed 
as follows: 
Where Ci [max] is the maximum cell index, Ci [initial] is the cell index before the 
addition of carbachol and Dtime is the time difference between Ci [initial] and Ci [max].
Cell growth arrest promoted by carbachol was always measured a minimum of 6h af-
ter carbachol addition to exclude blebbing from the proliferation calculation.  Proliferation 
was measured in all populations for 24h and was expressed as follows:
Where Ci [24h] is the cell index after 24 hours, Ci [0h] is the cell index at the time-
point when proliferation measure starts (usually 6h after the addition of carbachol) and 
Dtime is the time difference between Ci [initial] and Ci [max].
The negative effect of carbachol on cell growth was detected for a maximum of 72h 
after which time cells invariably started to proliferate again. 
Measurement of long-term cell viability 
All cell populations were monitored for varying times (70-150hrs) until reaching a 
maximum cell index (inflexion point) after which it rapidly decreases, which is indicative 
of cell death. In no case cell death was due to excessive confluency as confirmed by plate 
inspection with a microscope and by the different cell indexes at which cell death was 
initiated in each experiment. Apoptosis entry time was expressed as the time between the 
start of the experiment and the inflexion point.   
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n. Statistical analysis
In all cases, experiments were analysed for statistical significance by a two-tailed T 
test. Asterisks are indicative of the following significances: * = p<0.05, ** = p<0.005, *** = 
p<0.001. 
o. Bioinformatics modelling
Structural models were generated with Pymol software at the Bioinformatics Unit 
(CBMSO). Chain Q (corresponding to Gαq) of the crystal structure of the Gαq-GRK2-Gβγ 
complex (PDB accession number: 2BCJ) was utilised.
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1. THE Gaq/PKCζ/ERK5 AXIS IN THE CARDIOVASCULAR SYSTEM
At the start of this thesis, the biochemical mechanism of the activation of ERK5 by 
GPCRs had recently been unveiled in our laboratory. The identification of PKCζ as a  novel 
Gαq effector provided the link between Gq-coupled GPCRs and the ERK5 pathway. It was 
extensively demonstrated that the presence and activity of PKCζ was essential for the 
activation of the ERK5 pathway by Gq-coupled receptor ligands such as carbachol and 
sphingosine-1-phosphate in epithelial cells (see section 4d in the Introduction). The pro-
cess did not involve the classical Gαq effector PLCβ, nor cytoplasmic tyrosine kinases or 
EGF receptor transactivation. Since Gαq is a crucial protein in cardiovascular function, we 
sought to determine the occurrence of this signalling axis in the heart.   
a. Angiotensin-mediated activation of  ERK5 in cardiomyocytes 
 requires PKCζ
We sought to determine whether a key messenger acting through Gq-coupled GPCR 
such as angiotensin II also triggered the ERK5 cascade in different cardiac cell types. Pri-
mary cultures of neonatal mouse cardiomyocytes were incubated with angiotensin II for 
different periods of time and endogenous ERK5 activation was assessed by immunoblot 
analysis using an ERK5 antibody that detects ERK5 stimulation by the appearance of a 
band of slower electrophoretic mobility, corresponding to the phosphorylated, stimulated 
kinase (Fig. R1A). A clear, time-dependent increase in endogenous ERK5 activation was 
detected in response to this agonist. Our previous results in epithelial cells indicated that 
a functional association between Gαq and PKCζ was essential for stimulation of the ERK5 
pathway by Gq-coupled GPCR agonists. To establish whether this novel pathway was also 
operating in cardiomyocytes, primary neonatal cell cultures were treated either with 
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scrambled or PKCζ-targeting siRNA oligos. Interestingly, whereas a clear ERK5 activation 
(assessed using a specific phospho-ERK5 antibody) was noted in cardiomyocytes treated 
with scrambled siRNA, angiotensin-mediated endogenous ERK5 stimulation was not de-
tected upon siRNA-induced PKCζ downregulation (Fig. R1B). We also investigated ERK5 
stimulation by angiotensin in cardiomyocytes isolated from PKCζ-deficient mice or wild-
type littermates (SV129J background). As in cardiomyocytes obtained from the C57BL/6J 
strain, angiotensin promoted a clear ERK5 activation in cells from wild-type, with an 
earlier peak of activation, whereas this response was absent in PKCζ-/-  cardiomyocytes 
(Fig. R1C). 
Figure R1. Stimulation of Gq-coupled GPCR by angiotensin II promotes ERK5 activation in neonatal car-
diomyocytes in a PKCζ-dependent manner. (A) Neonatal mouse cardiomyocytes primary cultures were incu-
bated with 100 nM Angiotensin II for the indicated times, and endogenous ERK5 activation determined with 
an ERK5-antibody that recognises both the phosphorylated (upper band) and un-phosphorylated (lower 
band) forms of ERK5 as detailed in Methods. Data (mean ± SEM of 3 independent experiments) were ex-
pressed as fold-activation compared to the absence of agonist (*p<0.05, two tailed T-test). (B),(C), Angioten-
sin II-induced ERK5 activation is abrogated upon PKCζ down-regulation in neonatal mouse cardiomyocytes. 
(B), Primary cardiomyocytes were treated with scrambled or PKCζ-targeting siRNA oligos as detailed in the 
Methods section, and then challenged with angiotensin 100 nM for the indicated times. ERK5 activation was 
determined in cell lysates with a phospho-ERK5 specific antibody. Along with PKCζ expression, total ERK5 
and alpha-tubulin levels were also determined as loading controls. (C), Primary cultures of cardiomyocytes 
were obtained from wild-type (wt) or PKCζ-deficient (PKCζ-/-) mice as detailed in the Methods section, and 
challenged with angiotensin 100 nM for different time periods. ERK5 activation was monitored and quan-
tified and data (mean ± SEM of 3 independent experiments, with activation in the absence of angiotensin 
taken as control condition) expressed as percentage of the phosphorylated kinase (p-ERK5) versus total 
 ERK5.                                                                                                                                                                                                         
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It is well established that cardiac myocytes undergo dramatic phenotypical and 
functional changes from birth until becoming fully developed cells (Ahuja et al., 2007) 
(Fig. R2A). Hence, studies in neonatal cardiac myocytes may not reflect the situation in the 
adult mice. Thus, we sought to determine whether the Gαq-ERK5 pathway was conserved 
in adult cardiomyocytes. We found that angiotensin-dependent ERK5 stimulation could 
also be observed in cardiomyocytes isolated from adult mouse (Fig. R2B) or rat (Fig. R2C) 
and that this process was blocked in the presence of the specific PKCζ inhibitor (the cell-
permeable myristoylated PKCζ pseudosubstrate peptide) (Fig. R2C). Collectively, data in 
figures R1&2 indicate that PKCζ is strictly required for Gαq-mediated ERK5 stimulation in 
cardiomyocytes. 
Figure R2. The AngII-initiated Gαq-PKCζ-ERK5 pathway is operative in adult cardiac myocytes. Primary 
cultures of adult mouse (A) or rat (B) cardiomyocytes were isolated as detailed in the Methods section and 
challenged with Angiotensin 100 nM for 15 min. (B), Adult rat cardiomyocytes were preincubated with ve-
hicle or a specific PKCζ pseudosubstrate inhibitor (10 mM). ERK5 activation was detected in cell lysates with 
a phospho-ERK5 specific antibody, and data was normalised using GAPDH as loading control and expressed 
as fold-induction over basal conditions. Data are mean ± SEM of 3 independent experiments (*p<0.05, two 
tailed T-test).                                                                                                                                                                                        
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b. Angiotensin-mediated activation of  ERK5 in cardiac fibroblasts 
requires PKCζ
Although cardiac myocytes make up the bulk of the myocardial volume, cardiac fi-
broblasts are the most numerous cell type in the heart and play essential roles in myo-
cardial function. Thus, we also sought to ascertain whether angiotensin could promote 
ERK5 activation in cardiac fibroblasts in a similar fashion as in cardiomyocytes. Indeed, 
acute angiotensin II treatment promoted a clear stimulatory time-course of endogenous 
ERK5 in cardiac fibroblasts (Fig. R3A). In line with the data in cardiomyocytes, the pre-
treatment of primary neonatal cardiac fibroblasts prior to agonist challenge with a PKCζ 
inhibitor  markedly decreased endogenous ERK5 phosphorylation in response to angio-
tensin II (Fig. R3B). Also, since paracrine transmodulation of Gi-coupled-GPCR has been 
described to operate in certain pathways of cardiac fibroblasts, we treated the cells with 
pertussis toxin (PTX) to inhibit Gi-mediated signalling. In this context, ERK5 activation by 
angiotensin II in cardiac fibroblasts was not affected (Fig. R3C). Together, these data su-
ggest that PKCζ is also required for Gαq-mediated ERK5 activation in cardiac fibroblasts.   
Figure R3. The AngII-initiated Gαq-PKCζ-ERK5 pathway is operative in neonatal cardiac fibroblasts. (A) 
Neonatal mouse cardiac fibroblasts were challenged with angiotensin (AngII), and ERK5 stimulation was 
determined in cell lysates with a phospho-ERK5 specific antibody. Data (mean +/- SEM of 3 independent 
experiments) were normalised using actin as a loading control and expressed as fold induction compared 
with the absence of agonist (*p<0.05, **p<0.005, two tailed T-test). Rat (B) or mouse (C) cardiac fibroblasts 
were preincubated with vehicle or with a myristoylated PKCζ pseudosubstrate (PS) inhibitor (10μM, B) or 
pertussis toxin (Ptx 100ng/ml, C) and challenged with 100 nM angiotensin for the indicated times. ERK5 
activation was determined as in A. Blots are representative of 2-3 experiments.                                                        
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c. The angiotensin Gq-coupled receptor activates ERK5 through 
PKCζ in vivo
To assess the potential relevance of the Gαq/PKCζ pathway in cardiac cells in vivo, 
we subjected homozygous null mice (PKCζ-/-) and matched control littermates (wild-ty-
pe) to chronic angiotensin II (or control vehicle) infusion for 14 days using osmotic mi-
ni-pumps. This is a classical, well-established procedure to assess angiotensin effects in 
cardiac functions and to promote cardiac hypertrophy in mice models (Ikeda et al., 2005). 
At the end of the infusion period we performed an immuno-histological analysis of the 
hearts using specific antibodies against known upstream and downstream elements of 
the ERK5 cascade (Fig R4A). The use of phosphospecific antibodies showed that MEK5 
(the upstream activator of ERK5) and MEF2C (a well-established downstream target of 
ERK5) display a higher phosphorylation state upon angiotensin treatment in wild-type 
animals that is absent in PKCζ-deficient mice (Fig. R4B). Similarly, the expression of Ets-1 
(a known target of MEF2c) was augmented in wild-type animals as opposed to PKCζ KO 
mice (Fig. R4B). Quantification of the DAB staining (see methods) confirmed the signifi-
cant difference in the ERK5 pathway activation markers upon angiotensin treatment bet-
ween wild type and PKCζ-/- animals (Fig. R4C).These data further indicate that PKCζ is an 
important mediator of ERK5 activation by Gq-coupled GPCRs in murine heart in vivo and 
support that the Gαq/PKCζ/ERK5 pathway plays a relevant role in the response triggered 
by angiotensin II.
As part of a different PhD thesis in our laboratory, the physiological response of the-
se animals to angiotensin was studied and revealed that the Gαq/PKCζ/ERK5 signalling 
axis had an essential role in the development of cardiac hypertrophy programmes in res-
ponse to this challenge (see introduction, section 5d) (García-Hoz et al., 2010).
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Figure R4. Angiotensin II triggers the Gαq-PKCζ-ERK5 pathway in vivo (A) Cartoon depicting the steps of 
the AngII-ERK5 pathway in the heart leading to the activation of MEF2c and to the transcription of Ets-1. (B) 
PKCζ -/- and matched wt control littermates were subjected to chronic angiotensin II (AngII) infusion (or 
PBS, as a control vehicle) for 14 days using osmotic minipumps as detailed in Methods. Sections of hearts 
from each mouse population were analysed through immunohistochemistry. The activation status of the 
pathway was assessed through MEK5 and MEF2C stimulation by phosphorylation and expression levels 
of Ets-1. Brown shading indicates positive DAB staining. Signal intensity was quantified as detailed in the 
Methods section and data plotted below represent the average of 3 independent experiments (**p<0.005; 
***p<0.001, two tailed T-test). a.u., arbitrary units.                                                                                                                   
2. CONTRIBUTION OF Gaq/ b-ARRESTIN SIGNALLING ROUTES TO 
THE ACTIVATION OF ERK5 BY GPCR
Once established the relevance of the pathway in the heart, we aimed to identify 
the specific contribution of Gaq and β-arrestin signalling branches downstream of GPCRs 
towards the activation of ERK5. Since b-arrestin has been recently proposed as an alter-
native signalling node to heterotrimeric G proteins, it is essential to ascertain whether a 
known GPCR-initiated pathway like ERK5 is equally or differentially activated by these 
two signalling players. This is especially relevant in the heart where alternative Gαq- or 
β-arrestin-initiated pathways can have opposite physiological effects (see introduction, 
section 1d). 
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a. ERK5 activation by Gq-coupled GPCR does not require receptor 
internalisation
In order to facilitate the study of the mechanistic basis of GPCR-ERK5 activation we 
initially utilised different cell lines overexpressing Gq-coupled muscarinic receptors. This 
has been widely proven to be the most successful experimental approach to study ERK5 
phosphorylation due to the poor quality of currently available detection methods. In par-
ticular, the NIH-3T3 cell line that stably overexpresses the M1 muscarinic receptor (NIH-
3T3-M1) has been extensively used to detect endogenous ERK5 activation.
Upon activation, GPCRs internalise in a process that will lead to recycling or degrada-
tion of the receptor (see introduction, section 1d). Recently, these receptor desensitisation 
processes have been reported to also provide alternative ways for signalling propagation 
via β-arrestins. Since β-arrestin recruitment leads to GPCR internalisation in a process 
that virtually always involves the participation of clathrin, we determined the activation of 
the ERK5 pathway in a clathrin knock-down scenario. Thus, NIH-3T3-M1 cells were pre-
treated with scrambled siRNA or clathrin-targeting oligonucleotides and stimulated with 
the muscarinic agonist carbachol for 30 minutes (Fig. R5). Results indicated that ERK5 
phosphorylation was unaffected in the absence of clathrin thus suggesting that clathrin-
mediated receptor internalisation was not required for this process. 
Figure R5. Carbachol-induced activation of the Gαq-PKCζ-ERK5 pathway does not require clathrin-depen-
dent internalisation processes. NIH-3T3 cells stably overexpressing the muscarinic M1 receptor (NIH-3T3-
M1 cells) were transfected with siRNA oligonucleotides targeting clathrin heavy chain or non-targeting 
scrambled oligonucleotides as detailed in the Methods section. After 48h of incubation, cells were serum-
starved for 5h and challenged with carbachol (10μM) for the indicated times. ERK5 phosphorylation was 
assessed in cell lysates with a phospho-ERK5 specific antibody. Data (mean +/- SEM of 3 independent expe-
riments) were normalised using ERK5 as loading control and expressed as fold-induction over basal condi-
tions. Clathrin and alpha-tubulin expression levels were also determined (ns: non significant).                                           
Since other alternative internalisation processes have been reported for GPCRs, we 
sought to determine whether they played a role in ERK5 activation. To that purpose, we 
utilised a Cho cell line that overexpresses an internalisation-deficient mutant M3 musca-
rinic receptor. This receptor harbours several mutations on the third internal loop of the 
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receptor (motif SASS to AAAA) that prevent trafficking into endosomes (Torrecilla et al., 
2007). It is noteworthy that both M1 and M3 muscarinic receptors couple to Gαq with 
very similar affinity and both have recurrently been used as models to study Gαq signa-
lling. In the Cho cell lines used throughout this thesis, ERK5 is invariably transfected and 
immunoprecipitated due to the scarcity of ERK5 molecules in this cell type and the addi-
tional difficulty posed by the poor quality of phosphoantibodies available for this protein. 
Thus, we transfected HA-tagged ERK5 into Cho-M3 and Cho-M3-internalisation-deficient 
cells and stimulated with carbachol at different times. Surprisingly, we detected an increa-
sed and sustained activation of ERK5 by the internalisation deficient mutant compared 
to control (Fig. R6). This further confirmed that ERK5 activation by muscarinic receptors 
occurs independently of receptor internalisation.   
Figure R6. Carbachol-induced activation of the Gαq-PKCζ-ERK5 does not require receptor internalisation. 
Cho cells stably overexpressing wild-type muscarinic M3 receptor or internalisation-deficient M3 receptor 
(characterised in (Torrecilla et al., 2007)) were transfected with ERK5-HA. Twenty-four hours after trans-
fection, cells were serum-starved for 2h and stimulated with carbachol (10μM). ERK5-HA was immuno-
precipitated with an anti-HA agarose-conjugated antibody as detailed in the Methods section. ERK5 phos-
phorylation was assessed in the immunoprecipitate using a phosphospecific antibody. Data (mean +/- SEM 
of 3 independent experiments) were normalised using ERK5 as loading control and expressed as fold-induc-
tion over basal conditions (*p<0.05, two-tailed T-test) .                                                                                                   
b. ERK5 activation by Gq-coupled GPCRs does not involve receptor 
phosphorylation or β-arrestin recruitment
β-arrestin is known to be recruited to activated GPCRs through a mechanism depen-
dent on GRK2-mediated phosphorylation of the receptor. Thus, the translocation of arres-
tins to the plasma membrane occurs through the recognition of phosphorylation sites on 
the internal loops of receptors. To this point, we had determined that receptor internalisa-
tion was not required for ERK5 activation which consistently suggested that, if β-arrestin 
participates in ERK5 activation, this is not occurring in the endosomes. However, it re-
mained the possibility that β-arrestin could initiate pathways leading to ERK5 activation 
from the plasma membrane. In order to ascertain this, we utilised a Cho cell line overex-
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pressing a  phospho-deficient muscarinic M3 mutant receptor. This receptor, in which all 
the phosphorylatable serines within the internal loops are mutated to alanine, has been 
described to be completely unable to recruit βarrestins but to be otherwise functional 
(Kong et al., 2010). Notably, acetylcholine-induced ERK5 activation by the phosphodefi-
cient M3 receptor was augmented compared to wild-type M3 receptor as shown in Fig. 
R7A. To further confirm this, we used a similar phosphodeficient version of the M1 re-
ceptor and stimulated with submaximal doses of acetylcholine in order to highlight the 
differences in ERK5 activation by wild-type or mutant receptor. Indeed, we observed a 
clear enhancement of ERK5 activation by the phosphodeficient mutant M1 receptor (Fig. 
R7B). Taken together, these data suggest that the phosphorylation of the receptor and the 
subsequent recruitment of β-arrestins are not involved in ERK5 activation by Gq-coupled 
GPCRs. On the contrary, downregulation of these processes seems to favour the activation 
of the ERK5 pathway.
Figure R7. Acetylcholine-
induced activation of the 
Gαq-PKCζ-ERK5 does not 
require receptor phos-
phorylation. Different sta-
ble lines of Cho cells (pre-
viously characterised in 
(Kong et al., 2010)) that 
overexpress wild-type or 
phosphorylation-deficient 
muscarinic M3 recep-
tor (A)  and wild-type or 
phosphorylation-deficient 
muscarinic M1 receptor 
(B) were utilised. All cell 
lines were transfected with 
ERK5-HA. Twenty-four 
hours after transfection, 
cells were serum-starved 
for 2h and stimulated with 
acetylcholine (100μM) for 
the indicated times (A) or 
incubated for 15min with 
acetylcholine at various concentrations (B). ERK5 phosphorylation was assessed as in Fig. R6. In (A) repre-
sentative blot of two independent experiments is shown. In (B), data (mean +/- SD of 2 independent expe-
riments) were normalised using ERK5 as loading control and expressed as fold-induction over maximum 
activation (*p<0.05, **p<0.005; two-tailed T-test).                                                                                                                 
c. ERK5 activation by GPCRs is Gaq-biased
The data above indicated that Gαq-initiated signalling is the key participant in ERK5 
activation by muscarinic Gq-coupled GPCR. We sought to confirm this notion by stu-
dying the activation of ERK5 in a Gαq-enriched cell population. In these circumstances, 
134
Results
 Gαq-dependent pathways would be potentiated whereas β-arrestin-dependent pathways 
would either remain unaltered or be downregulated as a result of a functional competi-
tion. Interestingly, the activation of ERK5 in Cho-M3 cells overexpressing Gαq was greatly 
enhanced compared to control (Fig. R8). This confirms that Gαq activation is the predomi-
nant event in the ERK5 pathway. 
Figure R8. Gαq overexpression enhances ERK5 activation by carbachol. Cho cells stably expressing wild-
type muscarinic M3 receptor (Cho-M3 cells) were transfected with ERK5-HA and either pcDNA3 or Gαq. 
Twenty-four hours after transfection, cells were serum-starved for 2h and stimulated with carbachol 
(10μM) for the indicated times. ERK5 phosphorylation was assessed as in Fig. R6. Data (mean +/- SEM of 3 
independent experiments) were normalised using ERK5 as loading control and expressed as fold-induction 
over basal conditions (*p<0.05, **p<0.005, Two-tailed T-test).                                                                                                              
To further establish the biased nature of this pathway we utilised the angiotensin 
receptor ligand SII (Sar1-Ile4-Ile8 (SII) Ang II), which displays biased properties towards 
βarrestin-pathways. As shown in Fig. R9, the ERK5 pathway was not activated by the SII 
ligand compared to the unbiased natural ligand angiotensin II in primary cardiac fibro-
blasts. Collectively, data in fig R5-R9 suggest that ERK5 activation by muscarinic and an-
giotensin receptors is Gαq-biased.
Figure R9. ERK5 is not activated by a b-arrestin-biased angiotensin receptor agonist in cardiac fibroblasts. 
Neonatal mouse cardiac fibroblasts were challenged with angiotensin (AngII, 100nM) or Sar1-Ile4-Ile8-
Ang II (SII, 30mM) for 30 minutes, and endogenous ERK5 stimulation was determined in cell lysates with 
a phospho-ERK5 specific antibody. Data (mean +/- SEM of 3 independent experiments) were normalised 
using total ERK5 as a loading control and expressed as fold induction compared with the absence of agonist 
(*p<0.05, two tailed T-test).                                                                                                                                                            
135
Results
3. THE Gaq/PKCζ COMPLEX IN LIVING CELLS
Previous data suggested that the initial and key event for the activation of the ERK5 
pathway by Gq-GPCRs is the formation of a complex between Gαq and the novel effector 
PKCζ (García-Hoz et al., 2010). In order to further dissect the mechanisms of the pathway, 
we aimed at the detailed characterization of this protein-protein complex.
a. The Gaq/PKCζ complex is specifically detected in living cells
We had previously shown that a Gαq/PKCζ complex was transiently formed upon 
agonist stimulation (as indicated by immunoprecipitation experiments) and that these 
purified proteins could interact directly (García-Hoz et al., 2010). Thus, we sought to com-
plement the in vitro characterization with an approach that allowed detecting the interac-
tion in living cells. To that purpose we implemented the protein complementation assay 
(PCA) with the fluorescent protein venus-YFP, an engineered and more fluorescent ver-
sion of YFP. The assay consisted in expressing PKCζ and Gαq tagged to cognate fragments 
of YFP (N- or C-terminal halves) in living cells. Interaction events between PKCζ and Gαq 
would bring the YFP fragments together thus allowing reconstitution of the native fold of 
the fluorescent protein (see scheme in Fig. R10A). Therefore, fluorescence is a direct mea-
sure of the number of protein-protein complexes formed and, additionally, the irreversi-
ble nature of the assay allows easy detection and quantification of otherwise transient 
complexes. 
A known high-affinity interaction (Zipper dimerisation) was used as a positive con-
trol in the venus-YFP PCA assay. Furthermore, we also analysed the potential formation of 
complexes between Gαq and another member of the PKC family (PLCβ) and also between 
PKCζ and another member of the Gα family (Gαi1), to assess the specificity of the interac-
tion. As shown in Fig R10b and R10c, the Gαq/PKCζ complex can be readily detected in 
living cells compared to control and it is specific since neither PLCβ nor Gαi are able to 
reconstitute the fluorescence (e.g. to interact) with Gαq and PKCζ, respectively. This pro-
vides the in vivo confirmation to similar results from coimmunoprecipitation experiments 
(García-Hoz et al., 2010)
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Figure R10. The Gαq/PKCζ complex is specifically detected in living cells. (A) Conceptual explanation of 
the venus-YFP-based protein complementation assay (PCA). This technique utilises the reconstitution of a 
fluorescent protein from N/C-terminal halves that are fused to two proteins of interest. Fluorescence upon 
expression of the protein pair in living cells is thus a measure of the occurrence of an interaction between 
the proteins, which brings cognate fragments of YFP close enough to allow reconstitution of the native fold. 
The irreversible nature of fluorescent protein YFP-PCA assays allows for easy trapping and visualisation of 
transient complexes. (B) The interaction between Gαq and PKCζ occurs in living cells and is family-specific 
since PLCβ, as a control for other PKCs, and Gαi, as a control for other Galpha subunits, do not interact with 
Gαq and PKCζ, respectively.  Cho-M3 cells were transfected with different pairs of protein complementation 
assay (PCA) plasmids that express proteins fused to cognate fragments of venus-YFP: Control (PKCζ-Venus 
YFP[F1]+pcDNA3), Zipper+Zipper (Zipper-Venus YFP[F1]+ Zipper Venus YFP[F2]), Gαq+PKCζ (Gαq-Venus 
YFP[F1]+ PKCζ-Venus YFP[F2]), Gαq+PLCβ (Gαq-Venus YFP[F1]+ PLCβ-Venus YFP[F2]), PKCζ+Gαi (Gαi-
Venus YFP[F1]+ PKCζ-Venus YFP[F2]). Twenty-four hours after transfection cells were visualised under the 
microscope as detailed in the Methods section. Representative brightfield and YFP fluorescence images at 
40x magnification are shown.  (C) Fluorimetric analysis of the populations above was performed as detailed 
in the Methods section and data (mean +/- SEM of 3 independent experiments) were normalised with res-
pect to control.                                                                                                                                                                                    
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b. PKCζ does not associate with Gα11, the other ubiquitous mem-
ber of the  Gαq/11 family.
The Gαq/11 family is composed of four members of whom the most notable and 
ubiquitous are Gαq and Gα11. To date, Gαq and Gα11 are thought to play very similar ro-
les and to act on the same cellular effectors. Thus, by performing a PCA-based approach 
we initially aimed to confirm that the novel effector PKCζ would indifferently associate 
with Gαq and Gα11. Surprisingly, whereas PKCζ readily associated with Gαq, it did not 
achieve a significant fluorescent signal when coexpressed with Gα11 as demonstrated by 
microscopy images and fluorescence quantification (Fig. R11A). In order to confirm the 
lack of association detected in living cells we performed an immunoprecipitation appro-
ach. Similarly, when HA-tagged PKCζ is immunoprecipitated Gαq is clearly detected in the 
multimolecular complex, whereas this is not the case for Gα11 (Fig. R11B). 
Figure R11. PKCζ selectively interacts with Gαq but not with Gα11. (A) Venus-YFP-based PCA assay was 
performed as in Figure R10 in Cho-M3 cells: Control (PKCζ-Venus YFP[F1]+pcDNA3), Gαq+PKCζ (Gαq-Venus 
YFP[F1]+ PKCζ-Venus YFP[F2]), PKCζ+Gα11 (Gα11-Venus YFP[F1]+ PKCζ-Venus YFP[F2]). (B) COS-7 cells 
were transfected with different combinations of plasmids encoding HA-PKCζ, Gαq and Gα11. HA-PKCζ was 
immunoprecipitated with anti-HA antibody coupled to agarose beads. Immunoprecipitates and total lysates 
were analysed by western blot with specific antibodies. To compare the association of the different Gαq/11 
family members to PKCζ, blot bands were quantified and normalised by total HA-PKCζ. Data (mean +/- SEM 
of 3 independent experiments) were normalised taking the Gαq/PKCζ wt association as a control.                             
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Taken together, data in Figures R10 and R11 indicate that the Gαq/PKCζ complex is 
selectively detected in living cells and seems to be Gαq-specific since the closely related 
member of the Gαq/11 family, Gα11, is not able to interact with PKCζ. Indeed, PKCζ could 
be the first differential Gαq/Gα11 effector to be identified.
4. IDENTIFICATION OF  THE INTERACTION SURFACES INVOLVED IN 
THE Gaq/PKCζ COMPLEX 
We next aimed to characterise the interaction surfaces involved in Gαq/PKCζ asso-
ciation. The identification of such binding surfaces could provide an additional level of 
information with regards to the functionality and the biochemical mechanisms involved 
in the activation of this pathway.  
a. The PB1 domain of PKCζ is essential for Gαq association and 
ERK5 activation
Initially, we characterised the interaction surface within PKCζ. This protein displays 
a three-dimensional structure (Fig. R12A) in which the catalytic site is obstructed by an 
autoinhibitory domain called pseudosubstrate (see Introduction, section 3b). Additio-
nally, it harbours a C1 and a PB1 domain (Fig. R12A). PB1 domains are known protein-
protein interaction domains and, in PKCζ, this module alone accounts for the majority 
of known interactions (Moscat & Diaz-Meco, 2000; Sumimoto et al., 2007). Hence, we 
sought to determine whether this domain was involved in the activation of ERK5 by Gq-
coupled GPCRs. NIH-3T3-M1 cells were transfected with GST-tagged PKCζPB1 domain or 
GST alone as a control and the activation of ERK5 in response to carbachol was assessed 
(Fig. R12B). The overexpression of PKCζ-PB1 domain had a dominant-negative effect and 
was sufficient to abrogate ERK5 activation. Consistent with a key role of this PKCζ region, 
PB1 domain overexpression interfered with the formation of the Gαq/PKCζ complex (Fig. 
R12C), thus suggesting that PKCζ associates with Gαq through its PB1 domain. 
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Figure R12. Overexpression of 
the PKCζ-PB1 domain abrogates 
GPCR-mediated ERK5 activation 
and Gαq/PKCζ interaction. (A) 
Cartoon depicting the three-
dimensional structure of PKCζ 
showing the different domains: 
PB1, PSI (pseudo-substrate in-
hibitory region), C1, K (kinase 
domain). (B) NIH-3T3-M1 cells 
were transiently transfected 
with the PB1 domain of PKCζ 
fused to GST (aa1-122 of PKCζ). 
Forty eight hours after transfec-
tion, cells were challenged with 
10 mM carbachol for different 
times. Endogenous ERK5 acti-
vation was determined with a 
phospho-specific antibody. Data 
(mean +/- SEM of three inde-
pendent experiments) were nor-
malised using ERK5 as loading 
control and expressed as fold-
induction over basal conditions 
(*p<0.05, two tailed T-test).  (C) COS-7 cells were transfected with different combinations of plasmids enco-
ding HA-PKCζ, Gαq and GST-PKCζPB1. HA-PKCζ was immunoprecipitated with anti-HA antibody coupled to 
agarose beads. Immunoprecipitates and total lysates were analysed by western blot with specific antibodies 
to determine the coimmunoprecipitation of Gαq and PKCζ in the presence/absence of PKCζ-PB1 domain. A 
representative blot of 3 independent experiments is shown.                                                                                               
b. Lysine 19 is a crucial residue for PKCζ to interact with Gαq 
The PB1 domain of PKCζ, as that in PKCλ or p62, is composed of a PB1-type I (acidic) 
and a PB1-type II (basic) domain. It is predicted that type I and II dimerise/oligomerise 
providing signalling platforms in several cellular processes (see Introduction, section 3b). 
We initially sought to determine whether the PB1-type II domain of PKCζ was driving the 
interaction with Gαq. A rationale-based mutagenesis strategy was designed (Fig. R13) to 
mutate aminoacids that had been determined crucial in other PB1-type II interactions in 
the literature (Hirano et al., 2005). Lysine in position 19 has been pointed as an invaria-
ble aminoacid in all PB1-PB1 structures (Hirano et al., 2004, 2005) and to co-ordinately 
work with other basic residues located around the lysine. Additionally, residues around 
position 90 in the primary sequence are known to locate nearby the lysine in the three-
dimensional structure and contribute to form the binding surface (Fig. R13). 
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Figure R13. PKCζ-PB1 domain analysis and mutagenesis strategy. Cartoon depicting the primary sequence 
of PKCζ with different domains highlighted, and a specific focus on the PB1 type II domain. The PB1 type 
II domain, known to participate in ERK5 activation through an interaction with MEK5, was targeted for 
directed point mutagenesis. Selected residues are homologous to previously identified interaction-driving 
aminoacids in other PB1-type II harbouring proteins (Hirano et al., 2005).                                                                     
Based on Fig. R13, several alanine point mutations were generated in the PB1-type 
II domain of PKCζ. Mutant PKCζ forms were overexpressed in COS-7 cells together with 
Gαq wild-type and immunoprecipitated with an anti HA antibody. The presence of co-
precipitated Gαq with the different mutants was assessed by western-blot as shown in 
figures R14A&B. The most significant decrease in the interaction could be ascribed to the 
PKCζ-K19A mutation that alone accounted for a 70% decrease in the amount of copreci-
pitated Gαq (Fig. R14A). Other PB1-type II aminoacids such as R15 or I92 also seemed to 
participate in the interaction. Interestingly, the PKCζ-H21A mutant had an enhanced abi-
lity to associate to Gαq (Fig. R14B), which supports the involvement of that surface in the 
interaction. Additionally, it was demonstrated that lysine 19 in PKCζ is also essential for 
its interaction with MEK5 (Fig. R14C), as predicted by other PB1-PB1 structures. Taken 
together, these data indicate that the PB1 domain type II of PKCζ, and particularly lysine 
in position 19, is key for binding to both Gαq and MEK5. 
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Figure R14. Identification of key residues in PKCζ required for the interaction with Gαq. Alanine-scanning 
mutagenesis was performed in PKCζ following the strategy depicted in Fig. R13. (A, C) COS-7 cells were 
transfected with combinations of plasmids encoding Gαq and different HA-PKCζ mutants. HA-PKCζ was im-
munoprecipitated with anti-HA antibody coupled to agarose beads. Immunoprecipitates and total lysates 
were analysed by western blot with specific antibodies. To compare the association of Gαq to the diffe-
rent PKCζ mutants, blot bands were quantified and normalised by total HA-PKCζ. Data (mean +/- SEM of 
three independent experiments) were normalised with respect to Gαq/PKCζ wt association as a control. 
(B) COS-7 cells were transfected with different combinations of plasmids encoding MEK5-GST, HA-PKCζ 
and HA-PKCζK19A and a pull-down with glutathione sepharose was performed to precipitate MEK5-GST as 
described in the Methods section. Immunoprecipitates and total lysates were analysed by western blot with 
specific antibodies to determine the association of MEK5 to PKCζK19A mutant. Representative blot is shown 
of 3 independent experiments (*p<0.05, **p<0.005, two tailed T-test).                                                                                 
c. The C-terminus of Gαq is required for association to PKCζ
In order to start delineating the region of Gαq that is involved in PKCζ binding we 
utilised the previously generated information on the specificity of this complex. We have 
shown that members of the Gαi family cannot interact with PKCζ either in vitro (García-
Hoz et al., 2010) or in living cells (Fig R10). Thus, we utilised two different chimeras in 
which the C-terminus (aa222-353) of either Gαq or Gαi1 had been substituted by that 
of Gαi1 and Gαq, respectively (Fig. R15A). We co-expressed the two different chimeras 
together with HA-PKCζ in COS-7 cells and immunoprecipitated with an anti-HA antibody 
(Fig. R15B). It was clearly shown that the substitution of Gαq C-terminus by that of Gαi1 
completely abolished the association with PKCζ thus indicating that the interaction deter-
minants are predominantly located in this region. 
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Figure R15. The C-ter-
minus of Gαq (aa222-
353) is essential to inte-
ract with PKCζ. Chimeric 
constructs of Gαq and 
Gαi (known to not in-
teract with PKCζ) were 
utilised to delineate the 
region of Gαq that con-
tains the determinant to 
interact with PKCζ (A) 
Cartoon depicting the arrangement of the Gαq/Gαi chimeras. (B) COS-7 cells were transfected with diffe-
rent combinations of plasmids encoding EE-tagged chimeras (Gαi-ctGαq, Gαq-ctGαi) and HA-PKCζ mutants. 
HA-PKCζ was immunoprecipitated with anti-HA antibody coupled to agarose beads. Immunoprecipitates 
and total lysates were analysed by western blot with specific anti-HA and anti-EE antibodies to determine 
PKCζ association to the different chimeras. A representative blot of 3 independent experiments is shown.    
d. Identification of a pseudo-PB1 domain in the Gαq 
 effector-binding region
In order to carry out a rationale-based mutagenesis strategy, a careful analysis of 
binding surfaces was performed in the C-terminal region of Gαq. A highlight of common 
binding surfaces in Gαq is shown in Figure R16. Crystal structures and mutagenesis stu-
dies of Gαq have contributed to identifying the crucial aminoacids involved in known Gαq 
complexes (underlined in different colours in Fig. R16). In this regard, we performed se-
veral sequence alignments between known PKCζ-interacting partners and Gαq. The com-
parison between MEK5 PB1-type I domain and the effector binding region of Gαq showed 
some striking similarities, with predominance of acidic residues at the b4-a3 loop. Since 
we had previously established that PKCζ interacts with Gαq through its PB1-type II do-
main, we hypothesised that Gαq could harbour a pseudo-PB1 type I domain that would be 
responsible for the interaction. Additionally, PB1-PB1 interactions have been shown pre-
dominantly electrostatic between positively and negatively charged surfaces and it was 
tempting to suggest that a similar phenomenon would be occurring between lysine/argi-
nine residues in PKCζ PB1-type II and glutamic/aspartic acids in the Gαq  pseudo-PB1-type 
I domain. 
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Figure R16. Identification of a pseudo-PB1 domain in the Gαq effector-binding region. Cartoon depicting 
the different domains of Gαq and the corresponding secondary structure motifs. From top to bottom: Full-
length Gαq highlighting the helical and GTPase domains. The GTPase domain harbours the switch regions 
that undergo profound conformational changes upon GTP binding. The two regions (1-222, 222-353) asses-
sed in Fig R15 for PKCζ binding are indicated below. A close-up view of the switchII/III region illustrates the 
binding sites for RGS proteins and effectors. Important residues for Gαq interaction with PLCβ, GRK2, p63R-
hoGEF and RGS proteins are highlighted in different colours (data from(Fan et al., 2003; Shankaranarayanan 
et al., 2010; Tesmer et al., 2005; Tsuboi et al., 2008)). The region corresponding to the C-terminus of the b4 
strand and the b4-a3 loop presents a striking sequence similarity to the PB1 domain type I of MEK5, which 
is known to interact with PKCζ PB1 type II domain. Homologous residues in Gαq with acidic properties were 
selected for point mutagenesis.                                                                                                                                                        
e. Mutation of E234 and E245 in Gaq abrogates PKCζ binding 
According to information in Figure R16, we proceeded to mutate negatively-charged 
residues in the Gαq pseudo-PB1 domain. Gαq mutants were overexpressed in COS-7 cells 
together with wild-type HA-PKCζ and immunoprecipitation against the HA tag was per-
formed. Most representative results are shown in Fig. 17A. The combined mutation E234/
E245-AA in Gαq decreased association with PKCζ up to 70% (Fig. R17A). Interestingly, 
these two aminoacids are conserved in other PB1-type I domain-harbouring proteins 
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(MEK5, p62, PKCζ and PKCλ) (Fig. R17B). Additionally, their equivalents in PB1-type I 
domain proteins are crucial for their function and are part of the two conserved clusters 
of the PB1-type I domain (A1 and A2) (Fig. R17B)(Hirano et al., 2005). Moreover, an align-
ment between all members of the Gα family members showed that the coexistence of both 
E234 and E245 is a distinctive feature of the Gαq/11 subfamily (Fig. R17C).  Taken toge-
ther, data in figures R16 and R17 indicate that a Gαq region in the effector-binding site 
that resembles a PB1 type I domain is involved in the interaction with PKCζ, with glutamic 
acids in positions 234 and 245 playing an essential role. 
Figure R17. Identification and analysis of crucial aminoacids in Gαq to interact with PKCζ. Alanine-scanning 
mutagenesis was performed in Gαq as shown in Fig. R16. (A) COS-7 cells were transfected with combina-
tions of plasmids encoding HA-PKCζ and different Gαq mutants. HA-PKCζ was immunoprecipitated with 
anti-HA antibody coupled to agarose beads. Immunoprecipitates and total lysates were analysed by western 
blot with specific antibodies. To compare the association of PKCζ to the different Gαq mutants, blot bands 
were quantified and normalised by total HA-PKCζ. Data (mean +/- SEM of three independent experiments) 
were normalised with respect to PKCζ/Gαq wt association as a control (*p<0.05, two tailed T-test). (B) Se-
quence alignment of different PB1-type I domains and the b4-a3 loop (pseudo-PB1 domain) of Gαq. Gluta-
mic acids 234 and 245 (E234/E245) of Gαq are conserved in all PB1-type I proteins and are part of the two 
crucial clusters for their function (A1 and A2). (C) Sequence alignment of the b4-a3 region of different Ga 
subfamily member. The combined presence of Glutamic acids in positions 234 and 245 is an exclusive featu-
re of the Gaq/11 family.                                                                                                                                                                                      
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5. REQUIREMENT OF AN EFFICIENT Gαq/PKCζ ASSOCIATION FOR THE 
ACTIVATION OF THE ERK5 PATHWAY.
We next sought to establish whether altering the interaction between Gαq and PKCζ 
affects ERK5 activation. To that purpose, we generated the PKCζ-binding-deficient mutation 
(E234/E245-AA) in a constitutively activated Gαq background (R183C). We overexpressed 
GαqR183C with/without the E234/E245-AA mutation and assessed ERK5 activation in HeLa 
cells (Fig. R18A). The Gαq-R183C-E234/E245-AA mutant was unable to promote ERK5 phos-
phorylation compared to Gαq-R183C, consistent with the notion that the formation of the 
Gαq/PKCζ complex is strictly required for ERK5 activation by Gαq. In order to further confirm 
this, we took advantage of the Gaq-biased properties of the pathway in which the overex-
pression of Gαq potentiates ERK5 activation by GPCR (see Fig R8). Thus, we overexpressed 
empty vector (pcDNA3) and either wild-type or PKCζ-binding-deficient forms of Gαq in Cho-
M3 cells and stimulated with carbachol to assess the activation of ERK5 (Fig. R18B). Whereas 
ERK5 phosphorylation was greatly enhanced by wild-type Gαq overexpression, it was com-
pletely unaffected by the Gαq E234/E245-AA mutant to the same degree as by empty vector 
 overexpression. 
Figure R18. ERK5 activation by Gαq is abolished by the E234/E245-AA mutation. (A) HeLa cells were transfected 
with different combinations of plasmids encoding HA-ERK5 and the constitutively active mutants GαqR183C and 
GαqR183C-E234/E245-AA. 24hrs after transfection, cells were lysed and ERK5-HA was immunoprecipitated as 
previously described. Immunoprecipitates and total lysates were analysed by western blot. Data (mean +/- SEM 
of 3  independent experiments) were normalised using ERK5 as loading control and expressed as fold-induction 
of ERK5 phosphorylation over control conditions (**p<0.005, two tailed T-test). (B) Cho-M3 cells were transfec-
ted with different combinations of plasmids. 24hrs after transfection, cells were serum-starved for 2h and stimu-
lated with carbachol (10μM) for the indicated times. Samples were processed and analysed as in (A) (*p<0.05, 
***p<0.001, two tailed T-test). Gαq and alpha-tubulin lysate levels were also determined as expression controls. 
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To rule out the possibility that the Gαq E235/E245-AA mutant displayed general, 
non-specific functional defects, we assessed whether this mutation affects coupling to 
PLCβ and other signalling pathways. Constitutively active forms of Gαq with or without the 
E234/E245-AA mutation were transfected into HEK293 cells and total inositol phosphate 
(IP) production was measured. Both constructions significantly increased IP production 
with respect to empty vector, although the constitutively active form of Gαq without the 
E235/E245-AA mutation was more efficient (Fig. R19A). This suggests that the E234/
E245-AA mutation partly affects PLCβ coupling to Gαq, though it is still able to trigger 
significant IP production. In this regard, we also assessed the activation of ERK1/2, a pri-
mary downstream target of the PLCβ pathway. HEK293 cells were transfected with cons-
titutively active forms of Gαq with/without the PKCζ-association-impairing mutation and 
ERK1/2 phosphorylation was assessed (Fig. R19B). Results clearly show that both Gαq 
forms potently enhanced ERK1/2 phosphorylation in a similar fashion, indicating that our 
mutant does not display defects in its global functionality.
Figure R19. Functional selectivity of the Gαq E234/E245-AA mutant. The ability of the Gαq E234/E245-AA 
to initiate classic signalling downstream of Gαq was assessed. (A) HEK293 cells were transfected with empy 
vector (pcDNA3) or plasmids encoding the constitutively active mutants GαqR183C or GαqR183C-E234/
E245-AA. Twenty four hours after transfection cells were incubated overnight with titriated inositol. Total 
inositol phosphate content was determined as detailed in the Methods section. Data (mean +/- SEM of three 
independent experiments) were normalised to transfection of empty vector (* and # p<0.05, ***p<0.001 
two tailed T-test) (B) HEK293 cells were transfected with empy vector (pcDNA3) or plasmids encoding the 
constitutively active mutants GαqR183C or GαqR183C-E234/E245-AA. Twenty four hours after transfec-
tion cells were lised and ERK1/2 activation was assessed by western blot with specific phospho-antibodies. 
Data (mean +/- SEM of three independent experiments) were normalised to pcDNA3 transfection (*p<0.05, 
two tailed T-test). Gαq and alpha-tubulin lysate levels were also determined as expression controls.                         
Overall, we can conclude that a Gαq mutant with impaired ability to associate with 
PKCζ (Gαq E234/E245-AA) is completely unable to promote either direct (Fig. R18A) or 
GPCR-initiated (Fig. R18B) activation of ERK5. This strongly suggests that the Gαq/PKCζ 
complex is strictly required for the activation of ERK5 by Gq-coupled receptors.
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6. GRK2 REGULATES Gaq/PKCζ ASSOCIATION AND ERK5 
 ACTIVATION.
Desensitisation and signal termination processes are essential self-limiting mecha-
nisms of cells to control the duration and amplitude of a given response. For Gαq, two 
main modulation mechanisms have been described: GTPase activity enhancement by 
RGS2/4 proteins and sequestering from effectors by GRK2. Thus, we aimed to characteri-
se whether these processes were affecting the Gαq/PKCζ complex formation and in ERK5 
activation.
a. RGS proteins do not compete with PKCζ for the same binding site 
in Gαq
RGS proteins are known regulators of Gα function through the promotion of Gαq 
GTPase activity. Additionally, they have been reported to bind to the activated G protein 
without interfering with effector binding. In order to establish whether this was also true 
for PKCζ, we coexpressed Gαq and HA-tagged PKCζ with or without RGS4 and immuno-
precipitated with an anti HA antibody (Fig. R20A). The formation of the Gαq/PKCζ com-
plex was not affected by overexpression of RGS4, suggesting that effector and regulator 
can simultaneously bind to the G protein. To further confirm this, a similar experiment 
was carried out with RGS2 (Fig. R20B). The presence of PKCζ in the coimmunoprecipitate 
was not altered by overexpression of RGS2. Therefore, the two main RGS regulators of 
Gαq (RGS2 and 4) do not compete with PKCζ for binding. A three-dimensional Gαq mo-
del shows that the non-overlapping spatial localization of the RGS-binding region and the 
pseudo-PB1 domain is consistent with the possibility of simultaneous binding (Fig. R20C) 
and the occurrence of a ternary complex including effector, Gαq and regulator. Additio-
nally, these data are also consistent with the results for the Gαq/i1 chimeras (Fig. R15) 
showing that the removal of the RGS binding region (located upstream of the insertion 
site at position 222) did not affect PKCζ binding (see Fig. R15 and Fig. R16 for graphical 
explanation).
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Figure R20. RGS proteins 2 and 4 do not compete with PKCζ for binding to Gαq. COS-7 cells were transfec-
ted with combinations of plasmids encoding HA-PKCζ, Gαq and either RGS4 (A) or RGS2 (B). HA-PKCζ was 
immunoprecipitated with anti-HA antibody coupled to agarose beads in (A) and Gαq was immunoprecipi-
tated in (B). Immunoprecipitates and total lysates were analysed by western blot with specific antibodies 
to determine the effect of RGS protein overexpression on the Gαq/PKCζ complex. Blots shown are repre-
sentative of 3 independent experiments. (C) Gαq crystal structure was modelled from the Gαq-GRK2-Gbg 
crystal structures using Pymol software. Different binding regions are highlighted in green [switch I&II, GRS 
proteins binding region] and blue [b4-a3 region of Gαq, pseudo-PB1 domain (FLVALSEYDQVLVESDENEN), 
PKCζ binding region].                                                                                                                                                                       
b. GRK2 prevents both PKCζ and MEK5 to interact with Gαq  
GRK2 has been shown to negatively regulate binding of Gαq to effectors and to dam-
pen downstream signalling. We sought to determine whether this negative regulation link 
was also observed for the components of the Gαq-ERK5 pathway. To that purpose, we 
overexpressed Gαq and GRK2 together with either PKCζ (Fig. R21A) or MEK5 (Fig. R21B), 
and Gαq was immunoprecipitated. Analysis of the coprecipitates showed that GRK2 com-
pletely abolished Gαq association to either effector (Fig. R21A&B). The competition with 
PKCζ was further characterised and demonstrated not to depend on the kinase activity of 
GRK2, since a catalytically inactive mutant (GRK2 K220R) still competes with PKCζ (Fig. 
R21A). Indeed, the negative effect of GRK2 on Gαq-PKCζ association was found to be solely 
dependent on its RH domain, a region previously reported to interact with Gαq (Sterne-
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Marr et al., 2003) (Fig. R21A). The analysis of the binding regions of PKCζ and GRK2 on 
the Gαq crystal structure (Tesmer et al., 2005) suggest that although GRK2 and PKCζ do 
not bind the same subset of aminoacids in Gαq, the binding surfaces  are close enough to 
compete sterically (Fig. R21C). 
Figure R21. GRK2 is a negative regulator of Gαq association with PKCζ and MEK5 (A) COS-7 cells were 
transfected with combinations of plasmids encoding HA-PKCζ and Gαq with GRK2 wild type, GRK2 K220R 
(kinase-dead mutant) or the GRK2 RH domain. Gαq immunoprecipitates and total lysates were analysed 
by western blot with specific antibodies to determine the effect of the overexpression of GRK2 variants 
on the Gαq/PKCζ complex. Blots shown are representative of 3 independent experiments. (B) COS-7 cells 
were transfected with combinations of plasmids encoding GST-MEK5, Gαq and GRK2 and Gαq immunopre-
cipitates and total lysates analysed to determine the effect of the overexpression of GRK2 variants on the 
Gαq/MEK5 complex. Blots shown are representative of 3 independent experiments. (C) Gαq crystal struc-
ture was modelled from the Gαq-GRK2-Gβγ crystal structures. Different binding regions are highlighted in 
green [switch I&II, RGS proteins], blue [pseudo-PB1 domain (FLVALSEYDQVLVESDENEN), PKCζ] and orange 
(switch III (KALFRTIITYPWF), GRK2).                                                                                                                                                           
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c. GRK2 is a negative regulator of the Gαq/PKCζ complex in living 
cells  
In order to address whether the effect of GRK2 was also detected in a natural cell 
milieu, a venus YFP PCA-based approach was performed. The Gαq/PKCζ interaction can 
be detected through this technique as demonstrated in Fig. R10. We overexpressed Gαq 
and PKCζ fused to cognate fragments of venus-YFP in HEK93 cells and co-expressed either 
empty vector (pcDNA3) or GRK2. As clearly seen in the microscopy images (Fig. R22A) 
and in the fluorescence quantification (Fig. R22B), GRK2 significantly decreases the for-
mation of the Gαq/PKCζ complex. The expression of the different constructs was also as-
sessed in Fig. R22C, which showed equal expression of the PCA plasmids upon coexpres-
sion of GRK2.    
Figure R22. GRK2 is a ne-
gative regulator of the Gαq-
PKCζ complex in living cells. 
(A) HEK293 cells were 
transfected with different 
pairs of protein complemen-
tation assay (PCA) plasmids 
that express protein pairs 
fused to cognate fragments 
of venus-YFP: Control (PKCζ-
Venus YFP[F1]+pcDNA3), 
Gαq+PKCζ+pcDNA3 (Gαq-
Venus YFP[F1]+ PKCζ-
Venus YFP[F2]+pcDNA3), 
Gαq+PKCζ+GRK2 (Gαq-
Venus YFP[F1]+ PKCζ-Venus 
YFP[F2]+GRK2). Twenty-
four hours after transfection 
cells were visualised under 
the microscope as detailed 
in the Methods section. (B) 
Fluorimetric analysis was 
performed in order to de-
termine the effect of GRK2 
on the PKCζ-Gαq complex 
as detailed in the Methods 
section. Data (mean +/- SEM 
of three independent expe-
riments) were normalised 
with respect to control. (C) 
The different cell popula-
tions were lysed and analy-
sed by western blot to deter-
mine the correct expression of the different plasmids. Specific antibodies were utilised against PKCζ, Gαq, 
GRK2 and actin as a loading control. Blots shown are representative of 3 independent experiments.                  
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d. Disruption of the GRK2-Gαq complex upregulates PKCζ-Gαq 
 association
We have shown that the RH-domain of GRK2 is sufficient to inhibit the formation of 
the Gαq/PKCζ complex. Since this is the domain that has been reported to interact with 
Gαq, we hypothesised that the negative effect of GRK2 was due to a direct binding of GRK2 
and Gαq. In order to establish this, we utilised a GRK2 mutant (D110A) that does not in-
teract with Gαq (Sterne-Marr et al., 2003) and assessed the effect of its overexpression on 
the Gαq/PKCζ complex. Whereas GRK2 wild-type completely abrogated Gαq coimmuno-
precipitation with PKCζ, the presence of the GRK2-D110A mutant barely interfered with 
the formation of the complex (Fig. R23A). Additionally, we utilised two Gαq mutants that 
are unable to interact with GRK2 (Y261F and W263D)(Tesmer et al., 2005) and assessed 
their PKCζ-association ability (Fig. R23B). Surprisingly, these Gαq mutants co-immuno-
precipitated with PKCζ to a much greater extent. This seems to indicate that a lack of ne-
gative regulation by GRK2 on Gαq favours the formation of the Gαq/PKCζ complex. Taken 
together, these data indicate that GRK2 negatively regulates the Gαq/PKCζ interaction 
through a direct association with Gαq.
Figure R23. Modification of the GRK2-Gαq interaction surface modulates PKCζ-Gαq association. (A) COS-
7 cells were transfected with combinations of plasmids encoding Gαq, HA-PKCζ, GRK2 wt and the GRK2 
D110A mutant, which has impaired ability to associate to Gαq. HA-PKCζ was immunoprecipitated with anti-
HA antibody coupled to agarose beads. Immunoprecipitates and total lysates were analysed by western 
blot to compare the association of Gαq to PKCζ in the presence of the different GRK2 variants. (B) COS-7 
cells were transfected with combinations of plasmids encoding HA-PKCζ and Gαq mutants deficient in as-
sociation to GRK2 (GαqY261F and GαqW263D). HA-PKCζ was immunoprecipitated with anti-HA antibody 
coupled to agarose beads. Immunoprecipitates and total lysates were analysed by western blot with specific 
antibodies. To compare the association of PKCζ to the different Gαq mutants, blot bands were quantified 
and normalised by total HA-PKCζ. Data (mean +/- SEM of 3 independent experiments) were normalised 
with respect to PKCζ/Gαq wt association as a control. Blots shown are representative of 3 independent 
 experiments.                                                                                                                                                                                                            
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e. ERK5 activation by Gq-coupled GPCR is negatively regulated by 
GRK2
Since GRK2 negatively regulates association of Gαq with both PKCζ and MEK5, we 
hypothesised that the disruption of this interaction would impair the activation of ERK5. 
In order to establish that, we transfected Cho-M3 cells with either empty vector (pcDNA3) 
or GRK2 and assessed ERK5 activation by carbachol at different times (Fig. R24A). The 
results clearly show that the overexpression of GRK2 completely abolishes ligand-induced 
ERK5 phosphorylation. The negative effect of GRK2 on Gαq signalling pathways have been 
tied to receptor phosphorylation and desensitisation, and also to sequestering of  activated 
Gαq. Thus, we assessed whether a catalytically inactive mutant (GRK2 K220R) and a Gαq 
interaction-deficient mutant (GRK2 D110A) would differentially downregulate the ERK5 
pathway. We transfected cells with either GRK2 wild-type/K220R/D110A and assessed 
ERK5 maximal activation by carbachol at 15 min (Fig. R24B). It was observed that both 
mutants, and specially D110A, display a significantly reduced ability to  downregulate the 
ERK5 pathway compared to wild-type. Thus, it seems that both receptor desensitisation 
and Gαq sequestering are necessary processes for ERK5 pathway downregulation by 
GRK2. 
In order to further characterise the role of GRK2 in directly binding and seques-
tering Gαq away from effectors, we studied the effect of the RH domain of the kinase on 
ERK5 activation by carbachol. This domain binds to Gαq and is responsible for the inhi-
bitory effect on the G protein, and also we have observed that it is sufficient to displace 
PKCζ from a complex with Gαq (Fig R21a). As shown in Fig. R24C, the overexpression of 
the RH domain accounted for approximately half of the inhibitory effect of GRK2 on ERK5 
activation. This is consistent with the notion that ERK5 activation is inhibited by a com-
bined effect of GRK2 on the receptor and on Gαq through its RH domain. Finally, since we 
have seen that a lack of regulation by GRK2 on Gαq upregulates the Gαq/PKCζ complex 
(Fig R22b), we hypothesised that this would be accompanied by an upregulation of the 
activation of ERK5. Thus, we compared the activation of ERK5 by carbachol in Cho-M3 
cells transfected with either Gαq wild-type or Gαq Y261F (GRK2 binding-deficient mu-
tant) (Fig. R24D). As the results clearly show, Gαq Y261F mutant greatly enhances the 
duration and amplitude of ERK5 activation by carbachol compared to control. Taken to-
gether, these data strongly point at GRK2 as a major regulator of the Gαq-ERK5 pathway 
through a negative dual action on the activated receptor and on the formation of efficient 
G protein-effector complexes. 
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Figure R24. ERK5 activation by Gq-coupled GPCR is negatively regulated by GRK2. GRK2 abolishes ERK5 
activation by Gq-coupled muscarinic M3 receptor through both receptor phosphorylation and inhibition 
of Gαq-effector interactions. (A) Cho-M3 cells were transfected with different combinations of empty vec-
tor (pcDNA3) or plasmids encoding HA-ERK5 and GRK2. Twenty-four hours after transfection, cells were 
serum-starved for 2h and stimulated with carbachol (10μM) for the indicated times. Cells were lysed and 
ERK5-HA was immunoprecipitated with an anti-HA agarose-conjugated antibody as detailed in the Methods 
section. Immunoprecipitates and total lysates were analysed by western blot with specific antibodies. Data 
(mean +/- SEM of 3 independent experiments) were normalised using ERK5 as loading control and expres-
sed as fold-induction of ERK5 phosphorylation. (B) Cho-M3 cells were transfected with HA-ERK5 and GRK2 
wt, GRK2 K220R (kinase-dead mutant) or GRK2 D110A (Gαq-interaction deficient mutant). 24 hours after 
transfection cells were serum starved and stimulated with carbachol (10μM) for 15 min. Samples were pro-
cessed as above (two-tailed T-test with indicated significance). (C) Cho-M3 cells were transfected with HA-
ERK5 and pcDNA3, GRK2 wt or the GRK2-RH domain. Samples were processed as above. Blots shown are 
representative of 2 independent experiments. (D) Cho-M3 cells were transfected with HA-ERK5 and either 
Gαq wt or Gαq Y261F. 24 hours after transfection cells were serum starved and stimulated with carbachol 
(10μM) for the indicated times and processed as above. Data (mean +/- SEM of three independent experi-
ments) were normalised using ERK5 as loading control and expressed as fold-induction of carbachol-indu-
ced ERK5 phosphorylation upon Gαq wild type overexpression at each time point (**p<0.005, ***p<0.001, 
two tailed T-test).                                                                                                                                                                                 
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7. ACTIVATION MECHANISMS OF THE Gαq/PKCζ/ERK5 PATHWAY
During this work, we have put forward PKCζ as an essential effector of Gαq in the 
activation of ERK5 by Gq-coupled GPCRs. Extensive work has been done in order to dis-
sect the different protein-protein interactions that are involved in the Gαq/PKCζ/ERK5 
pathway but the activation mechanisms operating still remain to be elucidated. 
a. PKCζ is not phosphorylated on T410 or T560 upon Gq-coupled 
GPCR stimulation
PKCζ is a Ser/Thr protein kinase with different activation mechanisms (see Intro-
duction, Fig. I7). The most commonly described ones involve the trans-phosphorylation 
of its activatory loop on Thr410 and the autophosphorylation of Thr560. Since we have 
described that ERK5 activation by Gq-coupled GPCRs seems to require PKCζ activity as 
indicated by the consistent inhibition of the pathway by the pseudosubstrate catalytic in-
hibitor (Fig R2b, R3b and García-Hoz et al., 2010), we hypothesised that the kinase could 
be activated through phosphorylation-dependent mechanisms. Thus, we stimulated NIH-
3T3-M1 cells with carbachol at different times and assessed the phosphorylation status of 
endogenous PKCζ on both Thr410 and Thr560 (Fig. R25). Although PKCζ seems to be ba-
sally phosphorylated on both residues, no modulation can be ascribed to carbachol addi-
tion. This result suggests that PKCζ is not activated by Gq-GPCR through phosphorylation. 
Figure R25. PKCζ is not phosphorylated on T410 or T560 upon by Gq-GPCR stimulation. NIH-3T3-M1 cells 
were serum-starved for 5h and stimulated with carbachol (10μM) for the indicated times. Cells were lysed 
and analysed by western blot with specific antibodies against phospho-threonines 410 and 560. Antibodies 
against total PKCζ and phospho410 also recognise PKCλ, hence the double banding. PKCζ corresponds to 
the band of slower electrophoretic mobility. Blots shown are representative of 3 independent experiments.
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b. PKCζ transiently dimerises in response to Gq-coupled GPCR 
 stimulation
PKCζ has been previously shown to be activated independently of phosphorylation 
(see Introduction section 3b and Fig. I7). Indeed, a recently proposed mechanism involves 
catalytic activation due to a PB1-PB1 interaction with Par6 that releases the pseudosubs-
trate inhibitory domain from the active site of PKCζ. Since PKCζ also harbours a highly 
homologous PB1 domain to the one in Par6 (PB1-type II domain), we hypothesised that 
activation could also occur as a result of dimerisation events between different PKCζ mo-
lecules through their PB1 domains (type I and II). Thus, we initially set out to investigate 
whether PKCζ was able to form dimers in living cells. We performed a venus-YFP-based 
PCA with a pair of plasmids that encode for PKCζ tagged to either N- or C-terminal halves 
of YFP and expressed them in Cho-M3 cells. Fluorescence visualisation by microscopy and 
quantification show that PKCζ readily dimerises into high affinity complexes compared to 
Zipper dimer formation (Fig. R26A). In order to assess whether PKCζ dimerisation was 
modulated by Gq-GPCR stimulation, we performed a Renilla luciferase-based PCA assay. 
This approach was developed to study the dynamics of protein-protein interactions as the 
formation of complexes is reversible (Stefan et al., 2007). The detection of protein-protein 
interaction relies on the reconstitution of the enzyme Renilla luciferase that converts the 
substrate benzyl-coelenterazine into a bioluminescent product (Fig. R26B). Thus, biolumi-
nescence is an indirect measure of protein-protein interactions. We carried out this assay 
by overexpressing PKCζ tagged to N- and C-terminal halves of the enzyme in Cho-M3 cells, 
stimulated with carbachol and measured bioluminiscence at different times. As shown in 
Fig. R26C, carbachol promoted a clear and transient increase of PKCζ dimerisation com-
pared to control. Taken together, these data show that PKCζ forms high-affinity dimers in 
living cells, and that this process can be positively modulated by carbachol. Dimerisation 
might therefore provide a mechanism for PKCζ activation by Gq-coupled receptors.
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Figure R26. Transient PKCζ dimerisitation is promoted by Gq-coupled GPCR stimulation. (A) Cho-M3 cells 
were transfected with different pairs of protein complementation assay (PCA) plasmids that express proteins 
fused to cognate fragments of venus-YFP as indicated in the figure. Twenty-four hours after transfection cells 
were visualised under the microscope as detailed in the Methods section. Representative brightfield and YFP 
fluorescence images at 40x magnification are shown. Fluorimetric analysis of the populations was performed 
and data (mean +/- SEM of three independent experiments) were normalised with respect to control. (B) 
Conceptual explanation of renilla luciferase PCA, a technique that utilises the reversible reconstitution of a lu-
ciferase enzyme from N/C-terminal halves that are fused to two proteins of interest. Bioluminiscence in living 
cells upon the enzyme´s substrate (CTZ) addition is a measure of protein-protein interactions, which brings 
cognate fragments of renilla luciferase close enough to allow reconstitution of the native fold. (C) Cho-M3 cells 
were transfected with PKCζ-Venus YFP[F1] and PKCζ-Venus YFP[F2]. Twenty-four hours after transfection, 
cells were serum-starved for 2h and stimulated with carbachol (10μM). Bioluminiscence was measured at 
482 nm as detailed in the Methods section and data (mean +/- SEM of 3 independent experiments) were nor-
malised with respect to control (**p<0.005, ***p<0.001, two tailed T-test).                                                                                     
c. PKCζ acts as a scaffold between Gαq and ERK5 upon GPCR 
 activation 
The finding that PKCζ dimerises in response to carbachol poses new questions with 
regards to the formation of different protein complexes in the activation of ERK5. Indeed, 
the concentration of PKCζ dimers/oligomers within specific cellular locations might pro-
vide a signalling platform for the association of the different molecules involved in the pa-
thway. This scaffold role, driven by PB1 domains, has been widely documented for other 
processes (see Introduction, section 3b and fig. I9). It has previously been shown by us and 
others that PKCζ interacts directly with both Gαq and MEK5 (García-Hoz et al., 2010; Diaz-
Meco & Moscat) in the activation of ERK5. Additionally, it has recently been demonstrated 
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that PKCζ directly associates with ERK5 and this interaction involves the kinase domain of 
PKCζ (Nigro et al., 2010). In order to determine whether a PKCζ/ERK5 complex was also 
occurring in our system, we studied the association of these two proteins upon carbachol 
stimulation. Initially, we confirmed that PKCζ and ERK5 coimmunoprecipitated in COS-7 
cells (Fig. R27A). Then, HA-PKCζ was transfected into NIH-3T3-M1 cells and carbachol 
was added for different times. PKCζ complexes were immunoprecipitated with an anti-
HA antibody and were checked for the presence of endogenous ERK5. Indeed, ERK5 was 
detected to coimmunoprecipitate with PKCζ at 5 minutes after carbachol addition (Fig. 
R27B). Interestingly, this closely coincides with the time-frame of the Gαq/PKCζ associa-
tion in response to carbachol reported in the same system (García-Hoz et al., 2010). Thus, 
we investigated whether ERK5 and Gαq were part of the same multimolecular complex 
through an interaction with PKCζ. We found that wild-type Gαq coimmunoprecipitated 
with ERK5 (Fig. R27C, lane 2) and this was greatly enhanced when Gαq was active (Gαq-
Q209L) (Fig. R27C, lane 3). This indicated an activation-dependent association. Since the 
PB1 domain of PKCζ acts as a dominant negative on the Gαq/PKCζ complex (see Fig. R12C) 
we overexpressed this domain in order to determine whether PKCζ was bridging ERK5 
and Gαq together. Indeed, upon overexpresssion of the PKCζ-PB1 domain Gαq coimmu-
noprecipitation with ERK5 was completely abolished (Fig. R27C, lane 4). Taken together, 
these data suggest that PKCζ is acting as a scaffold between ERK5 and Gαq upon activation 
 GPCR.  
Figure R27. PKCζ interacts with ERK5 upon Gq-GPCR stimulation and brings it into an activated protein 
complex with Gαq.  (A) PKCζ coimmunoprecipitates with ERK5. COS-7 cells were transfected with combina-
tions of plasmids encoding Flag-PKCζ and HA-ERK5. PKCζ was immunoprecipitated with anti-Flag antibody. 
Immunoprecipitates and total lysates were analysed by western blot with specific antibodies. A represen-
tative blot from 3 independent experiments is shown. (B) PKCζ and ERK5 endogenous association is tran-
siently promoted by carbachol. NIH-3T3-M1 cells were transfected with HA-PKCζ. 48h after transfection 
cells were serum-starved for 5-6 hours and stimulated with carbachol for the indicated times. HA-PKCζ was 
immunoprecipitated with anti-HA antibody coupled to agarose beads. Immunoprecipitates and total lysates 
were analysed by western blot with specific antibodies to assess the coimmunoprecipitation of endogenous 
ERK5 and PKCζ. Representative blot of 2 independent experiments is shown. (C) Activated Gαq coimmuno-
precipitates through PKCζ with ERK5. COS-7 cells were transfected with combinations of plasmids encoding 
HA-ERK5, Gαq wt, GαqQ209L (constitutively active mutant) and the PKCζ-PB1 domain. HA-ERK5 was im-
munoprecipitated with an anti-HA antibody coupled to agarose beads. Immunoprecipitates and total lysates 
were analysed by western blot with specific antibodies to assess the coimmunoprecipitation of ERK5 and 
Gαq. A representative blot from 3 independent experiments is shown.                                                                                          
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8. CELLULAR FUNCTIONS OF THE Gαq/PKCζ COMPLEX
Gαq plays a large number of cellular functions (extensively covered in the Introduc-
tion, sections 2b and 5). Since we have established a signalling axis emanating from Gq-
coupled muscarinic receptors that requires the formation of the Gαq/PKCζ complex, we 
sought to determine its role in different cellular processes. To that purpose, we utilised 
a Gαq mutant with impaired binding to PKCζ (GαqE234/E245-AA; Gαq-EEAA) that was 
extensively characterised in figures R17, R18 and R19. The general procedure involved 
comparison of cell proliferation, cell surface, cell adhesion and cell viability between three 
different populations: Control (empty vector pcDNA3), Gαq (overexpressing Gαq wild-
type) and Gαq-EEAA (overexpressing GαqE234/E245-AA). The xCELLigence software 
was utilised to detect changes in the cell index (a measure of cell attachment to the plate) 
which can be correlated to proliferation, adhesion and viability changes (see Methods for 
detailed information). 
a. The Gαq/PKCζ complex is involved in carbachol-induced cell 
 blebbing and growth arrest
We aimed to determine the contribution of PKCζ as a Gαq effector in the cellular 
effects promoted by muscarinic receptor activation. Initially, we analysed the changes in 
the cell index upon carbachol addition to Cho-M3 cells. The most immediate effect was a 
drastic and transient increase in the cell index due to cell blebbing, a process that has pre-
viously been reported to follow muscarinic receptor stimulation (Street et al., 2006). We 
observed a clear dose-dependent increase in the slope of the cell index curve compared to 
control that peaked after 1 hour of carbachol stimulation (Fig. R28A). This indicated that 
carbachol-induced cell blebbing resulted in an enhanced cell surface coverage and could 
be readily detected through cell index changes with the xCELLigence software. Next, we 
compared the blebbing response between control, Gαq and Gαq-EEAA populations. As 
shown in Fig. R28B, Gαq cells displayed a significantly greater blebbing response com-
pared to control (pcDNA3) indicating that, as previously reported (Street et al., 2006), 
muscarinic-induced blebbing is Gαq-dependent. Interestingly, Gαq-EEAA cells displayed 
an overall blebbing response that does not significantly differ from control cells, thus su-
ggesting that PKCζ is involved in Gαq-dependent cell blebbing. If PKCζ is indeed playing a 
role in the formation of cell blebs through its interaction with Gαq we hypothesised that 
the Gαq/PKCζ complex could be detected in these cellular protrusions upon carbachol 
stimulation. Thus, we performed a venus-YFP-based PCA assay to detect the Gαq/PKCζ 
complex in living Cho-M3 cells. We expressed PKCζ and Gαq fused to cognate fragments 
of venus-YFP, stimulated with carbachol and monitored the cells for different times. As 
shown in Fig. R29, cells respond to carbachol addition by emitting different membrane 
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protrusions (blebs) in a reversible manner. During this process, the YFP fluorescent signal 
indicative of Gαq/PKCζ association was transiently redistributed and concentrated towards 
membrane blebs. Taken together, these data suggest that the Gαq/PKCζ pathway plays a rele-
vant role in cell blebbing taking place in response to muscarinic M3 receptor stimulation. 
Figure R28. An efficient interaction between Gαq and PKCζ is required for carbachol-induced membrane ble-
bbing. (A) Membrane blebbing is induced by carbachol as detected by the xCELLigence software. Cho-M3 cells 
were seeded onto 96-well gold electrode sensor plate in 3% FBS and allowed to attach to the plate. After 24hrs, 
cells were challenged to carbachol stimulation at 100μM and 1mM final concentrations. Monitoring of cell index 
changes was performed every 15min from the start of the experiment and was continued for a minimum of 6 
hours after the treatment. Cell index values were normalised at the time of carbachol addition. Blebbing response 
was calculated as the slope of the cell index curve between the addition of carbachol until reaching a maximum 
and was expressed as the mean +/- SEM of 3 independent experiments. (B) Carbachol-induced blebbing is not 
promoted by the Gαq-E234/E245-AA (Gαq-EEAA) mutant as compared to wild-type Gαq. Cho-M3 cells were 
transiently transfected with GFP and either pcDNA3 empty vector, Gαq wild-type or Gαq-EEAA. After 24hrs,  GFP-
positive cells were sorted with a cytometer (see Methods) and were seeded onto 96-well gold electrode sensor 
plate in 3% FBS.  The experiment proceeded as in (A). Blebbing response was calculated as slope of the cell index 
curve of each population from the addition of carbachol until reaching a maximum. Data (mean +/- SEM of 3 
independent experiments) was normalised to the maximum blebbing response corresponding to Gαq-wild type-
expressing cells (**p<0.005, two tailed T-test).                                                                                                                                                              
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Figure R29. The PKCζ/Gαq complex is localised in membrane blebbing processes upon carbachol stimula-
tion. Cho-M3 cells were transfected with Gαq-Venus YFP[F1] and PKCζ-Venus YFP[F2] plasmids that express 
proteins fused to cognate fragments of venus-YFP. Twenty-four hours after transfection cells were starved 
for 2 hours and visualised under the microscope upon carbachol addition for the indicated times, as detailed 
in the Methods section. Images shown were taken at 40x magnification and subsequently cropped to show 
single cells. White arrows indicate cell protrusion due to membrane blebbing. Images are representative of 3 
independent experiments and show two characteristic morphologies of Cho cells in this experimental setting: 
a fully-attached cell (above) and a rounded, partially-detached cell (below).                                                                        
In addition to studying early cell responses to carbachol, we also analysed long-term 
effect of the ligand. It has been previously reported that M3 muscarinic receptor causes cell 
growth arrest in Cho cells (Burdon et al., 2002). Indeed, we could reliably detect a dose-
dependent growth inhibition by carbachol in 3% fetal bovine serum (FBS) with the xCELLi-
gence software that lasted for a minimum of 24 hours after ligand addition (Fig. R30). 
Figure R30. Carbachol induces Cho cell growth arrest. Cho-M3 cells were seeded onto 96-well gold electrode 
sensor plate in 3% FBS and allowed to attach to the plate. Twenty four hours after plating, cells were challen-
ged with carbachol at various concentrations. Monitoring of cell index changes with the xCELLigence techno-
logy was performed every 15min from the start of the experiment and was continued after the treatment. The 
negative effect of carbachol on cell growth was detected for a maximum of 72h after which time cells invariably 
started to proliferate again. Cell index values were normalised 6 hours after the addition of carbachol (to ex-
clude the blebbing effect) and cell growth was calculated as the slope (hours-1) of the cell index curve during 
24 hours. Slope data was expressed as the mean +/- SEM of 3 independent experiments.                                             
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Since we reported in cell blebbing studies that overexpression of Gαq enhances carba-
chol-induced cellular responses, we compared control, Gαq and Gαq-EEAA populations in the 
promotion of cell growth arrest by carbachol (Fig. R31). In figure R31A we observe that car-
bachol inhibits growth in all three populations at two different concentrations (10μM and 
1mM) but there is a clear difference in the cell index slope between them. In order to highlight 
this distinct behaviour, we analysed the decrease in the cell index between control, Gαq and 
Gαq-EEAA populations at 1mM carbachol (Fig. R31B). Whereas Gαq cells displayed a greater 
cell growth inhibition, Gαq-EEAA cells did not differ from control. These results suggest that 
Gαq/PKCζ association is required for muscarinic M3 receptor-induced cell growth inhibition. 
Figure R31. The interaction between Gαq and PKCζ is required for carbachol-induced cell growth arrest. Cho-M3 
cells were transiently transfected with GFP and either pcDNA3 empty vector, Gαq wild-type or the Gαq-E234/
E245-AA (Gαq-EEAA) mutant. After twenty four hours, GFP-positive cells were sorted with a cytometer to gua-
rantee homogeneous cell populations (see Methods) and seeded onto 96-well gold electrode sensor plate in 
3% FBS. The experiment proceeded as in figure R30. The chart above shows the global experiment with two 
carbachol concentrations and including positive untreated controls. To appreciate differences, treated pcDNA3, 
Gαq and GαqEEAA populations at 1mM carbachol were amplified below and cell growth was calculated as the 
cell index increase during 24 hours starting from 6 hours after the addition of carbachol (to exclude the blebbing 
effect). Data (mean +/- SEM of 3 independent experiments) was normalised to the maximum cell growth arrest 
effect corresponding to Gαq-wild type-expressing cells (*p<0.05, Two-tailed T-test).                                                                          
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b. The Gαq/PKCζ complex is involved in apoptosis entry
The drastic cell index decrease in Gαq cells stimulated with carbachol (Fig. R31B) 
suggests the occurrence of apoptosis events in addition to cell growth arrest. This is in 
agreement with the reported apoptotic response of cells with overstimulated Gαq signa-
lling, especially in the heart (see introduction, section 5a). Additionally, although carba-
chol-induced cell blebbing is transient and apoptosis-related cell blebbing is irreversible, 
similar cytoskeletal changes are thought to operate in both processes (Mills et al., 1999). 
Thus, we were interested in ascertaining whether Gαq and Gαq-EEAA cells differed in 
their ability to enter apoptosis. To that purpose cells were grown for over 96 hours in 3% 
FBS and monitored with the xCELLigence software. Apoptosis entry was characterised by 
a drastic and irreversible decrease in the cell index that occurred after a minimum of 3 
days of growth in minimal medium. As shown in Fig. R32A, Gαq cells displayed a signifi-
cantly anticipated apoptosis entry compared to control cells. Interestingly, Gαq-EEAA cells 
entered apoptosis at similar times to control cells suggesting that the impairment in the 
Gαq/PKCζ complex abrogates Gαq-promoted apoptosis. Inspection of the cells through 
microscopy after approx. 130 hours of growth, at which time Gαq cells but not control or 
Gαq-EEAA cells had entered apoptosis, show clear differences in cell morphology (Fig. 
R32B). Indeed, blebbing processes are distinctively detected in Gαq cells but not in con-
trol or Gαq-EEAA cells supporting the different apoptotic properties of each population. 
Since our data suggest that the mutant Gαq-EEAA had a reduced ability to enter apoptosis, 
we sought to determine whether this was solely caused by a lack of interaction with PKCζ. 
To that purpose we studied apoptosis entry upon pharmacological inhibition of PLCβ 
(Fig. R32C). If PLCβ is involved in this process, the addition of the inhibitor would balance 
the differences between the apoptotic behaviour of Gαq and Gαq-EEAA cell populations. 
However, as clearly shown in Fig. R32C, the difference in apoptosis entry times was con-
served upon PLCβ inhibition, which suggests that PLCβ-downstream pathways are not 
responsible for the differences observed. Further work needs to be carried out to clearly 
establish the mechanisms of Gαq/PKCζ-dependent apoptosis promotion.  
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Figure R32. The interaction between Gαq and PKCζ regulates apoptosis entry. Apoptosis entry can be can 
be readily detected by the xCELLigence software by a characteristic sharp peak in the cell index curve, a 
rapid switch from positive to negative slope that invariably results in complete cell death. (A) Cho-M3 cells 
were transiently transfected with GFP and either pcDNA3 empty vector, Gαq wild-type or the Gαq-EEAA 
mutant. After twenty four hours GFP-positive cells were sorted with a cytometer to guarantee homogeneous 
cell populations (see Methods) and seeded onto 96-well gold electrode sensor plate in 3% FBS. Cell index 
changes were monitored every 15min for an average of 140 hours. Apoptosis entry time was determined for 
each population. Data were the mean +/- SEM of 5 independent experiments (*p<0.05, two tailed T-test). (B) 
After cytometer sorting, the same cell populations from (A) were seeded onto 48 well plates. Approx. 130 
hours after plating, when Gαq but not pcDNA3 or Gαq-EEAA cells had entered apoptosis, they were visuali-
sed under a brightfield microscope with a 40x objective. Images are representative of two independent ex-
periments. (C) Cho-M3 cells were transiently transfected with GFP and either Gαq wild-type or Gαq-EEAA, 
and proceeded as in (A). A PLCβ inhibitor (U73122, 10μM) was added to Gαq and Gαq-EEAA cells before 
the apoptotic phenotype was detected in any of the cell populations. Apoptosis entry time was determined 
for each population. Data were the mean +/- SD of 2 independent experiments (*p<0.05, two tailed T-test). 
     


V. DISCUSSION

169
Discussion
 In the present work, the role of PKCζ as a novel Gαq protein effector has been ex-tensively characterised with particular focus on the biochemical properties of the G protein/effector complex, as well as on the activation mechanisms and cellular re-
percussions of this new signalling axis. We have determined that the AngII/Gαq/PKCζ/
ERK5 pathway occurs in the cardiovascular system and displays Gαq-biased properties. 
The interaction between the activated Gαq protein, through its pseudo-PB1 type I domain, 
and its novel effector PKCζ, through its PB1 type II domain, is essential for the activation of 
ERK5 and is negatively regulated by GRK2. Additionally, the mechanisms of this signalling 
cascade seem to involve phosphorylation-independent activation of PKCζ and dimerisa-
tion. Finally, the Gαq/PKCζ complex is shown to play a role in membrane blebbing, cell 
growth arrest and apoptosis (graphical abstract in Fig. D1).   
Figure D1. Graphical abs-
tract of the PhD thesis. In-
tegration of data from the 
different sections of this 
work in a cartoon model.         
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The AngII/Gαq/PKCζ/ERK5 pathway in the cardiovascular system
Previously, the occurrence of a novel signalling axis emanating from Gq-coupled GP-
CRs and mediating the activation of ERK5 had been established in our laboratory (García-
Hoz et al., 2010). Briefly, the pathway was described in epithelial cells and involved a direct 
interaction between Gαq and two novel effectors, PKCζ and MEK5, leading to the activa-
tion of ERK5. Neither the activation of PLCβ, the main Gαq effector, nor the transactivation 
of the EGF receptor, previously shown to activate ERK5 (Kato et al., 1998), were found to 
be involved in ERK5 activation by Gq-GPCR, thus constituting a non-canonical pathway. 
Hereby, we have determined that Gαq, a key cardiovascular player involved in hypertro-
phy and heart failure (Tilley, 2011), initiates the ERK5 pathway in the heart through PKCζ, 
which might indicate the conservation of the activation mechanism previously described 
in epithelial cells (García-Hoz et al., 2010). We observe that angiotensin II promotes ERK5 
activation in both neonatal and adult murine cardiomyocytes, as well as in neonatal car-
diac fibroblasts, although the extent and kinetics of ERK5 stimulation can vary with the 
cell type or the mice strain. In agreement with our previous findings for other Gq-coupled 
GPCR in epithelial cells, this process does not appear to involve cross-talk with Gi-coupled 
signalling, as has been described for angiotensin II-mediated ERK1/2 activation in cardiac 
fibroblasts (Fielitz et al., 2008). On the other hand, pharmacological inhibition or siRNA-
mediated silencing of PKCζ completely abrogated angiotensin-induced ERK5 activation in 
neonatal and adult cardiomyocytes, or in neonatal cardiac fibroblasts. This is consistent 
with the lack of activation of this cascade in cardiomyocytes isolated from PKCζ-deficient 
mice. Despite PKC isoforms such as a, b, e and z expression have been reported to peak in 
foetal and neonatal hearts, and decrease in adult hearts (Goldberg & Steinberg, 1996), we 
demonstrate that PKCζ activity is essential for ERK5 activation in adult cardiomyocytes. 
Overall, these data suggest that PKCζ is required for angiotensin-induced ERK5 stimula-
tion in the two most predominant cell types in the heart. The establishment of a functio-
nal pathway in adult cardiac myocytes is relevant for the subsequent description of the 
pathway in adult murine hearts. As described in the Introduction (section 5d), long-term 
exposure to angiotensin II showed a strong correlation between the Gαq/PKCζ/ERK5 axis 
and the development of cardiac hypertrophy (García-Hoz et al., 2012). In this scenario, we 
were able to determine the activation of the immediate upstream ERK5 MAPKK, MEK5, as 
well as of the downstream target MEF2c in whole hearts from wild-type but not in PKCζ-
deficient mice. Also, we determined the upregulation in wild-type, but not in PKCζ-/- mice, 
of Ets-1, an important transcription factor whose expression is known to be promoted 
downstream of ERK5 (Dwivedi et al., 2002). Interestingly, Ets-1 is also a major regulator of 
Angiotensin-II-induced vascular inflammation and remodelling, thus suggesting that this 
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role might also be promoted through the Gαq/PKCζ/ERK5 pathway (Zhan et al., 2005). 
Our data are consistent with previous reports showing that Angiotensin II promotes ERK5 
activation in mice myocardium (Ikeda et al., 2005), that cardiac-specific overexpression 
of either upstream activators (MEK5)(Nicol et al., 2001) or downstream targets (MEF2A 
and C)(Xu et al., 2006) of ERK5 induces cardiac hypertrophy in mice, and that the activity 
of ERK5 is increased during left ventricular hypertrophy (Kacimi & Gerdes, 2003; Takeishi 
et al., 2001), whereas targeted deletion of ERK5 in cardiomyocytes attenuates the hyper-
trophic response in the heart (Kimura et al., 2010). Overall, our data strongly suggest that 
the AngII-initiated Gαq pathway leading to ERK5 activation is fully functional in murine 
hearts and might play an important role in the physiological function of Gαq.
Since we have found that AngII promotes ERK5 activation both in cardiac myocytes 
and fibroblasts it would be interesting to determine the specific contribution of each 
cell type in hypertrophy, given the emerging role of cardiac fibroblasts in cardiovascular 
function and dysfunction (Kakkar & Lee, 2010). This cell type, traditionally linked to the 
generation of extracellular matrix, has been recently shown to have a very interesting 
interplay with cardiac myocytes. Indeed, some reports have provided strong evidence for 
an essential role of cardiac fibroblasts in pressure-overload hypertrophy (Takeda et al., 
2010). Moreover, using a myocyte/fibroblast coculture system, it was reported that em-
bryonic cardiac fibroblasts induced proliferation of cardiomyocytes, in contrast to adult 
cardiac fibroblasts that promoted myocyte hypertrophy (Ieda et al., 2009). This paracrine 
modulation was found to require the secretion of collagen and fibronectin by fibroblasts 
and the presence of β1-integrin in cardiomyocytes. Interestingly, it was found that AngII-
stimulated wild-type mice had increased cardiac expression of type I a2 pro-collagen and 
procollagen type IVa, which was not observed in PKCζ-/- mice (García-Hoz et al., 2012). 
Thus, the possibility that the Gαq/PKCζ/ERK5 axis we have identified in cardiac fibro-
blasts is positively regulating cardiomyocyte hypertrophy through a paracrine route is an 
interesting avenue for future research (Fig. D2). 
Several subtypes of the PKC family, amongst which PKCζ is found, are known to par-
ticipate in cardiac fibroblast proliferation. Indeed, pharmacological inhibition of PKCζ 
was found to decrease basal and TGFβ-induced cardiac fibroblast proliferation (Braun & 
Mochly-Rosen, 2003). In line with this, preliminary results not included in this thesis su-
ggest a role for PKCζ in Angiotensin-II-mediated cardiac fibroblast proliferation. The role 
of cardiac fibroblasts in the promotion of fibrosis, characterised by excessive accumula-
tion of extracellular matrix components that correlates with heart dysfunction, is of par-
ticular relevance. Indeed, enhanced cardiac fibroblasts proliferation is caused by elevated 
levels of circulating cytokines and growth factors in events of cardiac hypertrophy and 
172
Discussion
ischemia, and this is directly linked with fibrosis (Churchill et al., 2008). However, there 
exists controversy on whether angiotensin exerts direct pro-mitogenic actions in cardiac 
fibroblasts. Since this hormone is not a strong proliferative factor, its effects are thought 
to be caused by stimulation of the synthesis of growth or inflammatory substances, like 
platelet-derived growth factor and cytokines, by integrin activation due to secreted ex-
tracellular matrix proteins, or by a combination of these mechanisms (Bouzegrhane & 
Thibault, 2002). Angiotensin II appears to differentiate cardiac fibroblasts into a growth 
substance-secreting phenotype, hence it would be difficult to ascertain whether the role 
of PKCζ is played downstream the angiotensin II receptor or in a secondarily-activated 
pathway. 
Figure D2. Proposed functions of the ERK5 pathway in the heart. Hypothetic roles of the AngII-activated 
ERK5 pathway in the interplay between cardiac myocytes and fibroblasts and in the development of cardiac 
hypertrophy.                                                                                                                                                                                           
In addition to the role of Gαq/PKCζ/ERK5 signalling axis in cardiac myocytes and 
fibroblasts, the possibility that PKCζ deficiency affects AngII signalling in other cell types, 
particularly the endothelium (Watanabe et al., 2005), cannot be disregarded. As described 
in the introduction (sections 3b and 5c) both PKCζ and ERK5 play a key role in endothelial 
integrity and, in the case of ERK5, this drastically affects heart function during develop-
ment. Thus, in order to clearly dissect the relative contribution of each relevant cell type in 
Angiotensin II-mediated hypertrophy, further investigation is required, and would greatly 
benefit from the use of cell type-specific PKCζ knock-out animals. 
 In summary, our data point at the Gαq/PKCζ/ERK5 signalling axis as a main player 
in heart function and disease. Throughout the subsequent sections of the present work, 
we have sought to identify the biochemical and cellular mechanisms underlying this pa-
thway in an attempt to improve our understanding of its physiological implications. 
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Gαq-biased properties of the GPCR/ERK5 pathway
The biological functions of GPCR are being currently revised in the light of novel fin-
dings on the ability of b-arrestins to promote signalling independently of G proteins. For 
instance, the activation of ERK1/2 by angiotensin II has been reported as dual; one initial 
and rapid stage (after 2 minutes) driven by Gαq and a later and more sustained activation 
(after 10 minutes) driven by arrestins after receptor internalisation (Ahn et al., 2004). 
Since ERK5 phosphorylation by Gq-coupled GPCR occurs at a relatively late stage after 
receptor activation (usually peaking around 15/30 minutes) is was tempting to suggest 
an involvement of b-arrestin through mechanisms dependent on receptor phosphoryla-
tion and internalisation. In the same line, the internalization of the p62/PKCζ complex is 
required for neutrophin-induced ERK5 activation in neurons (Geetha & Wooten, 2003). 
However, our results clearly show that activation of ERK5 by muscarinic M1/M3 recep-
tors does not require clathrin-mediated or any type of receptor internalisation, which is 
one of the mechanisms for β-arrestin to initiate signalling. The possibility remained that a 
β-arrestin-mediated event occurred at the plasma membrane. Indeed, ERK1/2 activation 
by M3 muscarinic receptor is not affected by receptor internalisation (Budd et al., 1999). 
However, we found that phosphorylation-deficient muscarinic receptors that cannot re-
cruit β-arrestin or internalise (Kong et al., 2010), managed to activate ERK5 even better 
than wild-type. Additionally, a β-arrestin-biased ligand failed to activate ERK5 in cardiac 
fibroblasts. On the contrary, we demonstrate that the overexpression of Gαq greatly po-
tentiates the pathway, as well as an absolute requirement of Gαq for the pathway´s activa-
tion through the inability of a binding-deficient Gαq mutant (Gαq-E234/E245-AA) to pro-
mote ERK5 stimulation by GPCR (discussed later). To summarise, in all the systems tested, 
ERK5 activation by GPCR is independent of β-arrestin and displays Gαq-biased proper-
ties. Thus, we propose that the unique properties of the Gαq/PKCζ/ERK5 pathway, where 
Gαq acts as a scaffold (García-Hoz et al., 2010) (a role usually assigned to β-arrestin), 
could represent a possible common mechanism for Gαq-bias. Indeed, although further 
investigation is necessary, to our knowledge ERK5 would be the first MAPK pathway not 
to be activated by b-arrestin. The activation of all the other families of MAPK have been 
shown to require β-arrestin-signalling to some degree, either through direct interaction 
between the MAPK and β-arrestin (McDonald et al., 2000), or being activated downstream 
β-arrestin-initiated pathways (DeWire et al., 2007). 
The Gαq-biased properties of the ERK5 pathway open new avenues for the reinter-
pretation of signalling in heart function and dysfunction. To date, a common approach in 
heart disease involves inhibitory targeting of GPCR such as b-adrenergic or angiotensin 
receptors. However, it is widely accepted that there is an urgent need to redesign therapies 
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in order to minimise secondary effects arising from the fact that both Galpha/β-arrestin-
dependent pathways are inhibited by this unbiased approach. It seems that receptors 
have evolved to initiate cardio-protective pathways through β-arrestins that would com-
pensate for the cardio-damaging Gαq signalling (Noma et al., 2007). Since a dual blockage 
of these antagonistic effects is not beneficial, a new class of specifically biased drugs is 
starting to be developed with promising results (Violin et al., 2010). In addition to this, 
we propose that the Gαq-biased ERK5 pathway would have strictly deleterious effects, as 
recently demonstrated in cardiac hypertrophy (García-Hoz et al., 2012), and would make 
a potential target for therapeutics. 
The Gαq/ PKCζ complex
The primary protein complex formed in the Gαq-ERK5 pathway involves the activa-
ted Gαq protein and its effector PKCζ. It has previously been described that Gαq interacts 
directly and in a stimulus-dependent manner with PKCζ and this is the earliest event that 
correlates with the activation of the ERK5 cascade (García-Hoz et al., 2010). However, no 
causal relationship had yet been established between the Gαq/PKC complex and the acti-
vation of ERK5. 
As a first approach to determine the biological significance of the PKCζ/Gαq complex 
we studied the association of these two proteins in living cells. The occurrence of pro-
tein complexes in a cellular scenario is a strict requirement for its functionality and can 
be detected through novel techniques such as the protein complementation assay (PCA)
(Michnick et al., 2011). We utilised the Venus-YFP PCA due to the feasibility to irrever-
sibly trap transient protein complexes. Indeed, the formation of a high-affinity complex 
between Gαq and PKCζ was readily detected. The complex was selective since Gαq did not 
interact with another PKC family member, PLCβ, and PKCζ did not interact with another 
Galpha family member, Gai1. These data are consistent with our coimmunoprecipitation 
experiments that previously showed the family-specificity of the Gαq/PKCζ association 
(García-Hoz et al., 2010). The localisation of the protein complex was invariably cytoplas-
mic which poses questions on whether this is a reliable representation of reality, since 
Galpha subunits are predominantly localised at the plasma membrane. Tagging of G alpha 
proteins at either the N or the C terminus may affect localisation and effective coupling to 
effectors and receptors. However, a PCA-based approach recently tagged Gαi1 and suc-
cessfully assayed its interaction with PKA regulatory subunit at the plasma membrane 
(Stefan et al., 2011). Thus, the question remains of whether the PKCζ/Gαq complex is mis-
localised due to tagging of the G protein or it actually resides in the cytoplasm. One pie-
ce of evidence that supports this latter possibility refers to the dynamics of the complex 
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upon ligand addition. We have observed that fluorescent signal transiently concentrates 
towards cell membrane protrusions (blebs) upon carbachol stimulation (see below). Sin-
ce YFP reconstitution is an irreversible event, these data suggest that, either new protein 
complexes are being formed in these cellular blebs or already preformed complexes are 
being redistributed towards these localisations. The possibility of simple diffusion as a 
cause for the redistribution is disregarded since this event would only explain an even 
distribution of complexes throughout the cell, but not a marked concentration of fluores-
cence at specific localisations, as it was observed. In sum, our data indicate that the PKCζ/
Gαq protein complex is selectively formed in living cells, although its precise subcellular 
localisation awaits further investigation. The ongoing generation of internally-tagged ver-
sions of G alpha subunits with renilla luciferase for utilising in bioluminescence resonance 
energy transfer (BRET) assays (Dr. Michel Bouvier, personal communication) is expected 
to shed light on the localisation of the Gαq/PKCζ complex.  
Regarding the specificity of the complex, it is of particular importance the surpri-
sing fact that PKCζ does not interact with Gα11 as detected by both immunoprecipitation 
experiments and the in vivo PCA assay. Gαq and Gα11, the only ubiquitously expressed 
members of the Gαq/11 family, are  highly homologous proteins (90% aminoacid identi-
ty) and have been considered to play complementary roles, and to indistinctively activate 
the same cellular effectors (Hubbard & Hepler, 2006).  Our results indicate that PKCζ is 
likely the first differential effector within the Gαq/11 family. This finding poses new ex-
citing questions regarding the formation of the Gαq/PKCζ complex (see below) and the 
differential functions of Gαq and Gα11. 
There is a relative paucity of reported differential functions between the main mem-
bers of the Gαq/11 family. An assumed functional redundancy has lead to a generalised 
use of experimental tools that do not differentiate between these two proteins (e.g. anti-
Gαq/11 antibodies). Indeed, only double Gαq/Gα11 knockout mice models show drastic 
cardiac abnormalities whereas mice with single deletions are seemingly normal. However, 
there are some differential roles in which only Gαq, but not Gα11, is involved. These refer 
to certain platelet functions, since only Gαq is expressed in platelets and specific Gαq KO 
mice show longer bleeding times, as well as to craniofacial defects that are also specifica-
lly shown by Gαq-/- mice (Hubbard & Hepler, 2006). Additionally, it has been shown that 
Gαq, but not Gα11, is involved in glutamate receptor-dependent long-term depression in 
the hippocampus (Kleppisch et al., 2001). Also, it is interesting to note that diabetic Gα11 
knockout animals show a decreased expression of PKCζ in coronary arteries, thus sugges-
ting that this might be a compensating effect for an enhanced Gαq signalling through PKCζ 
(Hoyer et al., 2010). Addressing whether PKCζ, as a selective Gαq effector, accounts for 
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some of the functional differences between Gαq and Gα11 remains an interesting research 
avenue.  
The characterization of the PKCζ/Gαq complex required an insight into the par-
ticular surfaces involved in complex formation. Initial experiments indicated the strict 
requirement of PKCζ PB1 domain for ERK5 activation by Gq-coupled GPCR and for Gαq 
interaction. This domain has previously been involved in a number of protein-protein in-
teractions required for processes such as NFκB activation or cell polarity (See Fig I9). 
Since PKCζ harbours two types of PB1 domains (type I and type II), we studied the type 
II domain (with basic properties), which has been involved in ERK5 activation by other 
stimuli (Diaz-Meco & Moscat, 2001). We found that lysine in position 19 (K19), a main 
driver of PB1-PB1 interactions (Hirano et al., 2005), was a crucial aminoacid for PKCζ to 
interact with Gαq. Interestingly, it has been previously reported that Gαi associates with 
the PB1-type II of p67phox and this results in an enhanced activity of the G protein (Marty 
et al., 2006).  With regards to the PKCζ binding region in Gαq we have identified a pseudo-
PB1 domain within the Gαq effector domain that shows a striking similarity with MEK5 
PB1 type I domain, suggesting that this could be a conserved PKCζ-binding region. Indeed, 
we demonstrated that mutations on two residues of this domain, E234/E245, abrogated 
PKCζ binding. The positions of aminoacids E234 and E245 in Gαq are highly conserved 
in PB1 proteins such as MEK5 or p62 and coincide with crucial clusters (A1 and A2) for 
the function of these PB1 domains (Hirano et al., 2005). It is thus tempting to suggest that 
electrostatic interactions between positively charged lysines (such as K19) and arginines 
in the PKCζ PB1-type II domain, and glutamic acids and aspartic residues in Gαq are key 
determinants for the formation of the complex. It should be noted that the involved Gαq 
region was termed pseudo-PB1 domain, since the three-dimensional fold is not that of 
canonical PB1 domains despite striking similarities in the primary sequence. Our data 
suggest, however, that the presence of some key charged residues would allow specific 
interactions between classical and pseudo PB1 domains. In fact, preliminary data indicate 
that Gαq is indeed able to bind other PB1 proteins through its pseudo-PB1-type I domain 
(data not shown in this thesis). 
The position of the PKCζ-binding region in Gαq sheds light on several aspects of 
the complex. First, the fact that the pseudo-PB1 domain lies within the effector binding 
area supports the notion that PKCζ is a bona-fide effector of Gαq. It was previously shown 
that G alpha protein effectors invariably associate to the effector binding region but the 
subsets of crucial aminoacids for these associations vary with the specific effector (Old-
ham & Hamm, 2006). Hence, we demonstrate that PKCζ binds a different subset of ami-
noacids to those previously described for other Gαq effectors (PLCβ, p63RhoGEFs, GRK2). 
177
Discussion
 Consistently, we find that GRK2-binding impairing mutations in Gαq did not affect PKCζ 
association nor did PLCβ-binding impairing mutations interfere with ERK5 activation 
(García-Hoz et al., 2010). 
In this context, our finding that Gα11 does not interact with PKCζ poses some intri-
guing questions. An analysis of the sequence alignment between Gαq and Gα11 (Appen-
dix, Fig. 1A) shows a high overall homology (90%) that reaches 100% in the C-terminal 
end, so the effector binding region, identified to bind PKCζ, is completely conserved in 
both proteins. The position of variable clusters II and III (cluster I is disordered and has 
not been crystallised in any of the Gαq structures) in the three-dimensional structure is 
very distant from the PKCζ binding site (Appendix I, Fig. 1B); hence it is unlikely that these 
residues would provide contacts for PKCζ. It would still be possible that the disordered N-
terminus (Cluster I) would be more proximal to PKCζ than the other clusters. However, it 
may well be that the absence of interaction between Gα11 and PKCζ is not due to changes 
in specific aminoacids responsible for PKCζ binding. Instead, we propose that this pheno-
menon is a matter of pre-steady state kinetics: a differential availability of protein part-
ners before the binding reaction that leads to differential association, being Gαq and PKCζ 
more prone to interact due to a similar subcellular localisation. In this line, cluster I at the 
N-terminus, where some of the divergent aminoacids between Gαq and Gα11 are found, is 
known to be crucial for membrane localisation. This predominantly basic region interacts 
with membrane lipids and also contains palmitoylated residues that target the G proteins 
to specialised membrane microdomains like lipid rafts (Hubbard & Hepler, 2006). There 
are reports for agonist-dependent localisation of both Gαq (Dave et al., 2009) and PKCζ 
(Hajduch et al., 2008) in lipid rafts enriched in caveolae. Particularly, Gαq is often used 
as an experimental marker of lipid rafts (Qiu et al., 2011). Thus, it would be interesting 
to explore whether lipid rafts, or other membrane microdomains, would provide specific 
microenvironments for the formation of the Gαq/PKCζ complex.
In sum, although we have roughly identified the binding regions for the PKCζ/Gαq 
complexes through mutagenesis studies, no claims can be made regarding the precise mo-
lecular architecture of the complex, and further structural work needs to be carried out 
to specifically characterise the surfaces involved. In this line, we are currently performing 
molecular dynamics and protein docking simulations to determine other potential bin-
ding sites of PKCζ in the threedimensional structure of Gαq (ongoing collaboration with J. 
Klett). The mutants generated for Gαq are, however, very useful tools for studying the ce-
llular events that depend upon the formation of a Gαq/PKCζ complex. Indeed, we demons-
trate the strict requirement of ERK5 activation by Gq-GPCR on the Gαq/PKCζ complex. A 
constitutively active mutant Gαq harbouring the E234/E245-AA mutation was unable to 
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activate ERK5, and similarly, the same mutation on a wild-type background impaired Gαq 
enhancement of ERK5 activation by GPCR. In parallel experiments, expression of the Gαq 
E234/E245-AA mutant still activated inositol phosphate signalling (although to a lesser 
extent than wild-type Gαq) and did not impair the full stimulation of ERK1/2, that lays 
downstream of DAG-activated PKC. Overall, these data constitute the first direct demons-
tration of a biological function for the protein complex between novel effector PKCζ and 
Gαq, and supported the reliability of the mutagenesis strategy.
Effect of Gαq modulators on Gαq/PKCζ complex formation and 
 dowstream signalling
We were also interested in addressing the modulation of the Gαq/PKCζ complex and 
the resulting effects on the activation of the ERK5 cascade. In the case of Gαq signalling, 
the two main modulators are GRK2 and RGS2/4 proteins. GRK2 phosphorylates and des-
ensitises activated GPCRs and also negatively regulates Gαq activity through a seques-
tering effect. This has been described as a strong competition between the kinase and 
effectors, that displaces the latter from the Gαq binding site and dampens downstream 
signalling (Carman et al., 1999). Gαq can also be deactivated by RGS proteins, which en-
hance the GAP activity of Gαq to promote GTP hydrolysis. The latter proteins have been 
reported not to compete with the effector binding site. In agreement with this notion, we 
demonstrate that Gαq/PKCζ complexes are undisturbed by the overexpression of RGS2 
and 4. Similar results have been reported for other known Gαq partners that associate 
with the effector binding site, such as p63rhoGEF and GRK2 (Shankaranarayanan et al., 
2008).  This strengthens the idea that PKCζ is a bona-fide effector and opens the possi-
bility to the formation of a ternary complex whereby RGS allosterically, but not sterically, 
modulates PKCζ binding to Gαq. 
On the other hand, we report that GRK2 sterically impedes the association of PKCζ 
to Gαq in vitro and in living cells, and abrogates ERK5 activation due to Gαq sequestering 
and to receptor desensitisation. GRK2 was also able to down-regulate the association of 
Gαq to MEK5, the other Gαq effector in the ERK5 pathway, which suggests that MEK5-Gαq 
association also requires the effector-binding surface of the G protein. Additionally, we 
show that the impairment of the GRK2/Gαq complex with a specific association-deficient 
Gαq mutants upregulates the Gαq/PKCζ complex and greatly enhances ERK5 activation. 
This suggests that cellular contexts in which GRK2 levels are decreased would allow for 
hyperactive signalling of the ERK5 pathway. Inversely, the fact that GRK2 overexpression 
downregulates the Gαq/PKCζ complex and ERK5 activation also suggests that similar 
events will be occurring in cellular contexts with increased GRK2 levels. Indeed, GRK2 
expression or functionality is altered in a number of physiopathological conditions where, 
179
Discussion
according to our findings, Gαq signalling towards the ERK5 pathway might be modified. In 
the cardiovascular system GRK2 is known to play a key role (see Introduction, section 6d) 
through the desensitisation of b-adrenergic receptors and resulting modulation of car-
diac contractility (Penela et al., 2010). In failing human hearts increased GRK2 levels have 
been associated to a decrease in b-adrenergic signalling (Ungerer et al., 1994). Additional 
pathways would similarly be downregulated in this context which poses for questions 
regarding the triggering event of cardiac failure. Our experiments in the PKCζ-/- mouse 
model only address the role of the Gαq/PKCζ/ERK5 axis in heart hypertrophy and have 
not investigated the potential role in heart failure (García-Hoz et al., 2012). However, it is 
tempting to speculate that increased GRK2 levels would lead to an inhibition of the ERK5 
pathway in the transition from hypertrophy to heart failure. The overexpression of GRK2 
in the myocardium also attenuates angiotensin II-mediated increases in contractility and 
heart rate (Rockman et al., 1996). Additionally, inhibitors against MEK1/2 and MEK5 have 
been shown to reduce contractility increases promoted by the endothelin-1 receptor, ano-
ther prevalent Gq-coupled receptor in the heart (Münzel et al., 2005). Thus, we suggest 
that GRK2 might regulate the contractile effects of Gq-coupled angiotensin and endothe-
lin receptors through the inhibition of the ERK5 pathway.  In conclusion, the functional 
relationship between GRK2 and the Gαq/PKCζ/ERK5 pathway in different pathological 
settings deserves to be addressed in future research projects.
Activation mechanisms of the Gαq/PKCζ/ERK5 pathway
Once established that the interaction between Gαq and PKCζ is necessary for the 
stimulation of the ERK5 pathway by GPCRs it remained unclear how this interaction trig-
gered the activation of the cascade. Our starting assumption was that the kinase activity 
of PKCζ was involved since the PKCζ-pseudosubstrate catalytic inhibitor abrogates ERK5 
activation by Gq-GPCR in a number of systems [(García-Hoz et al., 2010), (García-Hoz et 
al., 2012) and results within this thesis]. Several mechanisms have been described for 
atypical PKC activation (see Introduction section 3b). Insulin provokes increases in PKCζ 
enzymatic activity through PDK-1-dependent T410 phosphorylation in the activation 
loop, T560 autophosphorylation at the turn motif, and phosphorylation-independent/
conformational-dependent relief of pseudosubstrate autoinhibition (Standaert et al., 
2001). However, we did not found changes in the phosphorylation status of either T410 
or T560 in response to Gq-GPCR stimulation. Still, we could detect basal phosphorylation 
on both residues consistent with other reports that suggested that most of the Thr410 of 
PKCζ is phosphorylated following ectopic expression in HEK-293 cells (Smith & Smith, 
2002). Since it is uncertain whether PKCζ is catalytically active if not phosphorylated on 
Thr410 (Smith & Smith, 2002), the pathway might require a previously phosphorylated 
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form of the kinase. Regardless, it is increasingly clear that additional activation mecha-
nisms can operate on PKCζ independently of phosphorylation, which is evidenced by the 
ability of insulin to activate the phospho-mimetic mutant PKCζ-T410E/T560E (Standaert 
et al., 2001). Thus, we postulate that a conformational-dependent relief of pseudosubstra-
te autoinhibition could be operating between Gαq and PKCζ. Consistent with this notion, 
the activation mechanism exerted by Gαq on main effectors, PLCβ and p63RhoGEF, invol-
ves the allosteric relief of an autoinhibitory loop buried within an active region promoted 
upon Gαq binding (Shankaranarayanan et al., 2010; Waldo et al., 2010). A similar mecha-
nism involving the disruption of an intramolecular inhibitory interaction in the effector 
has been proposed for Gαq-mediated Btk activation (Ma & Huang, 1998). Regarding PKCζ, 
it has been recently described that PB1-PB1 interactions with Par6 allosterically activate 
the kinase by pseudosubstrate displacement (Graybill et al., 2012). Since we have shown 
that Gαq interacts through a pseudo-PB1 domain with the PB1 type II domain PKCζ, we 
suggest that a similar activation mechanism might be taking place between Gαq and PKCζ 
(Fig. D3). 
Figure D3. Proposed activation mecha-
nism of PKCζ by Gαq. Gαq might activate 
PKCζ in a phosphorylation-independent 
manner through a PB1-pseudoPB1 inte-
raction that relieves autoinhibition of the 
kinase domain by the pseudosubstrate 
region.                                                                      
As described throughout this thesis, protein molecules form modular complexes 
that are required for correct signal propagation. Protein dimerisation is a common event 
in the function of numerous enzymes, ion channels, receptors or transcription factors. 
This process of self-association has been positively selected throughout evolution as it 
minimises genome size and still allows for modular organisation (Marianayagam et al., 
2004). Particularly, PB1 domains are known modules for homo/hetero- dimer/oligomer 
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formation (Noda et al., 2003). Proteins harbouring two types (I, II) of PB1 domains such 
as p62 are known to oligomerise in a process where the basic cluster of one p62 mole-
cule binds to the acidic motif of another in a front-to-back arrangement (Wilson et al., 
2003). Since PKCζ also harbours two PB1 domains, we investigated whether dimerisa-
tion could be an additional event downstream GPCR activation, along with the formation 
of heterodimers between PB1 domains from MEK5 and PKCζ, or between pseudo-PB1 
and PB1 domains of Gαq and PKCζ. Thus, we used the protein complementation assay 
with PKCζ tagged to different fragments of YFP and we could detect high-affinity dimeri-
sation in living cells. Most interestingly, by using a reversible PCA with renilla luciferase 
fragments, we determined that PKCζ dimerisation is transiently induced by Gq-coupled 
GPCR stimulation in vivo. PKCζ dimerisation occurs in a coincident time-course (between 
2 and 10min) to Gαq-PKCζ interaction after receptor stimulation (García-Hoz et al., 2010), 
which suggests that dimerisation might be necessary for PKCζ function in Gαq signalling. 
Also, our results clearly indicate that there is a transient increase of PKCζ molecules in a 
particular cellular location driven by GPCR stimulation. Since PKCζ is known to directly 
associate with Gαq, MEK5 and ERK5, there is a possible scenario in which PKCζ could oli-
gomerise and serve as a signalling platform for the activation of ERK5. An analysis of the 
PLCλ-Par6α crystal structure, shows that the PB1-type I domain of PLCλ is free to interact 
with other PB1-harbouring proteins (Appendix I, Fig. 2). Since PKCζ and PLCλ PB1 do-
mains are structurally very similar, we suggest that the spatial disposition of PB1 domains 
I and II in PKCζ would allow for oligomerisation of several molecules in a front-to-back 
arrangement, as previously described for p62 (Wilson et al., 2003). Additionally, since it 
is known that PB1-PB1 interactions can result in PKCζ activation, it is tempting to suggest 
that activation events might occur as a result of PKCζ oligo/dimerisation. Thus, we propo-
se that PB1-driven PKCζ dimerisation might be a cellular mechanism for imposing spatial 
and temporal specificity during Gαq-initiated signalling. 
Also relevant to our understanding of protein complex architecture in the Gαq-ERK5 
pathway, we have found that PKCζ interacts with ERK5 in a stimulus-dependent manner, 
at a coincident time-frame with dimerisation and Gαq/PKCζ complex formation. In addi-
tion, we demonstrated that Gαq and ERK5 are found together in an activated macromo-
lecular complex through an interaction with PKCζ. These results are consistent with the 
scaffold role of PKCζ in the ERK5 cascade. 
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Based on all the information collected (including binding regions and activation and 
deactivation mechanisms), we propose a global working model to account for the sequen-
tial events and macromolecular complexes involved in ERK5 activation by Gq-coupled 
GPCR (Fig. D4): Ligand binding to the receptor causes Gαq activation (1) which, in turn, 
promotes an interaction with PKCζ (2). The Gαq/PKCζ complex is formed between the 
PB1 domain type II of PKCζ (shown in blue) and the pseudo-PB1 type I of Gαq (shown in 
brown). We hypothesise that Gαq would then allosterically activate PKCζ by relieving au-
toinhibition exerted by the pseudosubstrate domain (2). Open conformation of the kinase 
due to activation and high concentration of PKCζ molecules in specific Gαq-directed cellu-
lar location favours the formation of dimers/oligomers of PKCζ (3). Additional activation 
events might occur in the dimerisation process between different PKCζ molecules due to 
PB1-PB1 interactions and pseudosubstrate relief. In an open (active) conformation, the 
kinase domain of PKCζ is free to interact with ERK5 [as previously described in (Nigro et 
al., 2010)], which is recruited by PKCζ into a multimolecular complex together with Gαq 
(4). Next, MEK5 is recruited into the signalling complex through a direct interaction with 
activated Gαq that does not involve MEK5 PB1 domain (García-Hoz et al., 2010) (5). Even-
tually, a transient complex between MEK5, Gαq and PKCζ/ERK5 is formed. Gαq acts as an 
adaptor bringing PKCζ and MEK5 into close proximity (García-Hoz et al., 2010). This in-
termediate complex rapidly progresses to MEK5 binding PKCζ with high affinity and Gαq 
displacement from the PB1 domain type II of PKCζ (García-Hoz et al., 2010), so Gαq leaves 
the multimolecular complex (6). The formation of PKCζ-MEK5 complexes might contribu-
te to decreasing PKCζ dimers due to PB1-PB1 competition between different PKCζ mole-
cules and MEK5. From this point onwards we speculate that the activation mechanisms 
involved are similar to those reported for EGF-mediated ERK5 activation (Diaz-Meco & 
Moscat, 2001). Subsequently, the interaction between MEK5 and PKCζ favours MEK5 au-
tophosphorylation (7), and PKCζ acts as scaffold in the activation of the MAPK cascade by 
allowing MEK5 to phosphorylate ERK5 (8). Activated ERK5 will be able to phosphorylate 
several substrates and initiate diverse cellular functions. GRK2 and RGS proteins would 
act as negative modulators of this cascade by sequestering Gαq away from PKCζ (2’) or 
from MEK5, or by binding to Gαq in the complex to promote GTPase activity and deacti-
vation of Gαq (3´), respectively. This model may serve as a theoretical framework for the 
subsequent studies on the pathway.   
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Figure D4. Model of the activation of ERK5 by Gq-coupled GPCR. Proposed sequential formation of protein 
complexes involved in the Gαq-ERK5 pathway. PB1 type I domain and pseudo-PB1 type I domain are shown 
in brown, PB1 type II in blue. See text for detailed information.                                                                                          
A number of questions remain to be addressed. For instance, the interplay between 
PKCζ and ERK5 activities has to be clarified. On the one hand, we have shown that the pre-
sence and a pseudosubstrate-inhibited function of PKCζ is strictly required for the phos-
phorylation of ERK5 in response to Gq-coupled GPCR stimulation (muscarinic M1 (García-
Hoz et al., 2010) and M3, and angiotensin II (García-Hoz et al., 2012) receptors), whereas 
it was previously reported that PKCζ protein, but not its kinase activity, was required for 
ERK5 phosphorylation upon EGFR stimulation (Diaz-Meco & Moscat, 2001). On the other 
hand, in our gene expression studies performed in AngII-treated mice we showed that 
both ERK5 and several products downstream from ERK5 were upregulated in wild-type 
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animals compared to PKCζ-/- mice (ETS-1, NPPA, Col1a2, BCL2, CCNA2)(García-Hoz et 
al., 2012), consistent with the notion that ERK5 transcriptional activity is enhanced by 
PKCζ. However, a recent publication reported that TNF-α promoted ERK5-PKCζ associa-
tion in the endothelium which resulted in an ERK5 phosphorylation in Ser486 that inhi-
bited its transcriptional activity (Nigro et al., 2010). Although the phosphorylation was 
not endogenously detected, the authors showed that the sole expression of PKCζ or its 
catalytic domain was sufficient to decrease ERK5 transcription of a luciferase reporter 
gene. These seemingly contradictory findings might provide the basis for a novel regu-
lation mechanism of ERK5 activity through GPCR. In this model PKCζ would be required 
for the activatory phosphorylation of ERK5 in its kinase domain (TEY motif) and additio-
nally PKCζ would itself phosphorylate the C-terminus of ERK5 (Ser486) thus inhibiting 
its transcriptional activity. It is still unclear whether this mechanism would only operate 
in the endothelium, since it does not fit with our results in whole hearts (containing car-
diomyocytes, cardiac fibroblasts and endothelial cells). Thus, the interplay between PKCζ 
and ERK5 could be more complex than expected and deserves a detailed characterization 
in each particular scenario.  
The Gαq/PKCζ axis is involved in membrane blebbing, cell growth 
arrest and in the promotion of apoptosis 
In an attempt to expand our understanding of the functionality of the Gαq/PKCζ 
complex, the last section of the present work was devoted to characterising the participa-
tion of this protein complex in diverse cellular effects, using the XCELLigence system (Ro-
che) due to its unique features for real-time monitoring of cell proliferation, cell surface 
coverage, cellular adhesion strength or cell viability (see Methods). 
Acetylcholine muscarinic receptors are involved in the regulation of a wide variety 
of physiological responses, including apoptosis, cellular proliferation and neuronal diffe-
rentiation (Caulfield, 1993). Indeed, muscarinic signalling has been shown to be abnor-
mal in many diseases, such as overactive bladder, chronic obstructive pulmonary disease, 
neurodegenerative diseases, Sjogren’s disease, vascular dementia and others (Resende & 
Adhikari, 2009). The stimulation of the Gq-coupled muscarinic M1 and M3 receptors by 
carbachol results in measurable phenotypical changes; the most immediately noticeable 
effect is plasma membrane blebbing (Street et al., 2006). Blebs are spherical protrusions 
of the plasma membrane that result from actinomyosin contractions of the cortex (Cha-
rras, 2008). These processes in which the cytosol steams out of the cell body, are repor-
ted to have a transient nature lasting for approximately 40min-1hr, after which time cells 
retract to their basal state (Meshki et al., 2009). Bleb expansion does not involve actin 
polymerisation, which distinguishes blebs from all other known cellular protrusions, but 
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instead they are a result of local disruption of membrane-actin cortex interactions. Ble-
bbing correlates with changes in electrical impedance measured in cellular monolayers 
with the XCELLingence software (Meshki et al., 2009). In Cho-M3 cells, blebbing was de-
tected by a sharp increase in the cell index indicative of a higher cell surface coverage that 
peaked after approximately one hour of ligand addition. This effect showed a clear dose-
dependence on carbachol concentration. Interestingly, cells overexpressing wild-type Gαq 
displayed a greatly enhanced carbachol-promoted blebbing whereas those expressing the 
Gαq-EEAA (E234/E245-AA) mutant behaved as control, empty vector-transfected cells. 
Moreover, we find the Gαq/PKCζ complex localised in blebbing processes upon carbachol 
stimulation. These data suggest that PKCζ interaction with Gαq is essential for M3 recep-
tor-induced blebbing processes upon carbachol addition, supporting the notion that PKCζ 
is a functional Gαq effector that plays relevant roles in different cellular functions. 
Classically, muscarinic-induced reorganisation of both actin and myosin  has been 
tied to the activation of RhoA (Linseman et al., 2000; Strassheim et al., 1999) and that 
of its main downstream target Rho associated kinase (ROCK)(Chernyavsky et al., 2004). 
Interestingly, the angiotensin II type I receptor (AT1R) was shown to induce blebbing in a 
process that involved RhoA, ROCK and myosin light chain kinase but was independent of 
PLCβ activation (Godin & Ferguson, 2010). Contradictory evidence was shown by a recent 
report in which the muscarinic M1 receptor induced blebbing through reversible remo-
delling of the spectrin cytoskeleton in Cho cells (Street et al., 2006). The authors showed 
that this effect was dependent on PLCβ, conventional PKC and ROCK, but independent of 
RhoA activation. Thus, it seems that different pathways can promote blebbing through 
different mechanisms downstream Gq-coupled GPCR. Our results suggest that the M3 re-
ceptor-induced blebbing in Cho cells requires the association between Gαq and PKCζ but 
the particulars of this signalling axis have not yet been determined. It is unclear whether 
the ERK5 pathway is located downstream of the PKCζ/Gαq complex in carbachol-induced 
blebbing or, alternatively, other pathways are emanating from this functional relationship. 
ERK5 has been shown to promote actin cytoskeleton disruption in Src-transformed cells, 
which was required for an oncogenic phenotype (Barros & Marshall, 2005). Since actin 
disruption is a hallmark of blebbing, we suggest that ERK5 activation downstream the 
Gαq/PKCζ complex might provide a feasible explanation of the most distinctive feature 
of blebbing. Additionally, PKCζ has been shown to associate with actin upon insulin sti-
mulation of Cho cells and to participate in the remodelling of the actin cytoskeleton (Liu 
et al., 2007).  Since Gαq has also been shown to associate to actin (Mizuno & Itoh, 2009), 
the Gαq/PKCζ complex might form in actin-rich regions and thus promote ERK5 activa-
tion that would lead to cytoskeleton disruption.  Alternatively, PKCζ has been reported to 
activate RhoA downstream of the Gq-coupled thrombin receptor in the endothelium and 
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to initiate a pathway involving ROCK and myosin light chain kinase that leads to increased 
endothelial permeability (Minshall et al., 2010). Interestingly, the authors suggest that 
there might be a link between Gαq and PKCζ that had not yet been described. Thus, we 
speculate that the Gαq/PKCζ activated complex might have a role in promoting RhoA ac-
tivation independently of the Gαq effector p63RhoGEF. In summary, we propose two pos-
sible mechanisms to explain the observed abrogation of muscarinic M3 receptor-induced 
blebbing upon Gαq/PKCζ complex disruption: ERK5-mediated actin cytoskeleton disrup-
tion or the activation of RhoA downstream the Gαq/PKCζ complex (Fig. D5). 
To date, the function of blebbing is far from being understood. Blebs are known to 
contribute to cell movement (Fackler & Grosse, 2008), as described for other membrane 
protrusions like lamellipodia or filopodia, but in other contexts such as cytokinesis and 
apoptosis, blebbing function is much speculative (Charras, 2008). As for receptor-induced 
blebbing, though being a known cellular effect, its function is unknown. Some authors have 
suggested a role for blebs in providing a dynamic and reversible signalling platform to the 
specific domains of the plasma membrane in response to stimulation of GPCR (Street et 
al., 2006). Since the visualisation of the Gαq/PKCζ complex in living cells showed a clear 
concentration at these protrusions (discussed above), this opens the possibility for se-
lective localisation of Gαq/PKCζ signalling at cellular blebs. Thus, we speculate that blebs 
require the formation of a Gαq/PKCζ complex and might additionally provide a specific 
signalling microenvironment for this signalling axis.   
Generally speaking, muscarinic receptors were initially thought to mediate cell sur-
vival and antiapoptotic responses (Gutkind et al., 1991). However, in the Cho-M3 cell line, 
used throughout this thesis, stimulation of the muscarinic M3 receptor leads to inhibition 
of cell growth and apoptosis. Carbachol-mediated stimulation of these cells resulted in 
cell growth arrest at the G1 phase that correlates with JNK activation and p21cip1/waf1 
increased expression (Burdon et al., 2002). Opposite results were obtained for the stimu-
lation of the Cho-M2 cell line, suggesting that the effect observed is dependent on Gαq/11-
coupling of the receptor. Indeed, the activation of Gq-coupled muscarinic receptors (M1 
and M3) has been shown to inhibit cell proliferation in a number of cell lines (Shafer & Wi-
lliams, 2004).  In our experiments, we observed a clear dose-dependent cell growth arrest 
effect of carbachol in Cho-M3 cells that was reliably detected through the XCELLigence 
system. This effect, which was also detected in the 3T3-M1 cell line (data not shown), 
is transient and, invariably, cells started growing again after approximately 72 hours of 
ligand addition. The analysis of this process in cells overexpressing either Gαq wild type 
or Gαq-EEAA (E234/E245-AA) showed that Gαq cells had a more drastic decrease of cell 
proliferation upon carbachol addition than control (pcDNA cells) or Gαq-EEAA cells, both 
of which behaved indistinctively. This suggests that an absence of interaction  between 
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Gαq and PKCζ abrogates the cell growth arrest effect of carbachol-activated Gαq. The spe-
cific effects downstream of the Gαq/PKCζ complex that contribute to cell growth arrest 
are unknown. ERK5 effects have been virtually always associated to the promotion of cell 
proliferation as it activates NFκB and promotes the expression of cyclin D1, both of which 
contribute to cell cycle progression (Cude et al., 2007; Mulloy et al., 2003). The effects 
reported for carbachol-induced cell growth arrest involve the inhibition of CDK2, cyclin A 
and cyclin D, and the arrest at the S phase (Burdon et al., 2002). Thus, ERK5 reported roles 
do not seem to fit with our results and it is likely that other players are acting downstream 
the Gαq/PKCζ complex in this process. Since most anti-proliferative actions of carbachol 
in Cho-M3 cells have been tied to JNK activation, it would be interesting to address whe-
ther the interaction between Gαq and PKCζ affects this pathway. Tiam1, a known ups-
tream activator of Rac in the Gq-GPCR-initiated JNK cascade (Buchsbaum et al., 2002), has 
been shown to form an active complex with Par proteins and PKCζ that controls polarity 
in keratinocytes (Pegtel et al., 2007). Thus, it is tempting to speculate with the possibility 
that a similar complex would be promoted by the Gαq/PKCζ signalling axis leading to JNK 
activation. Indeed, several studies have found PLCβ-independent activation of JNK. Mus-
carinic M1 receptors in NIH-3T3 cells promoted JNK activation at a different timeframe 
from other MAPK pathways and entirely independently of DAG-activated PKC (Coso et al., 
1995). Also, the activation of JNK downstream the a1A-adrenergic receptor was found to 
be both calcium- and PKC-independent in PC-12 cells (Berts et al., 1999). Therefore, the 
activation of Tiam1 by the Gαq/PKCζ complex would not only provide a feasible explana-
tion for its participation in cell growth arrest (Fig. D5), but also a novel mechanism for the 
Gαq-mediated activation of JNK independently of PLCβ.
Other reports analysed the ability of Cho-M3 cells to undergo apoptosis induced by 
the DNA damaging agent etoposide (Budd et al., 2004). In this scenario, the stimulation 
of M3 muscarinic receptor activated anti-apoptotic pathways through a mechanism that 
is independent of PLCβ activation and involves Bcl-2 upregulation. Also, the induction of 
apoptotic processes by DNA damage, oxidative stress and mitochondrial inhibition was 
reported to be reverted by muscarinic receptor activation in human neuroblastoma cells 
(De Sarno et al., 2003). However there is evidence that some of the anti-apoptotic pa-
thways downstream the M3 receptor may be initiated independently of Gαq. An M3 recep-
tor truncation mutant, d565-M3, that preserves the G protein activation capacity did not 
have this anti-apoptotic effect (Tobin & Budd, 2003). Thus, Gαq signalling downstream 
the M3 receptor in Cho cells would be responsible for cell growth arrest whereas apopto-
sis protection upon DNA damage might be mediated by β-arrestin-dependent pathways. 
In our hands, it was noteworthy that the combination of carbachol stimulation and Gαq 
overexpression lead to significant decreases in the cell index, which is indicative of cell 
death. This is consistent with the notion that overactivated Gαq promotes the transition 
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from survival/proliferative responses to apoptosis (Dhanasekaran et al., 1998). Indeed, 
muscarinic M3 activation with pilocarpine has been shown to promote apoptosis in hu-
man skin fibroblast cells, which correlated with JNK and caspase-3 activation (Reina et 
al., 2010). In our experimental setting, we observed that the slope of the cell index curve 
for Gαq cells is negative for approx. 48 hours following carbachol but it progressively in-
creases afterwards. Thus, we suggest that, in a context of excessive signalling downstream 
the M3 muscarinic receptor, growth arrest responses might coexist with apoptosis events. 
Coincidently, it has been reported that M3 activation upon overexpression of Rac1 or a 
constitutively active Rac1 mutant results in apoptosis, whereas the expression of a do-
minant-negative form of Rac1 leads to a diminished cell growth inhibition (Shafer & Wi-
lliams, 2004). Our results show that the ability to promote apoptosis differs between Gαq 
and Gαq-EEAA cells, suggesting a potential role for the Gαq/PKCζ complex in this process. 
In sum, the possibility that Gαq/PKCζ acts upstream Tiam1 in the activation of the Rac1/
JNK pathways clearly deserves further investigation. 
In order to confirm the involvement of the Gαq/PKCζ complex in apoptosis promo-
tion, we studied cell death upon nutrient-starvation, an established model of apoptosis. 
Our results clearly show that Gαq overexpression promotes apoptosis entry with respect 
to control, whereas the Gαq-EEAA mutant fails to do so. We examined the different cell po-
pulations with a brightfield microscope after the slope in the growth curve of Gαq cells had 
turned negative. This showed cellular shrinkage and membrane blebbing in Gαq, but not 
in control or Gαq-EEAA cells, which reflected the boiling action of the membrane (zeiosis) 
characteristic of an apoptotic phenotype (Squier & Cohen, 2001). Indeed, in the absence 
of a clear molecular definition of apoptosis, this process can be defined by morphologi-
cal markers such as those mentioned. The drastic change in the growth curve observed 
in all our experiments together with the homogeneous phenotypical changes visualised 
suggest that this is an event of programmed cell death (apoptosis) instead of accidental 
cell death (necrosis). This is also consistent with the reported role for Gαq in apoptosis 
(Adams et al., 2000). Additionally, preliminary results not shown in this thesis suggest 
that several molecular markers related to apoptosis are differentially regulated in Gαq 
and Gαq-EEAA populations. It seems that pro-survival protein Akt is dephosphorylated, 
and the proapoptotic protein Bad is upregulated, at an earlier stage in Gαq compared to 
Gαq-EEAA cells. Additionally, the performance of vital-dye exclusion assays and the deter-
mination of other biochemical markers would be necessary to further confirm the notion 
of apoptosis-related cell death in our experimental settings. 
Evidences commented above suggest the possibility that the Gαq/PKCζ axis might 
activate the JNK cascade in the context of cell growth arrest and apoptosis (Fig. D5). In 
this line, several reports suggest that Gαq can promote apoptosis independently of its 
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classical effector PLCβ. Vascular smooth muscle cells (VSMC) that express activated Gαq 
undergo caspase activation and apoptosis. Although the precise apoptotic mechanisms 
are undefined, cell death is independent of PLCb as inhibitors of IP
3
- or PKC-dependent 
signalling did not block Gαq-induced apoptosis (Peavy et al., 2005). Since the EEAA mu-
tation has been shown to partly affect PLCβ-mediated IP
3
 generation, although it did not 
seem to affect ERK1/2 downstream signalling, we assessed whether PLCβ had a role in 
the apoptotic events observed in our system. We speculated that if diminished PLCβ signa-
lling downstream the Gαq-EEAA mutant was responsible for its retarded apoptotic entry 
compared to Gαq-wt, a PLCβ inhibitor would balance the difference observed. However, 
apoptosis entry of the mutant Gαq population was still delayed with respect to Gαq-wild 
type cells. This strongly suggests that PLCβ is not involved in Gαq-mediated apoptosis 
responses in Cho cells. In addition to JNK, we should consider the possibility that the acti-
vation of ERK5 by the Gαq/PKCζ axis might contribute to apoptosis promotion. This might 
seem paradoxical in principle since ERK5 is a key pro-survival factor shown to inhibit 
apoptosis (Nithianandarajah-Jones et al., 2012), but it also has been found to promote 
apoptosis in certain contexts. Indeed, it was recently found that the ERK5 signalling axis 
positively regulates apoptosis of developing thymocytes and its activity correlates with 
the expression of Nur77, a family of orphan nuclear receptors (Sohn et al., 2008). The in-
trinsic function Nur77 has been characterized as cell type-dependent and agent context-
dependent, which might explain why ERK5 plays a distinct role in thymocytes. Since ERK5 
is to date the only pathway known to act downstream of the Gαq/PKCζ complex, a possible 
function in apoptosis deserves to be clarified.
Since we have described the occurrence of a Gαq/PKCζ signalling axis in the heart 
it is tempting to speculate that it might be important for apoptosis-related processes like 
heart failure. A role for PKCζ in apoptosis promotion in the heart has been previously 
proposed. Stimulation of the Gq-coupled thromboxane TxA2 receptor in isolated adult 
cardiac  myocytes directly induces apoptosis which can be ascribed to PKCζ function (Shi-
zukuda & Buttrick, 2002). In this process it seemed that PKCζ was required for the inhi-
bition of the PI3K/Akt pathway downstream the TxA2 receptor. This is consistent with 
the reported negative role of Gαq on the Akt pathway (Ballou et al., 2000), which has also 
been shown to occur independently of PLCβ (Fan et al., 2003). Several reports suggest that 
Gαq-mediated apoptosis involves the inhibition of Akt signalling (Ben-Ami et al., 2011), 
and particularly in the heart this seems to involve the depletion of PIP
2
 (Howes et al., 
2003). Distinctive features in angiotensin II and Gαq overexpression-induced heart failu-
re are the production of reactive oxygen species (ROS) and mitochondrial dysfunction. It 
is known that angiotensin stimulates NADPH oxidase (NOX), an enzyme responsible for 
ROS production in the cytoplasm (Mollnau, 2002). NOX-dependent ROS  formation in turn 
 stimulates mitochondrial ROS production, which leads to the dysfunction of mitochondria 
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(Zimmerman & Zucker, 2009).  The first step for the activation of NOX is the translocation 
of the p47phox subunit to the plasma membrane which is followed by subsequent acti-
vation steps, including an interaction between p40phox and p67phox subunits through 
their PB1 domains (Wilson et al., 2003). Angiotensin II was reported to induce p47phox 
translocation in the heart, which was correlated with cardiac hypertrophy (Bendall et al., 
2002). Notably, PKCζ has been previously shown to promote activatory phosphorylation 
and to colocalise with the p47phox subunit at the membrane (Frey, 2002). Thus, PKCζ 
might be the link between Gαq-mediated signalling and mitochondrial dysfunction in the 
heart leading to apoptosis, through the promotion of NOX activation. In summary, we pro-
pose two different potential mechanisms for the induction of apoptosis downstream the 
Gαq/PKCζ complex in the heart: Akt pathway downregulation and NOX pathway activa-
tion (Fig. D5). 
Figure D5. Possible pathways downstream the Gαq/PKCζ complex in blebbing, cell growth arrest and apop-
tosis. Graphical representation of potential downstream targets for the Gαq/PKCζ complex in muscarinic 
M3 receptor-induced blebbing and growth arrest/apoptosis (blue lines) and in Gαq-dependent activation of 
apoptosis (red lines). Punctuated lines are hypothetical links whereas solid lines are reported connections. 
To summarise, we have described the involvement of the Gαq/PKCζ complex in mus-
carinic M3 receptor-induced blebbing and cell growth arrest and in nutrient-deprivation 
apoptosis. Further work is required for the integration of these preliminary evidences 
into a comprehensible biochemical model that explains the novel functions of PKCζ as a 
cellular effector of Gαq. 
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Conclusions
1. The Gαq/PKCζ/ERK5 pathway is fully functional in cardiac myocytes and fibroblasts 
and in murine hearts in vivo. 
2. ERK5 activation by Gq-GPCRs is Gαq-biased. 
3. The Gαq/PKCζ complex can be detected in living cells and is highly specific.
4. PKCζ interacts with Gαq through its PB1 type II domain. Lysine 19 is a key aminoacid 
for this interaction. In turn, Gαq interacts with PKCζ through a pseudo-PB1 type I domain 
located within the effector-binding region. Glutamic acids at positions 234 and 245 are 
key determinants of the interaction.
5. The formation of an efficient Gαq/PKCζ complex is essential for ERK5 activation by Gq-
coupled GPCRs. 
6. GRK2 negatively regulates Gαq association to PKCζ and ERK5 activation by Gq-coupled 
GPCRs. 
7. PKCζ transiently dimerises in response to Gq-GPCR stimulation and acts as a scaffold 
between Gαq and ERK5 upon activation of the G protein.
8. The Gαq/PKCζ complex is involved in membrane blebbing and cell growth arrest indu-
ced by muscarinic M3 receptor activation, and in the promotion of apoptosis. 
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Abstract
The cell is a dynamic entity with highly intertwined biochemical networks respon-ding to internal and external perturbations in an orchestrated manner. The ele-ments in those networks are usually proteins that build complex circuits through 
protein-protein interactions. G proteins are essential cellular components for the sig-
nalling events following G protein-coupled receptor (GPCR) activation. This function is 
achieved through specific and evolutionary conserved interactions between activated G 
proteins and a number of cellular effectors. We have recently reported that ERK5 acti-
vation by Gq-coupled GPCR requires participation of a novel Gαq effector, PKCζ. Here we 
present a biochemical and cellular characterization of the Gαq/PKCζ signalling axis. We 
demonstrate that the Gαq/PKCζ  cascade is responsible for ERK5 activation in response to 
Angiotensin II in the heart. Also, it was show that this pathway displays Gαq-biased pro-
perties which has potentially interesting therapeutic implications. Next, we performed a 
cellular and biochemical characterization of the Gαq/PKCζ complex. We determined the 
occurrence and the specificity of the Gαq/PKCζ complex in living cells.  Also, we identified 
lysine 19, located in the PB1 domain of PKCζ, and two glutamic acids at positions 234 
and 245, located in a novel region of Gαq termed pseudo-PB1 domain, to be essential 
for the formation of the Gαq/PKCζ complex. Introduction of the double mutation (E234/
E245-AA) in Gαq completely abrogated ERK5 activation, demonstrating requirement of 
an efficient Gαq/PKCζ complex for the activation of the pathway. Additionally, we found 
that GRK2, but not RGS2/4, prevents the association of PKCζ to Gαq due to sequestering 
of the G protein. This effect, together with receptor desensitisation, impaires the downs-
tream activation of ERK5 by Gq-coupled GPCR. Next, we demostrated that PKCζ is not 
phosphorylated in response to Gq-coupled GPCR stimulation, but instead we provide the 
first evidence for a transient dimerisation of PKCζ. This protein was found to physically 
link activated Gαq and ERK5. Finally, we studied the role of the Gαq/PKCζ complex in Gαq-
dependent cellular effects. The formation this protein complex was shown to be required 
for muscarinic M3 receptor-induced membrance blebbing and cell growth arrest. Additio-
nally, the Gαq/PKCζ complex was found to be necessary for apoptosis promotion. Overall, 
this study provides important biochemical and cellular insight into Gq-coupled receptor 
signalling via the novel effector PKCζ. 
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INTRODUCCIÓN
Los receptores acoplados a proteínas G (GPCR) son la familia más numerosa de re-ceptores de membrana en mamíferos y tienen un papel esencial en procesos fisio-patológicos. La señalización por GPCRs depende de la activación de proteínas G y, de 
manera alternativa, del reclutamiento de β-arrestinas. La proteína Gαq es un importante 
mediador intracelular de la propagación de la señal iniciada tras la estimulación de GP-
CRs. Su función está regulada por la quinasa de receptores GRK2  y por las proteínas RGS. 
Gαq interacciona con más de 20 proteínas celulares, denominadas efectores, a través de las 
cuales inicia diversas cascadas de señalización. Por tanto, la funcionalidad de Gαq depende 
directamente de los efectores celulares a los que active. El ejemplo más paradigmático de 
proteína efectora de Gαq es la enzima PLCβ, encargada de la conversión de PIP2 en IP3 y 
diacilglicerol. Estos dos segundos mensajeros inician diversas vías intracelulares depen-
dientes de lípidos y calcio. Sin embargo, recientemente se han descubierto numerosas cas-
cadas de señalización dependientes de Gαq que ocurren al margen de PLCβ. Por ejemplo, 
la familia de proteínas RhoGEF (del inglés Rho guanine exchange factors) se unen a Gαq lo 
cual promueve la activación de la proteína Rho por GPCR. Recientemente, hemos descrito 
una nueva activación de la vía de ERK5 por GPCR que depende de la interacción de Gαq con 
dos nuevos efectores, PKCζ y MEK5. Esta vía es el objeto de estudio del presente trabajo y 
la introducción se ha centrado en describir procesos relevantes en dicho contexto de seña-
lización.
Las proteínas quinasas C (PKC) son una gran familia de serina/treonina quinasas con 
importantes roles en señalización celular. PKCζ pertenece a la familia de las PKC atípicas 
ya que, al contrario que las PKC clásicas, no pueden ser  activadas por calcio ni diacilglice-
rol  Sin embargo, estas quinasas atípicas muestran una interesante variedad de funciones a 
través de interacciones proteína-proteína. Tanto PKCζ como PLCλ (el otro miembro de las 
PKC atípicas) tienen un dominio PB1 a través del cual interaccionan con diversas proteínas, 
participando de esta manera en procesos como la polaridad celular, la activación de la vía 
NFκB o la respuesta alérgica y el asma. 
Las quinasas activadas por mitógenos (MAPKs) son serina/treonina quinasas con una 
función esencial en el control de la transcripción en respuesta a diversos estímulos exter-
nos. ERK5 es el miembro más reciente de esta gran familia y, por lo tanto, el más descono-
cido. Esta proteína es fosforilada dualmente en su dominio quinasa, como el resto de las 
MAPK, pero presenta de manera diferencial un singular dominio C-terminal a través del 
cual es capaz de actuar de activador transcripcional. ERK5 es una proteína que promueve 
la supervivencia y juega un papel esencial en el desarrollo cardiaco, a través de su función 
endotelial.
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Gαq es un importante mediador de la función cardiaca. Su sobreexpresión está aso-
ciada con hipertrofia cardiaca y fallo cardiaco. Hemos descrito que la vía de activación 
de ERK5 a través de PKCζ tiene un papel fundamental en el desarrollo de hipertrofia en 
respuesta a la estimulación crónica con Angiotensina II. Por tanto, el estudio detallado de 
los mecanismos bioquímicos y celulares de esta nueva vía puede aportar datos relevantes 
para el tratamiento de patologías cardiacas.
OBJETIVOS
1. Determinar si la vía de señalización Gαq/PKCζ/ERK5 es operativa en tejido cardiaco.
 
2. Determinar la contribución relativa de Gαq y β-arrestinas en la activación de ERK5 por 
GPCRs acoplados a Gαq.  
3. Determinar la especificidad del complejo Gαq/PKCζ en células vivas.
4. Identificar las superficies de interacción entre Gαq y PKCζ .
5. Determinar la dependencia de la vía de ERK5 por el complejo Gαq/PKCζ.
6. Estudiar la función reguladora de GRK2 en la vía de activación de ERK5 por GPCRs aco-
plados a Gαq. 
7. Estudiar los mecanismos de activación del nuevo efector PKCζ en la vía de activación de 
ERK5 por GPCRs acoplados a Gαq.
8. Explorar las funciones potenciales del complejo Gαq/PKCζ en procesos celulares de-
pendientes de la activación  de Gαq. 
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RESULTADOS
La célula es una entidad dinámica compuesta de redes bioquímicas altamente in-
trincadas que le permiten responder de una manera orquestada a distintas perturbacio-
nes. Las proteínas son elementos fundamentales de dichas redes y forman circuitos de 
alta complejidad a través de interacciones proteína-proteína. Las proteínas G son compo-
nentes celulares esenciales para la señalización de los receptores acoplados a proteínas G 
(GPCR). Esta función se ejerce a través de interacciones específicas, y conservadas a lo lar-
go de la evolución, entre proteínas G activadas y numerosos efectores celulares. Reciente-
mente hemos descrito que la activación de ERK5 por GPCRs acoplados a Gαq precisa de la 
participación de un nuevo efector, PKCζ. En este estudio presentamos una caracterización 
bioquímica y celular del eje de señalización Gαq/PKCζ. Hemos demostrado que la cascada 
Gαq/PKCζ es responsable de la activación de ERK5 en respuesta a Angiotensina II en el 
corazón. También hemos descrito que esta cascada de señalización tiene propiedades ses-
gadas hacia Gαq, lo cual puede tener implicaciones terapéuticas interesantes. El complejo 
Gαq/PKCζ ha sido caracterizado en células in situ. Además, mediante experimentos de 
mutagénesis se han identificado residuos importantes en ambas proteínas para esta inte-
racción. Así, la lisina 19, localizada en el dominio PB1 de PKCζ, y los ácidos glutámicos en 
posiciones 234 y 245, localizados en una nueva región de Gαq denominada dominio pseu-
do-PB1, parecen ser aminoácidos esenciales para la formación del complejo Gαq/PKCζ. 
Notablemente, la doble mutación (E234/E245-AA) en Gαq impide la activación de ERK5, 
demostrando el requerimiento de un complejo Gαq/PKCζ eficiente para la activación de 
la cascada. También hemos descrito que GRK2, pero no RGS2/4, previene la asociación de 
PKCζ con Gαq, mediante el secuestro de la proteína Gαq. Este efecto de GRK2, junto con 
la desensibilización de receptores también promovida por GRK2, resulta en la inhibición 
de la activación de ERK5 por GPCRs acoplados a Gαq. Además, hemos descrito que PKCζ 
no es activado por GPCRs a través de fosforilación y demostramos, por primera vez, la di-
merización transitoria de PKCζ inducida por un receptor. Esta proteína actúa de andamio 
entre la proteína Gαq activada y ERK5. Finalmente, hemos estudiado la participación del 
complejo Gαq/PKCζ en las funciones celulares de Gαq . La formación de este complejo 
demostró ser necesaria para el “blebbing” de membrana y la parada del crecimiento ce-
lular inducidos por el receptor muscarínico M3. Nuestros resultados también apuntan a 
la participación del complejo Gαq/PKCζ en la promoción de apoptosis en situaciones de 
privación de nutrientes. Globalmente, este estudio aporta datos bioquímicos y celulares 
de gran relevancia para entender la señalización de GPCRs acoplados a Gαq a través del 
nuevo efector PKCζ. 
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DISCUSIÓN
Hemos descrito la vía de activación de ERK5 por GPCR acoplados a Gαq en cardio-
miocitos, fibroblastos y tejido cardiaco. Estos resultados apoyan la conservación de la vía 
previamente descrita en células epiteliales y sugiere importantes funciones para este nue-
vo eje de señalización. Así, PKCζ se confirma como el efector fundamental de Gαq en la 
activación de ERK5. Como parte de otra tesis se describió la implicación de esta vía en el 
desarrollo de hipertrofia cardiaca. En este trabajo, hemos especulado sobre los posibles 
mecanismos de este fenómeno proponiendo un modelo en el que  ERK5 es responsable 
de la secreción de colágeno en fibroblastos, el cual se uniría a integrinas en la superficie 
de los cardiomiocitos, promoviendo hipertrofia de manera aditiva a la propia activación 
de ERK5 en este tipo celular. En el contexto cardiovascular, resulta muy relevante, el haber 
determinado la preponderancia de vías Gαq frente a vías β-arrestina, para la activación 
de ERK5 por GPCRs.  Esto sugiere que la activación de ERK5 en corazón es estrictamente 
deletérea, al contrario que ERK1/2 que también participa en vías cardioprotectoras, y por 
tanto, podría constituir una diana terapéutica de interés para el tratamiento de la hiper-
trofia cardiaca. 
La visualización del complejo PKCζ/Gαq en células vivas, de manera altamente espe-
cífica, indica la relevancia celular de esta interacción. Sin embargo, la localización concreta 
del complejo no se ha podido determinar con seguridad, ya que en nuestro sistema se 
encuentra disperso por el citoplasma. Existe la posibilidad de que la adición de un epítopo 
a la proteína G haya interferido con su localización en la membrana. El reciente desarrollo 
de epítopos internos para proteínas G será de utilidad en futuros proyectos para clarificar 
este tema. El resultado más sorprendente en lo que se refiere a la especificidad del com-
plejo es la ausencia de interacción entre PKCζ y Gα11, miembro de la familia Gαq/11 y con 
alta homología de secuencia con Gαq. El análisis de este resultado junto a los datos de las 
superficies de interacción del complejo Gαq/PKCζ presentados en esta tesis, sugiere que 
la deficiencia de asociación entre PKCζ y Gα11 no se debe a una diferencia en las interfa-
ses (idénticas en Gαq y Gα11), sino posiblemente a una diferente localización celular. Este 
punto deberá ser confirmado en el futuro.
El principal hallazgo del estudio bioquímico en la formación del complejo Gαq/PKCζ 
es la descripción de una región en Gαq homóloga a un dominio PB1. La mutación de este 
dominio interfiere con la asociación con PKCζ. Es interesante sugerir que el complejo 
Gαq/PKCζ sea el nexo entre la activación de GPCRs y procesos en los que se ha descrito 
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la importancia de dominios PB1. A través del mutante en la región pseudo-PB1 de Gαq 
hemos podido determinar el requerimiento estricto de la asociación con PKCζ  para la 
activación de ERK5. Además, el hecho de que GRK2 sea un regulador de la asociación de 
PKCζ con Gαq y de la activación de ERK5 coincide con datos previos obtenidos para otros 
efectores de Gαq. Debido a  que la deficiencia de asociación de Gαq con GRK2 potencia la 
vía de ERK5, sugerimos que, en aquellos contextos patológicos en los que los niveles de 
GRK2 se encuentran alterados, la vía de ERK5 podría estar hiperactivada con posibles im-
plicaciones en dichas patologías. 
Con respecto a los mecanismos de activación de PKCζ por GPCR, hemos descrito 
que no son dependientes de fosforilación pero que parecen involucrar la dimerización de 
PKCζ. Estos datos sugieren que PKCζ puede estar actuando de proteína andamio general 
de la vía, formando oligómeros que sirvan de plataforma de señalización para la activa-
ción de ERK5 por GPCRs. La presencia de Gαq activada y ERK5 en el mismo complejo 
molecular a través de PKCζ apoya dicha teoría. Así, proponemos un modelo de uniones 
secuenciales para explicar la activación de la vía. En este modelo, Gαq estaría activando 
PKCζ alostéricamente tal como se ha descrito para el resto de los efectores de Gαq y como 
previamente se ha demostrado que pueden actuar los dominios PB1 sobre PKCζ. 
Por último, parece que el complejo Gαq/PKCζ juega un papel relevante en las fun-
ciones de “blebbing” y parada del ciclo celular dependientes de la activación del receptor 
muscarínico M3. De este modo, proponemos que la promoción de “blebbing” puede de-
berse a la reorganización del esqueleto de actina dependiente de ERK5 o a una posible 
activación de rhoA dependiente del complejo Gαq/PKCζ. Asimismo, la parada del ciclo 
celular puede suceder a través de JNK, tal como se he descrito recientemente. Por tanto, 
nuestros datos sugieren que el complejo Gαq/PKCζ podría ser responsable de esta activa-
ción. A su vez, hemos observado que el complejo Gαq/PKCζ participa en la promoción de 
apoptosis. Este resultado puede ser muy relevante en el sistema cardiovascular donde se 
ha visto que la sobreexpresión de Gαq puede conducir a fallo cardiaco. En este contexto, 
basándonos en datos preliminares, proponemos que la inhibición de la vía de Akt por 
Gαq puede ser dependiente de PKCζ. Asimismo, sugerimos que la función de la NADPH 
oxidasa, responsable de la producción de radicales libres de oxígeno y de la promoción de 
apoptosis es una diana potencial del eje de señalización Gαq/PKCζ.  La descripción precisa 
de los eventos bioquímicos involucrados en las diversas funciones celulares del complejo 
Gαq/PKCζ deberá ser clarificada en futuros proyectos de investigación.
246
CONCLUSIONES
1. La vía de señalización Gαq/PKCζ/ERK5 es operativa en cardiomiocitos y fibroblastos, así 
como en corazones murinos in vivo. 
2. La activación de ERK5 por receptores acoplados a Gαq es “Gαq-sesgada” y no requiere la 
internalización ni la fosforilación del receptor.  
3. El complejo Gαq/PKCζ es detectado en células vivas y es altamente específico.
4. PKCζ interacciona con Gαq a través de su dominio PB1 tipo II. La lisina en posición 19 es un 
aminoácido clave para esta interacción. Por otra parte, Gαq interacciona con PKCζ a través de 
un dominio pseudo-PB1 type I localizado en la zona de unión a efector. Los ácidos glutámicos 
en posiciones 234 y 245 son cruciales en la interacción.
5. La formación de un complejo de señalización eficiente entre Gαq y PKCζ es esencial para la 
activación de ERK5 en respuesta a estimulación por GPCRs acoplados a Gαq. 
6. GRK2 es un regulador negativo de la asociación entre Gαq y PKCζ. GRK2 también es un 
regulador negativo de la activación de ERK5 por GPCRs acoplados a Gαq. 
7. PKCζ dimeriza de manera transitoria en respuesta a la estimulación de GPCRs acoplados a 
Gαq, y actúa como una proteína andamio entre Gαq activada y ERK5.
8. El complejo Gαq/PKCζ está involucrado en el proceso de “blebbing” y en la parada del 
ciclo celular inducidos por la activación del receptor muscarínico M3, y en la promoción de 
apoptosis.
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Figure 1. Primary sequence differences between Gαq and Gα11. (A) Sequence alignment between Gαq and 
Gα11 with highlighted variable clusters. Underlined in blue is the Gαq region determined to contain PKCζ-
interaction derminants. (B) Cluster II and III, and aminoacids E234/E245 are marked in the crystal structure 
of Gαq (PDB accession number: 2BCJ).                                                                                                                                               
Figure 2. PB1typeII domain of PLCλ is 
free in the PLCλ-Par6 complex. Crystal 
structure of the complex between PLCλ 
(through its PB1 type I domain) and Par6 
(through its PB1 type II domain) (PBD 
accession number: 1WMH).                                                                       
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